Name:
Mauricio Tohen
Office Address:
Director of Bipolar Disorder Program
University of San Antonio
Texas.
United States of America
Place of Birth:
Mexico City, Mexico
Education:
1976 M.D. National University of Mexico
1982 D. Psych. Diploma in Psychiatric Research, Department of Psychiatry, University of Toronto
1984 M.P.H. Master of Public Health, Harvard School of Public Health (Epidemiology)
1988 Dr.P.H. Doctor of Public Health, Harvard School of Public Health (Epidemiology)
2000 M.B.A. Kelley School of Business, Indiana University
Postdoctoral Training:
Residencies:
1976-1979 Resident in Internal Medicine, National Institute of Nutrition, National University of Mexico
1979-1980 Resident in Psychiatry, Toronto General Hospital, University of Toronto
1980-1982 Resident in Psychiatry, Clarke Institute of Psychiatry, University of Toronto
Clinical and Research Fellowships:
1982 1985 Clinical and Research Fellow in Psychopharmacology, Mailman Research Center, McLean Hospital, Harvard Medical School
1985 1988 Teaching Fellow in Epidemiology, Harvard School of Public Health
Licensure and Certification:
1976 Medicine and Surgery, Ministry of Health, Mexico
1976 Educational Commission for Foreign Medical Graduates (E.C.F.M.G.) Certificate
1980 Specialist in Internal Medicine, National Autonomous, University of Mexico, Diploma
1980 Mexican Board of Internal Medicine, Certificate
1980 Massachusetts License Registration, (F.L.E.X.), Number 45492
1980 United Kingdom General Medical Council Registration. P.L.A.B. examination
1982 Specialist in Psychiatry, Royal College of Physicians and Surgeons of Canada, F.R.C.P.(C)
1982 Licentiate of the Medical Council of Canada L.M.C.C. Examination. Certificate of Registration
1984 American Board of Psychiatry and Neurology Specialty of Psychiatry, Certificate
1997 Indiana Medical License, number 01047973A
Other Professional Positions:
1996-2000 Medical Advisor, Lilly Research Laboratories, Indianapolis, IN
2000-2003 Medical Director, Zyprexa Product Team, Lilly Research Laboratories, Indianapolis, IN
2001-2004 Lilly Clinical Research Fellow, Lilly Research Laboratories, Indianapolis, IN
2001-2002 Co-Chair, Clinical Research Committee (CRC), Lilly Research Laboratories
2003 Executive Director, Bipolar Studies, Lilly Research Laboratories
2003-2004 Zyprexa Product Team Leader, Lilly Research Laboratories
2004- Distinguished Lilly Scholar, Lilly Research Laboratories
Academic Appointments:
1991 1993 Assistant Professor of Psychiatry, Harvard Medical School
1991 1994 Assistant Professor of Epidemiology, Harvard School of Public Health
1994-1997 Associate Professor of Psychiatry, Harvard Medical School
1994-1997 Associate Professor of Epidemiology, Harvard School of Public Health
1997 - Associate Clinical Professor of Psychiatry, Harvard Medical School
Hospital or Affiliated Institution Appointments:
1983 1988 Assistant Psychiatrist, McLean Hospital, Belmont MA
1988 1994 Associate Psychiatrist, McLean Hospital
1992 1994 Associate Epidemiologist, McLean Hospital
1994-1997 Psychiatrist, McLean Hospital
1994-1997 Epidemiologist, McLean Hospital
1997- 2004 Consultant, McLean Hospital
2004 - Clinical Associate, McLean Hospital
Awards and Honors:
1985 1988 NIMH National Research Service Award in Psychiatric Epidemiology ,Harvard Program in Psychiatric Epidemiology
1991 1993 NARSAD Young Investigator Award
1992 Alfred Pope Award for Young Investigators
1995-2000 FIRST Award, NIMH
1999 Lilly Research Laboratories President's Recognition Award
Major Committee Assignments:
National and Regional:
1991-1992 DSM IV Field Trial Coordinator (McLean Hospital site) for Psychotic Disorders, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
1991 Grant Reviewer, Medical Research Council of Canada
1992 Grant Reviewer, Canadian Research Foundation
1992 1996 NIMH, Epidemiology Review Committee (IRG)
1997-2001 NIMH, Clinical Centers and Special Projects Review Committee
2002 - NIMH, Ad hoc Reviewer
Medical and Public Health Schools:
1980 1981 Resident Representative, Research Committee, Department of Psychiatry, University of Toronto
1981 1982 Vice President, Psychiatric Residents, Association of Toronto
1984 1987 Developer and Coordinator, Doctoral Students Research Group, Harvard Program in Psychiatric Epidemiology
1989 1991 McLean Hospital Representative, Ethel Dupont Warren Fellowship Award Committee
1989-1997 McLean Hospital Representative, Neal Alan Mysell Fund Committee
1990 1993 Chairman, Neal Alan Mysell Fund Committee
1993 Founding Coordinator, First Annual Research Day, Department of Psychiatry, Harvard Medical School
Hospital:
1980 1981 Resident Representative, Pharmacy Committee, Clarke Institute of Psychiatry
1987-1997 Residents' Education Committee, McLean Hospital
1987 1993 Medical Records Committee, McLean Hospital
1987 1997 Quality Assurance Committee, Department of Psychiatry, McLean Hospital
1987 1988 Clinical Case Conference Committee, McLean Hospital
1988-1997 Residents' Selection Committee, McLean Hospital
1989 1990 General Director's Vision of Excellence Award Committee, McLean Hospital
1990-1997 Pharmacy Committee, McLean Hospital
1990 1994 Rate Review Committee, McLean Hospital
1992-1997 Institutional Review Board, McLean Hospital
1994-1997 Research Committee, McLean Hospital
Memberships, Offices and Committee Assignments in Professional Societies:
1981 American Psychiatric Association
1982 Royal College of Physicians and Surgeons of Canada Fellow Specialty of Psychiatry F.R.C.P. (C)
1982 1997 Massachusetts Psychiatric Society
1990-1997 Psychopharmacology Update Coordinator, Massachusetts Psychiatric Society
1990-1993 Nominating Committee, Massachusetts Psychiatric Society
1992 Member - American College of Psychiatrists (ACP)
1993 Member - American Psychopathological Association [APPA]
1994 Fellow - American Psychiatric Association
1994-1997 American Psychiatric Association, Research Council
1995-1997 American Psychiatric Association, Hispanic Committee
1996-1999 Committee on the Dean Award (ACP)
1997- Indiana Psychiatric Society
1998-1999 American Psychiatric Association Health Services Research Committee
1999- Member - Academia Nacional de Medicina (Mexico)
2000-2002 Associate Member, American College of Neuropsychopharmacology (ACNP)
2000-2003 Committee on the Award for Research in Mood Disorders (ACP)
2003 Fellow - American College of Psychiatrists (ACP)
2003 Fellow - American Psychopathological Association [APPA)
2003 Member - American College of Neuropsychopharmacology (ACNP)
2003 Distinguished Fellow - American Psychiatric Association
2003-2006 History Committee (ACNP)
2005-2008 Liaison Committee with Government and Industry (ACNP)
2006-2009 Psychiatric Treatment Committee (APA)
2005 Councilor, International Society of Bipolar Disorders (ISBD)
2006 Chairman, Committee on Nomenclature on Outcome in Bipolar Disorder (ISBD)
2006-2009 Membership Committee (ACP)
Editorial Boards:
1995- Editorial Board, Bipolar Disorder Letter
1998- Editorial Board, Harvard Review of Psychiatry
2000- Editorial Board, Bipolar Disorders
2001- Editorial Board, Journal of Clinical Psychiatry
2002- Editorial Board, TEN, Trends in Evidence-Based Neuropsychiatry
2004- Editorial Board, Journal of Affective Disorders
2004- Editorial Board, Current Psychiatry Reviews
2006- Editorial Board, Early Intervention in Psychiatry
Major Research Interests:
1) Psychopharmacology
2) Clinical Epidemiology
3) Longitudinal studies in Bipolar Disorder and First Episode Psychosis
Funding Information:
Federal Grants:
1985 1988 NIMH 17119 Trainee National Research Service Award Training in Psychiatric Epidemiology
1991-1994 NIMH 1RO3MH4844 01, Principal Investigator: "Predictors of Outcome After a First-Episode of Psychosis: Follow-up study of first-episode psychotic patients" $103,000
1995-2000 NIMH R29MH1948-01A2 FIRST Award "Longitudinal study of first-episode mania" $508,000
Private Foundation Grants:
1991-1992 John D. and Catherine T. MacArthur, Principal Investigator: "McLean Site DSM-IV field trial in Psychotic Disorders" $10,000
1991-1994 NARSAD Young Investigator Award, Principal Investigator: "First Episode Psychosis" $50,000
1994- Atlas Foundation, Principal Investigator: "The McLean First-Episode Psychosis Project" $100,000
Pharmaceutical Industry Grants:
1993-1994 Otsuka America Pharmaceutical Inc. Principal Investigator: "Efficacy and Tolerability of Ascending Doses of OPC-14597 compared to placebo and Haloperidol in acutely relapsing psychosis" $150,000
1993-1995 Lilly Research Laboratories, Principal Investigator: "Olanzapine vs. Haloperidol in the treatment of schizophrenia and other psychotic disorders" $216,000
1993-1995 Janssen Pharmaceutical Research Foundation, Principal Investigator: (Investigator initiated study) "Open study of Risperidone in schizophrenic patients" $64,000
1994-1995 The UpJohn Co., Principal Investigator: Dose-response study in the treatment of negative symptoms of schizophrenia with pramipexole" $35,000
1994-1996 Janssen Pharmaceutical Inc. , Principal Investigator: "Risperidone QD vs. BID dosing schizophrenia" $168,000
1994-1996 Pfizer Inc., Principal Investigator: "Forty week double-blind study evaluating the safety and efficacy of two dose regimens of ziprasidone in maintenance treatment of outpatients with schizophrenia and schizoaffective disorders" $268,000
1994-1996 Pfizer, Inc., Principal Investigator: "A 52-week, open extension study evaluation (ziprasidone)" $160,000
1994-1997 Different Industry Funds, Principal Investigator: McLean Hospital Pharmacoepidemiology Fund
1995-1996 Abbott Pharmaceutical, Principal Investigator: "Cost-effectiveness study of Valproate vs. Lithium" $174,000
1995-1996 Lilly Research Laboratories, Principal Investigator: "Olanzapine vs. Risperidone in the treatment of schizophrenia" $287,000
1995-1996 Abbott Laboratories, Principal Investigator: "Sertindole vs. risperidone in treatment resistant schizophrenia" $162,000
1966-1997 Zeneca Pharmaceuticals, Principal Investigator: "Seroquel vs. standard treatment cost effectiveness study" $138,000
1996-1997 Glaxo-Wellcome, Principal Investigator: "Lamotrigine vs. placebo in the treatment of bipolar depression" $286,000
1996-1997 Parke-Davis, Principal Investigator: "Gabapentin vs. placebo as an adjunct treatment of bipolar mania" $138,000
1996-1997 Hoechst Marion Roussel, Principal Investigator: MDL 100, 907 in the treatment of schizophrenia"
Hospital and Health Care Organization Clinical Responsibilities:
1985 1988 Psychiatrist in Charge, Proctor House II, McLean Hospital, Belmont, Massachusetts
1988-1997 Clinical Director, Bipolar and Psychotic Disorders Program, McLean Hospital, Belmont, Massachusetts
Major Administrative Responsibilities:
1990-1997 Chief, Epidemiology Laboratory, Mailman Laboratories for Psychiatric Research, McLean Hospital, Belmont, Massachusetts
1992-1997 Associate Director, Psychopharmacology Service, McLean Hospital, Belmont, Massachusetts
1992-1997 Director, Pharmacoepidemiology Center, McLean Hospital, Belmont, Massachusetts
1994-1997 Director, New and Experimental Psycho pharmacology, Clinic, McLean Hospital
2000-2003 Medical Director, Zyprexa Product Team, Lilly Research Laboratories
2003 Executive Director, Bipolar Disorder Studies, Lilly Research Laboratories
2003-2004 Team Leader, Zyprexa Product Team, Lilly Research Laboratories
2004- Distinguished Lilly Scholar, Lilly Research Laboratories
Report of Teaching:
Harvard Medical School:
1984 Teaching Assistant, Epidemiology and Public Health (EPI 201a), Harvard School of Public Health (60 students) 40 hours/year
1984-1987 Teaching Assistant, Epidemiology of Mental Disorders (EPI 216bc), Harvard School of Public Health (15 students) 20 hours/year
1985-1986 Teaching Assistant, Introduction to Biostatistics (B1O 201ab), Harvard School of Public Health (60 students) 40 hours/year
1985-1986 Teaching Assistant, Epidemiologic Reasoning and Practice (EPI 202b). Harvard School of Public Health (60 students) 40 hours/year
1985-1988 Clinical Instructor in Psychiatry for residents and medical students McLean Hospital, Harvard Medical School, 2 Psychiatric residents/year, 5 hours/week
1985-1988 Lecturer for: Biogenetic Aspects in Personality Disorders and Epidemiology of Schizophrenia, McLean Hospital Residency Training Program in Psychiatry, 8 students, 2 hours/year
1986 1987 Course Developer (with Professor Gerald L. Klerman and Jane Murphy, Ph.D.) and Teaching Assistant, Assessment Methods in Psychiatric Epidemiology (EPI 219d), Harvard School of Public Health (15 students) 20 hours/year
1986 1988 Seminar developer and director: "Research Methods and Critical Reading of the Literature" for Residents in Psychiatry, McLean Hospital, 12-15 residents, 10 hours/year
1986 1997 Associate Course Director (Course Director: Professor Ross J. Baldessarini): Advanced Clinical Clerkship in Diagnosis and Treatment of Major Psychosis, Harvard Medical School (Psychiatry 501M.10b) McLean Hospital, 4-6 students/year, Advisor for research projects
1987 1988 Tutor, The New Pathway Clerkship in Psychiatry, Harvard Medical School, 2 students, 10 hours/year
1987 1990 Instructor and lecturer in Introduction to Clinical Psychiatry (Psychiatry 700), Harvard Medical School, 10 students, 4 hours/year
1989-1993 Seminar Director, "Psychopathology of Psychotic Disorders," for residents in Psychiatry, McLean Hospital, 8-10 residents, 8 hours/year. Harvard School of Public Health
1990 1992 Associate Director (Course Director: Professor Ming Tsuang). Risk Factors in Psychiatric Epidemiology (EPI 218b), Harvard School of Public Health (8-10 students) 20 hours/year
1990-1997 Clinical Research Coordinator, Harvard Program in Psychiatric Epidemiology, Advisor to students conducting clinical research
1990 1997 Instructor, Research in Psychiatric Epidemiology (EPI 3502), Harvard School of Public Health, Advisor to students conducting research
1992-1993 Advisor to Jose Castillo, M.D., graduate student in Epidemiology, 1 hour/week
1992-1997 Primary Instructor, The Epidemiology of Major Psychiatric Disorders (EPI 217a), Harvard School of Public Health (15 students) 24 hours/year
1992 1997 Primary Instructor, Diagnosis of Major Psychotic Disorders in a Clinical Setting (EPI 290), Harvard School of Public Health (1-2 students) 20 hours/year
1993 Member Examination Committee for Bei Chang, M.S., Doctor of Science degree Candidate in Biostatistics Harvard School of Public Health
1994 Member Examination Committee for Qing Liang, M.S., Doctor of Science degree Candidate in Biostatistics Harvard School of Public Health
2004- Teaching at McLean Hospital. Meets with residents every 6 weeks to lead a seminar on outcome and treatment of bipolar disorder
Advising Responsibilities (McLean Hospital):
1983-1985 Thesis Advisor for George Dion for the degree of Doctor of Science, Boston University, Sargent College of Allied Professions. Thesis: "Parameters and Predictors of Functional Outcome in Bipolar Patients Hospitalized for a Manic Episode: Results of Two and Six Month Follow Ups"
1989-1998 Thesis Advisor for Alexis Henry for the degree of Doctor of Philosophy. Boston University School of Occupational Therapy Thesis: "Functional Recovery in Acute Psychosis." Obtained NARSAD Young Investigator Award
1989 1992 Preceptor for Elyse Dubo, M.D. Resident in Psychiatry, McLean Hospital
1989-1990 Primary Supervisor for Shelly Greenfield, M.D., Chief Resident of Psychotic Disorders Program, McLean Hospital
1990-1991 Primary Supervisor for Andrew Stoll, M.D., Chief Resident of Psychotic Disorders Program, McLean Hospital: obtained American Psychiatric Association Research Award
1990-1993 Preceptor and Primary Supervisor for Michael Banov, M.D. Resident in Psychiatry, McLean Hospital: obtained Loughlin Award by American College of Psychiatrists, and Best Resident Poster at Department of Psych Res Day
1991-1992 Preceptor and Primary Supervisor for Stephen Strakowski, M.D., Chief Resident in Psychiatry, McLean Hospital: obtained Loughlin Award by American College of Psychiatrists
1991-1994 Advisor to Jose Castillo, M.D., Research Fellow in Psychiatry, Harvard Medical School
1992-1993 Advisor to Jong-Won Kim, M.D., Research Fellow in Psychiatry, Harvard Medical School
1992-1994 Advisor to German Baraibar, M.D., Research Fellow in Psychiatry, Harvard Medical School
1993-1994 Advisor to Patrick Stapleton for Master of Health Care Administrator, Simmons College. Thesis: "The Impact of Managed Care on a Free-Standing Psychiatric Hospital"
1993-1994 Primary Supervisor for James Hegarty, M.D., Chief Resident of Bipolar and Psychotic Disorders Program, McLean Hospital: obtained American Psychiatric Association Research Award: Lily/APA Award: Loughlin Award and Alfred Pope Award
1994-1997 Advisor to Carlos Zarate, M.D.: Obtained Dupont-Warren and Livingstone Award, McLean Hospital: NARSAD Young Investigator Award: APA Minority Fellowship
2001- Advisor to Paola Salvatore MD, Fellow in the McLean/Harvard First Episode Project: Obtained NARSAD Young Investigator Award (2003, 2006)
2001-2003 Advisor to Robert Irvin MD Lilly/McLean Fellow in Bipolar disorder
2002 Advisor to Harkaitz Imaz MD, Fellow in the McLean/Harvard First Episode Project
2003-2004 Advisor to Christopher Baethge MD, Fellow in the McLean/Harvard First Episode Project
2005- 2006 Advisor to Jesus Perez MD, Fellow in the McLean/Harvard First Episode project - Established First Episode Project in Cambridge, England
Regional, National and International Contributions:
Invited Scientific/Academic Presentations:
1. Discussant for: Mortality and Causes of Death in Schizophrenia and Manic Depression. Speaker: Dr. Ming T. Tsuang, 26th meeting of the Boston Society of Neurology and Psychiatry, Boston, MA, September 8, 1987.
2. Lecturer, Psychiatric Epidemiology. Comprehensive Review and Update in Psychiatry, McLean Hospital, April 8, 1988.
3. Lecturer, Psychiatric Epidemiology. CME Lecture, Hampstead Hospital, Hampstead, NH (invited speaker), May 3, 1988.
4. Outcome in Bipolar Disorder. Mailman Research Center Academic Conference, McLean Hospital, September 6, 1988.
5. Outcome in Bipolar Disorder. CME lecture, Emerson Hospital, Concord, Massachusetts (invited speaker). October 6, 1988.
6. Outcome in Bipolar Disorder. McLean Hospital Academic Conf., Dec. 8, 1988.
7. Outcome in Bipolar Disorder. Massachusetts Mental Health Center Psychopharmacology Lecture Series, February 24, 1989.
8. Psychiatric Epidemiology. Comprehensive Review and Update in Psychiatry, McLean Hospital, March 18, 1989.
9. Outcome in Bipolar Disorder. Hampstead Hospital CME lectures, Hampstead, NH, March 28, 1989.
10. Predicting Outcome in Manic Depressive Patients, Mount Auburn Hospital, Psychiatry Grand Rounds, Cambridge, MA, April 25, 1989.
11. Psychotic Disorders. Comprehensive Clinical Update in Psychiatry, McLean Hospital, October 28, 1989.
12. Outcome in Mania. Psychiatric Epidemiology Colloquium, Harvard Program in Psychiatric Epidemiology, Boston, MA, October 20, 1989.
13. Differential Diagnosis in Psychotic Disorders. Waltham Weston Hospital CME lecture, Waltham, MA, January 12, 1990.
14. Bias in Outcome Research. Advances in Psychopharmacology and Behavioral Neurobiology, 1990 seminar series. Massachusetts General Hospital, April 13, 1990.
15. Psychotic Disorders, McLean Hospital Comprehensive Update in Clinical Psychiatry, Hyatt Regency Hotel, Cambridge, MA, November 2, 1990.
16. Mania in Old Age, Psychopharmacology Lunch Program, McLean Hospital, November 12, 1990.
17. Psychiatric Epidemiology, McLean Hospital Comprehensive Update in Psychiatry, Hyatt Regency Hotel, Cambridge, MA, March 16, 1991.
18. Psychiatric Epidemiology Lecture, Tufts Univ., MD MPH Program, April 18, 1991.
19. Mental Illness: Myths and Realities. "Friend-Raising" meeting with local civic leaders, McLean Hospital, April 25, 1991.
20. Outcome of Research in Mania. Manic Depressive and Depressive Association of Boston (MDDA Boston), June 6, 1991.
21. Outcome in Mania. Manic Depressive and Depressive Association of Worcester, University of Massachusetts, Worcester, MA, September 16, 1991.
22. Psychotic Disorders, McLean Hospital Comprehensive Update in Clinical Psychiatry, October 18, 1991.
23. Psychiatric Epidemiology Lecture, University of Massachusetts, PGII III Psychiatric Residents, November 27, 1991.
24. Psychiatric Epidemiology, McLean Hospital Comprehensive Review and Update in Psychiatry, March 14, 1992.
25. Mania, NARSAD Benefit, Belmont, MA, March 16, 1992.
26. Outcomes in Mania, Grand Rounds, University of Massachusetts, Worcester, MA, April 16, 1992.
27. Latest Advances in Research and Medications Workshop. Tenth Annual State Convention Alliance of the Mentally Ill of Massachusetts, Boston Park Plaza Hotel, Boston, MA, May 2, 1992.
28. Outcome in Mania, Grand Rounds, Department of Psychiatry, Lahey Clinic, Burlington, MA, May 27, 1992.
29. Course of Mania, Grand Rounds, Sunnybrook Hospital, University of Toronto, Toronto, Ontario, June 12, 1992.
30. The First Annual Alfred Pope Award for Young Investigators. Outcome in Mania. Four Year Prospective Follow Up of 75 Patients Utilizing Survival Analysis. Mauricio Tohen, M.D., Dr.P.H., recipient, McLean Hospital, June 19, 1992.
31. First Episode Psychosis, Grand Rounds, Worcester State Hospital, Worcester, MA, November 10, 1992.
32. New Directions in Assessment of Psychiatric Outcome, (Faculty). Department of Postgraduate and Continuing Education, McLean Hospital, December 18, 1992.
33. Manic Depressive Illness. "Talk About the Mind," hosted by Dr. J. Dreyfus, Milton Cable System, Milton, MA, February 2, 1993.
34. The McLean First Episode Psychosis/Mania Project Massachusetts Mental Health Center Psychopharmacology Lecture Series, February 26, 1993.
35. Psychiatric Epidemiology. Comprehensive Update in Psychiatry, McLean Hospital, March 12, 1993.
36. The McLean First-Episode Mania Project, Psychopharmacology Grand Rounds, Cambridge Hospital, Cambridge, MA, March 24, 1993.
37. Preventing Recurrence of Affective Disorders. Mood Disorders, The Ontario College of Family Physicians, Toronto, Ontario, Canada, June 23, 1993.
38. Course and Outcome in Mania, Grand Rounds, University of Cincinnati, Cincinnati, OH, October 2, 1993.
39. Diagnosis and Treatment of Bipolar Disorder. Universidad de Nuevo Leon, Monterrey, MX, October 16, 1993.
40. Outcome in Mania, Universidad de Monterrey, Monterrey, MX, October 22, 1993.
41. Psychiatric Epidemiology Comprehensive Update in Psychiatry, McLean Hospital, March 11, 1994.
42. Bipolar Disorder, MDDA of Southern Massachusetts, Pembroke Hospital, Pembroke, MA, July 7, 1994.
43. Mood Disorders Throughout the Lifespan. Satellite Symposium, 44th Canadian Psychiatric Association Annual Meeting, Ottawa, Ontario, September 24, 1994.
44. New Management Options in Bipolar Disorder. Pharma-Care, Inc. Annual Staff Meeting, Princeton, NJ, September 28, 1994.
45. New Management Options in Bipolar Disorder, St. Vincent Hospital Grand Rounds, October 4, 1994.
46. Bipolar Disorder, MDDA Meeting, McLean Hospital, October 12, 1994.
47. Predictors of Outcome After a First-Episode of Psychosis Recovery from Psychiatric Disability, State House, Boston, MA, May 10, 1995.
48. What Works: Services for People with Dual Diagnosis, NAMI Annual Convention, Washington, DC, June 21, 1995.
49. Use of antipsychotics in bipolar disorder. Third International Conference on Bipolar Disorder, Pittsburgh, PA. June 17-19, 1999.
50. The McLean First-Episode Project: Two-Year Syndromal and Functional Recovery in 219 Cases of Major Affective Disorders with Psychotic Features. Third International Conference On Bipolar Disorder. Pittsburgh, PA, June 17-19, 1999.
51. New Pharmacological Interventions in the Treatment of Schizophrenia and Bipolar Disorders, 49th Annual Meeting of the Canadian Psychiatric Association, Westin Harbour Castle, Toronto, Canada, September 15, 1999.
52. Current and Emerging Clinical Data with Atypical Antipsychotics in the Treatment of Bipolar Disorder, 49th Annual Meeting of the Canadian Psychiatric Association, Westin Harbour Castle, Toronto, Canada, September 15, 1999.
53. New advancements in the management of bipolar disorder. 12th Congress of the European College of Neuropsychopharmacology. London, UK. September 21-25, 1999.
54. McLean Harvard First Episode Study, Grand Rounds Presentation, University of Illinois at Chicago, Chicago, Illinois, September 29, 1999.
55. The Psychiatric Hospital in the Next Millennium, Regional Meeting of the World Psychiatric Association, Buenos Aires, Argentina, October 20-23, 1999.
56. Novel Antipsychotics and Mania, Symposio Internazionale dedicato a I 100 Anni Della "Follia Maniaco Depressiva" Di Emil Kraepelin, Rome, Italy, November 26-27, 1999.
57. Outcome Studies in Bipolar Disorder, 50 Years of Treatments for Bipolar Disorder: A Celebration of John Cade's Discovery, Sydney, Australia, December 4-5, 1999.
58. Treatment of Acute Mania. Annual Meeting of the Italian Psychiatric Association. Rome, Italy, February, 2000.
59. Use of Antipsychotics in Mania. Annual Meeting of the Israel Psychiatric Association. Jerusalem, Israel, April 10, 2000.
60. Il Disturbo Bipolare: Clinica E Terapia. Parma, Italy, June 3, 2000.
61. Olanzapine versus Divalproex Sodium for the Treatment of Acute Mania. European Stanley Foundation Conference on Bipolar Disorder. Amsterdam, Netherlands, September 21-22, 2000.
62. The McLean First Episode Project: Two year syndromal and functional recovery in 219 cases of major affective disorders with psychotic features. 2nd Annual Stanley Foundation Conference on Bipolar Disorder. Amsterdam. September 21-22, 2000.
63. Use of Antipsychotics in Bipolar Disorder. Bipolar Disorder: From Biological Mechanisms to Treatment. Canadian Psychiatric Association 50th Annual Meeting, Victoria, BC, October 5, 2000.
64. The Course of Mania and Schizobipolar Variants. Coming of Age of the Bipolar Spectrum International Conference. San Diego, CA, November 18-29, 2000.
65. Use of Olanzapine in Mania - SOPSI 2001, Rome Italy, February 21, 2001.
66. Prediction of recovery and recurrence in patients with first episode mania. ISAD 2nd Biennial Conference, Cancun, Mexico, March 2004.
67. Predictors of Outcome in 52 cases of psychotic nonaffective disorders. CME Syllabus & Proceedings Summary. 2004 APA Annual Meeting, New York, NY, May 1-6, 2004.
68. Nuevas fronteras en el trastorno bipolar, Tratamiento farmacologico en depresion bipolar y prevencion de recaidas. 1lth Congreso International de Psiquiatria, Buenos Aires, October 26-29, 2004.
69. Predictors of time to relapse in bipolar I disorder. World Psychiatric Association International Congress, Florence, Italy. November 10-13, 2004.
70. El proyecto de primeros episodios de trastornos del espectro bipolar del Hospital McLean. The 2nd National Meeting on the Early Phases of Mental Illness: The Bipolar Spectrum Disorder, Santander, November 25-27, 2004.
71. Moving the field forward: The impact of research driven educational initiatives on bipolar patients and providers. Symposium 13, International Society for Bipolar Disorders, Philadelphia, Pennsylvania, June 12-15, 2005.
72. Predictors of time to relapse in bipolar I disorder. XXIV CINP Congress, Paris, June 20-24, 2005.
73. Thoughtful Psychopharmacotherapy. 15th Annual Meeting of the Japanese Society of Clinical Neuropsychopharmacology, Tokyo, Japan. October 11-13, 2005.
74. Moving the field forward: The impact of research driven educational initiatives on bipolar patients and providers. , Symposium 13, International Society of Affective Disorders, Lisbon Portugal, March 2006.
75. Outcomes in Bipolar Disorder. Ninth Annual Mental Health Symposium. Indianapolis, Indiana, June 2, 2006.
76. Mood Stabilizers: Clinical Evidences of Efficacy from Acute to Maintenance Phase. XV congresso Nazionale Della Societa Italiana Di Neuropsicofarmacologia, Genova 6-9 giugno 2006.
77. Analyses of Treatment Efficacy in Subtypes of Adolescent Patients with Bipolar Disorder Treated with Olanzapine for Acute Mania: A 3-Week Randomized Double-Blind Placebo-Controlled Study. NCDEU, 46th Annual Meeting, Boca Raton, Florida, June 12-15, 2006.
78. Relapse Prevention in Bipolar Disorder. ISCTM Meeting, Chicago, IL, July 11, 2006.
79. The McLean Harvard First Episode Mania Study. 2nd Biennial Conference of the International Soc. for Bipolar Disorders. Edinburgh, Scotland, August 2-4, 2006.
80. Outcomes in Bipolar Disorders. Grand Rounds Presentation, University of Colorado. September 20, 2006.
81. Outcomes in Bipolar Disorders. Indiana University School of Medicine, September 22, 2006.
82. Comparison of Olanzapine response for teens and adults. 2006 AACAP, San Diego, California, October 24, 2006.
83. Analyses of Treatment Efficacy and Safety in Adolescents Compared to Adults with Bipolar Disorder Treated with Olanzapine for Acute Mania. American Academy of Child and Adolescent Psychiatry, 2006 Research Forum, Oct., 2006.
84. Protective and Risk Factors for Pediatric Bipolar Disorder: Predicting Outcomes. Amer. Academy of Child and Adolescent Psych., 2006 Research Forum, October, 2006.
85. Olanzapine in Adult and Adolescent Mania: A Summary of Two RCT. Fifth European Stanley Conference on Bipolar Disorder, Barcelona, Catalonia, Spain, October 5-7, 2006.
86. Nomenclature in Course and Outcome in Bipolar Disorders. 7th International Conference on Bipolar Disorder, Pittsburgh, PA. June 8, 2007.
87. Defining Mood Stabilizers. 2nd International Symposium on Bipolar Disorders, Budapest, Hungary, September 7, 2007.
88. Predictors of syndromal and functional recovery in patients with a first-episode of mania. Australasian Society for Bipolar Disorders Conference 2007, Sydney, Australia, September 20 - September 22, 2007.
89. Career Development Seminar Series, Indiana University School of Medicine, Indianapolis, Indiana, October 15, 2007.
90. The International Society for bipolar Disorders Task Force on the Nomenclature of Course and Outcome in Bipolar Disorders. Delhi, India January 27-28, 2008. Agra, India January 30, 2008.
91. Nomenclature in Course and Outcome in Bipolar Disorders. 3rd Biennial Conference of the International Society for bipolar Disorders. Delhi, India, January 27-28, 2008, Agra, India, January 30, 2008.
91. The 2008 Career Development Institute for Bipolar Disorder, Launching and Maintaining a Career in Bipolar Disorder Research. The University of Pittsburgh Department of Psychiatry, Biomedical Science Tower, South Conference Center, April 26-29, 2008.
92. Maintenance treatment of bipolar disorders. East Asia Bipolar Symposium, Keynote Speaker, Fukuoka, Japan, July 25, 2008.
Professional Leadership Related to Teaching
1987- Examiner, Part II American Board of Psychiatry and Neurology
Professional Leadership in the Pharmaceutical Industry
1996 Joined Eli Lilly & Company as a Medical Advisor and Leader of the Venture Subteam of the Zyprexa Product Team
1998 Led the team that successfully obtained the indication for Zyprexa in the treatment of Acute Mania from the Food & Drug Administration (FDA)
2000 Appointed Medical Director of the Zyprexa Product team
2001 Led the team that successfully obtained the indication for Zyprexa in the treatment of Acute mania from the European Regulatory Agency (CPMP)
2003 Promoted to Leader, Zyprexa Product Team (Executive level)
2004 Promoted to Distinguished Lilly Scholar, the senior-most scientific technical level at Lilly Research Laboratories
BIBLIOGRAPHY
Original Publications:
1. Tohen M, Frankenburg F. Preparation for the certification examination. Can J Psych 1983:28:471 474.
2. Lipinski JF, Cohen BM, Frankenburg F, Tohen M, Waternaux CM, Altesman R, Jones BG, Harris P. S Adenosyl L Methionine in the treatment of depression results of an open trial. Am J Psych 1984:141(3):448 450.
3. Pope HG, Jonas JM, Hudson JI, Cohen BM, Tohen M. An empirical study of psychosis in borderline personality disorder. Am J Psych 1985:142(11): 1285 1290.
4. Frankenburg F, Tohen M, Cohen BM, Lipinski JF. Long term response to carbamazepine: A retrospective study. J Clin Psychopharm 1987:8:130 132.
5. Dion GL, Tohen M, Anthony W, Waternaux CM. Symptom and functioning of patients with bipolar disorder six months after hospitalization. Hosp and Comm Psych 1988:39:652 657.
6. Hudson JI, Lipinski JF, Frankenburg FR, Tohen M, Kupfer DJ. Effects of lithium on sleep in mania. Biol Psych 1989:25:665 668.
7. Tohen M, Waternaux CM, Tsuang MT, Hunt AT. Four year follow up of twenty four first episode manic patients. J Affect Disord 1990:19:79 86.
8. Tohen M, Waternaux CM, Tsuang MT. Outcome in Mania. A four year prospective follow up of 75 patients utilizing survival analysis. Arch Gen Psych 1990:47:1106 1111.
9. Strakowski SM, Hudson JI, Keck PE, Wilson DR, Frankenburg FR, Alpert JE, Teschke GC, Tohen M. Obstructive sleep apnea associated with treatment resistant mania. J Clin Psych 1991:52:156 158.
10. Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM, Waternaux CM. Episode sequence in bipolar disorder and response to lithium treatment. Am J Psych 1991:148:1237 1239.
11. Suppes P, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in Bipolar Disorder. Arch Gen Psych 1991:48:1082 1088.
12. Tohen M, Castillo J, Cole JO, Miller MG, de los Heros R, Farrer RJ. Thrombocytopenia Associated With Carbamazepine. J Clin Psych 1991:52:496 498.
13. Shulman K, Tohen M, Satlin A, Mallya G, Kalunian D. Mania compared with unipolar depression in old age. Am J Psych 1992:149:341 345.
14. Strakowski SM, Tohen M, Stoll AL, Faedda GL, Goodwin DC. Comorbidity in mania at first hospitalization. Am J Psych 1992:149:554 556.
15. Tohen M, Stoll AL, Strakowski SM, Faedda GL, Mayer PV, Goodwin DC, Kolbrener ML, Madigan AM. The McLean first episode psychosis project: six month recovery and recurrence outcome. Schiz Bull 1992:18(2):172 185.
16. Strakowski SM, Faedda GL, Tohen M, Goodwin DC, Stoll AL. Possible affective state dependence of the tridimensional personality questionnaire in first episode psychosis. Psych Res 1992:41:215 226.
17. Stoll AL, Tohen M, Baldessarini RJ. Increasing diagnostic frequency of obsessive compulsive disorder. Am J Psych 1992:149:638 640.
18. Tohen M, Tsuang MT, Goodwin DC. Prediction of outcome in mania by mood congruent or mood incongruent psychotic features. Am J Psych 1992:149:1580 1584.
19. Faedda GL, Tondo L, Baldessarini RJ, Suppes P, Tohen M. Outcome after rapid vs. gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psych 1993:50:448-455.
20. Strakowski SM, Tohen M, Stoll AL, Faedda GL, Mayer PV, Kolbrener ML, Goodwin DC. Comorbidity in first episode psychosis. Am J Psych 1993: 150:752 757.
21. Strakowski SM, Wilson DR, Tohen M, Woods BT, Douglas AW, Stoll AL. Structural brain abnormalities in mania at first hospitalization. Biol Psych 1993: 33:602-609.
22. Strakowski SM, Woods BT, Tohen M, Wilson Dr, Douglas AW, Stoll AL. MRI signal hyperintensities in mania at first hospitalization. Biol Psych 1993:33:204-206.
23. Strakowski SM, Stoll AL, Tohen M, Faedda GL, Goodwin DC. The tridimensional personality questionnaire as a predictor of six month outcome in first episode mania. Psych Res 1993:48:1-8.
24. Stoll AL, Tohen M, Baldessarini RJ, Goodwin DC, Stein SM, Katz SM, Swinson RP, McGlashan T. Shifts in the diagnostic frequencies of schizophrenia and affective disorders from 1972 through 1988: A combined analysis from four North American Psychiatric Hospitals. Am J Psych 1993:150:1669-1673
25. Banov MD, Tohen M, Friedberg J. High risk of eosinophilia in women treated with clozapine. J Clin Psych 1993:54:466-469.
26. Suppes T, Baldessarini RJ, Faedda GL, Tondo L, Tohen M. Discontinuing maintenance treatment in bipolar disorder: Risks and implications. Harvard Rev Psych 1993 Sep-Oct;1(3):131-144.
27. Tohen M, Castillo J, Pope HG, Herbstein J. Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J Clin Psychopharm 1994:14:67-70.
28. Tohen M, Shulman KI, Satlin A. First episode mania in late life. Am J Psych 1994:151:130-132.
29. Shulman KI, Tohen M. Unipolar mania reconsidered: evidence from an elderly cohort. Br J Psych 1994:164:547
30. Greenfield SF, Strakowski SM, Tohen M, Batson SC, Kolbrener ML. Childhood abuse in first-episode psychosis. Br J Psych 1994:164:831-834.
31. Banov MD, Zarate CA, Tohen M, Scialabba B, Wines JD, Kolbrener ML, Kim JW, Cole JO: Clozapine therapy in refractory affective disorders: Polarity predicts response in long-term follow-up. J Clin Psych 1994:55:295-300.
32. Kando JC, Tohen M, Castillo J, Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psych 1994:55:255-257.
33. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux CM, Oepen G: One hundred years of schizophrenia. Am J Psych 1994:151:1409-1416.
34. Strakowski SM, Tohen M, Flaum M, Amador X. The DSM-IV field trial: Substance abuse in psychotic disorders. Associations in affective syndromes. Schiz Res 1994:14:73-81.
35. Stoll AL, Mayer PV, Kolbrener M, Goldstein E, Suplit B, Lucier J, Cohen BM, Tohen M: Antidepressant-associated mania. A controlled comparison with spontaneous mania. Am J Psych 1994:151:1642-1645.
36. Stoll AL, Banov M, Kolbrener M, Mayer PV, Tohen M, Strakowski SM, Castillo J, Suppes T, Cohen BM: Neurological factors predict a favorable valproate response in bipolar and schizoaffective disorder. J Clin Psychopharm 1994:14:311-313.
37. Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF: A double-blind trial of buproprion vs. desipramine for bipolar depression. J Clin Psych 1994:55:391-393.
38. Tohen M. Application of pharmacoepidemiology in psychiatry. Harvard Rev Psych 1994:2:117-118.
39. Weiss MK, Tohen M, Zarate C, Iversen A: Diagnosis and management of bipolar II disorder. Comp Ther 1994:20:121-124.
40. Renshaw PF, Yurgelun-Todd DA, Tohen M, Gruber S, Cohen BS. Temporal lobe proton magnetic resonance spectroscopy of first-episode psychosis. Am J Psych 1995:152:444-446.
41. Tohen M, Castillo J, Baldessarini RJ, Kando JC, Zarate C. Blood dyscrasias with carbamazepine and valproate: A pharmacoepidemiological study of 2,228 cases at risk. Am J Psych 1995:152:413-418.
42. Zarate CA, Tohen M, Banov M, Harris MK, Cole JO. Is Clozapine a mood stabilizer? J Clin Psych 1995:56:108-112.
43. Zarate CA, Tohen M, Baraibar G, Kando J, Mirin S. Prescribing trends of antidepressants in bipolar depression. J Clin Psych 1995 Jun;56(6):260-264.
44. Zarate CA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psych 1995 Sep;56(9):411-417.
45. Popli AP, Kando JC, Pillay SS, Tohen M, Cole JO. Occurrence of seizures related to psychotropic medication among psychiatric inpatients. Psych Serv 1995 May;46(5):486-488.
46. Tohen M. The adverse effect profile and safety of divalproex. Rev Contemp Pharmaco Ther 1995:6:564-595.
47. Kirkpatrick B, Amador XF, Flaum M, Yale SA, Gorman JM, Carpenter WT, Tohen M, McGlashan T. The deficit syndrome in the DSM-IV field trial: I. Alcohol and other drug abuse. Schizophr Res. 1996 May;20(1-2):69-77.
48. Kirkpatrick B, Amador XF, Yale SA, Bustillo JR, Buchanan RW, Tohen M. The deficit syndrome in the DSM-IV trial II. Depressive episodes and persecutory beliefs. Schizophr Res 1996 May;20(1-2):79-90.
49. Zarate CA, Kando JK, Tohen M, Weiss MK, Cole JO. Does intolerance or lack of response with fluoxetine predict the same will happen with Sertindole? J Clin Psych 1996 Feb;57:67-71.
50. Tohen M, Zarate C, Centorrino F, Hegarty JD, Froeshl M, Zarate SB. Risperidone in the treatment of mania. J Clin Psych 1996:57:249-253.
51. Kando JC, Tohen M, Castillo J, Zarate C. The use of valproate in an elderly population with affective symptoms. J Clin Psych 1996 Jun;57(6):238-40.
52. Tohen M, Zarate C, Zarate SB, Pike S. The McLean/Harvard first-episode study: Pharmacological treatment & outcome. Psych Annals 1996:S26:5444-5448.
53. Strakowski S, Flaum M, Amador X, Bracha HS, Pandurangi AK, Robinson D, Tohen M. Racial differences in the diagnosis of psychosis. Schizophr Res. 1996 Aug 23;21(2):117-124.
54. Viguera AC, Baldessarini RJ, Hegarty JD, Van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psych 1997 Jan;54:49-55.
55. Zarate CA, Tohen M, Zarate SB. Thyroid function tests in first-episode bipolar disorder manic and mixed types. Biol Psych 1997 Aug 15;42(4):302-304.
56. Zarate CA, Baldessarini RJ, Siegel AJ, Nakamura A, Muir-Hutchinson LA, McDonald J, Cherkerzian T, Tohen M. Risperidone in the elderly: A pharmacoepidemiologic study. J Clin Psych 1997 Jul;58(7):311-317.
57. Zarate CA, Tohen M, Baraibar G. Combined valproate or carbamazepine and electroconvulsive therapy. Annals Clin Psych 1997 Mar;9(1):19-25.
58. Revicki DA, Tohen M, Gyulai L, Thompson C, Pike S, Davis-Vogel A, Zarate C. Telephone versus in-person clinical and health status assessment interviews in patients with bipolar disorder. Harvard Rev Psych 1997 Jul-Aug;5(2):75-81.
59. Lyons MJ, Tyrer P, Gunderson J, Tohen M. Hueristic models of comorbidity of Axis I and Axis II disorders. J. Personal Disord, Fall 1997, 11 (3) p260-269.
60. Tyrer P: Gunderson J, Lyons M, Tohen M. Extent of comorbidity between mental state and personality disorders (comment). St. Charles Hospital, London, UK. J Personal Disord 1997 Fall;11(3):242-259.
61. Kwon JS, Shenton ME, Hirayasu Y, Salisbury DF, Fischer IA, Dicket CC, Yurgelun-Todd D, Tohen M, Kokonis R, Jolesz FA, McCarley RW. MRI Study of cavum septi pellucidi in schizophrenia affective disorder, and schizotypal personality disorder. Am J Psych 1998 Apr;155(4):509-515.
62. Hirayasu Y, Shenton ME, Salisbury DF, Dicket CC, Fischer IA, Mazzoni P, Kisler T, Arakaki H, Kwon JS, Anderson JE, Yurgelun-Todd D, Tohen M, McCarley RW. Lower left temporal lobe MRI volumes in patients with first-episode schizophrenia compared with psychotic patients with first-episode affective disorder and normal subjects. Am J Psych 1998:155:10:1384-1391.
63. Stromberg D, Ronningstam E, Gunderson J, Tohen M. Brief Communication: Pathological narcissism in bipolar disorder patients. J Personal Disord 1998 Summer;12(2):179-185.
64. Tohen M, Zarate C. Jr. Antipsychotics agents and bipolar disorder. J Clin Psych 1998;59 Suppl 1:38-48;discussion 49.
65. Weiss RD, Greenfield SF, Najavits LM, Soto JA, Wyner D, Tohen M, Griffin ML. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psych 1998 Apr;59(4):172-174.
66. Kinney D, Yurgelun T, Tohen M, Tramer S. Pre- and perinatal complications and risk for bipolar disorder: A retrospective study. J Affect Disord 1998 Sep;50(2-3):117-124.
67. Tondo L, Baldessarini RJ, Hennen J, Floris G, Silvetti F, Tohen M. Lithium Treatment reduces risk of suicidal behavior in bipolar disorder patients. J Clin Psych 1998:59:1-10.
68. Tohen M, Greenfield SF, Weiss RD, Zarate CA, Vagge L. The effect of comorbid substance use disorders on the course of bipolar disorder: Harvard Rev Psych 1998 Sep-Oct;6(3):133-141.
69. Zarate CA, Narendran R, Tohen M, Greaney JJ, Berman A, Pike S, Madrid A. Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psych, 1998 Jan;59(1):24-28.
70. Salisbury DF, Shelton ME, Sherwood AR, Fischer IA, Yurgelun-Todd DA, Tohen M, McCarley RW. First-episode schizophrenic psychosis differs from first-episode affective psychosis and controls in p300 amplitude over left temporal lobe. Arch Gen Psych 1998 Feb;55(2):173-180.
71. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr., Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psych, 1999 Jan;156(1):79-87.
72. Tohen M, Grundy S. Management of acute mania. J Clin Psych 1999;60 Suppl 5:31-4; discussion 35-36.
73. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KNR, David GD, Petty F, Centorrino F, Wang R, Grundy S, Greaney M, Jacobs T, David S, Toma V. Olanzapine versus placebo in the treatment of acute mania. Am J Psych 1999 May;156(5):702-709.
74. Tohen M, Hennen J, Zarate C, Baldessarini R, Strakowski S, Stoll A, Faedda G, Suppes T, Gebre-Medhin P, Cohen B. The McLean/Harvard First Episode Project: Two-year syndromal and functional recovery in 219 cases of major affective disorders with psychotic features. Am J Psych 2000 Feb;157(2):220-228.
75. Tohen M, Sanger T M, Feldman P, Breier A. Gender differences in responses to treatment in first-episode psychosis: Olanzapine versus haloperidol. Special Report. Essential Psychopharm 2000:(3):37-49.
76. Zarate Ca Jr, Tohen M. Antipsychotic drug treatment in first-episode mania. A six-month longitudinal study. J Clin Psych 2000 Jan;61(1):33-38.
77. Street JS, Tollefson GD, Tohen M, Sanger TM, Clark WS, Gannon KS, Hanxin W. Olanzapine for psychotic conditions in the elderly. Psych Annals 2000:30:3.
78. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, Tollefson GD, Breier A. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. Arch Gen Psych 2000 Sep;57(9):841-849.
79. Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, Chang HJ, Zarate CA Jr, Poesner J, Lee H, Richards J, Cole JO, Schatzberg AF. Clozapine in the treatment of refractory psychotic mania. Am J Psych 2000 Jun;157(6):982-986.
80. Zarate CA Jr, Tohen M. Functional impairment and cognition in bipolar disorder. Psychiatric Quarterly, Winter 2000;71(4):309-29.
81. Tohen M, Jacobs T, Feldman P. Onset of action of antipsychotics in the treatment of mania. Bipolar Disord 2000 Sep; 2(3 Pt 2):261-268.
82. Chengappa KNR, Jacobs TG, Sanger TM, Tohen M, Levine J, Thase M, Kupfer DJ. Response to placebo or olanzapine among bipolar I disorder patients experiencing their first manic episode. Bipolar Disord 2000 Dec;2(4):332-335.
83. Street JS, Clark WS, Gannon KS, Sanger TM, Tohen M, Tollefson GD, Wei H. Olanzapine in psychotic conditions in the elderly. Psych Annals 2000:30(3):191-196.
84. Baldessarini R, Tohen M, Tondo L. Maintenance treatment in bipolar disorder (A Commentary). Arch Gen Psych 2000 May ;57(5):490-492.
85. Zarate C A, Jr., Tohen M, Land M L. First-episode schizophreniform disorder comparisons with first-episode schizophrenia. Schiz Res 2000:46(1):31-34.
86. Tohen M, Bromet E, Murphy J, Tsuang M. Psychiatric Epidemiology. Harvard Rev Psych 2000 Sep;8(3):111-125.
87. Tohen M, Zhang F, Taylor C, Burns P, Zarate C, Sanger T, Tollefson G. A meta-analytic study of the use of typical antipsychotic agents in bipolar disorders. J Affect Disord 2001:65:85-93.
88. Tohen M, Strakowski SM, Zarate C Jr, Hennen J, Stoll A, Suppes T, Faedda GL, Cohen BM, Gebre-Medhin P, Baldessarini RJ. The McLean-Harvard First-Episode Project: six-month symptomatic and functional outcome in affective and non-affective psychosis. Biol Psych 2000 Sep 15;48(6):467-476.
89. Vieta E, Reinares M, Corbella B, Benabarre A, Gilaberta I, Colom F, Martinez-Aran A, Gasto C, Tohen M. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharm 2001 Oct;21(5):469-473.
90. Lim PZ, Tunis SL, Edell WS, Greenwood KL, Tohen M. Medication prescribing patterns for adult and geriatric inpatients with bipolar disorder. Bipolar Disord 2001 Aug;3(4):165-173.
91. Zarate CA, Tohen M, Fletcher K. Cycling into depression from a first-episode of mania. Am J Psych 2001 Sept;158(9):1524-1526.
92. Gonzalez-Pinto A, Laluguna B, Mosquera F, Perez de Heredia J L, Gutierrez M, Excurra J, Gilaberte I, Tohen M. Use of olanzapine in dysphoric mania. J Affec Disord 2001 Oct;66(2-3):247-253.
93. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY. A novel augmentation strategy for treating resistant major depression. Am J Psych 2001 Jan;158(1):131-134.
94. Sanger T, Grundy S, Gilbon PJ, Namjoshi M, Greaney M, Tohen M. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psych 2001 Apr;62(4):273-281.
95. Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, Koch K, Rizk R, Walker D, Tran PV, Breier A. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharm 2001 Aug;21(4):389-397.
96. Silva CJ, Mazzotti AN, Gattaz W, Ospina J, Larach V, Starkein S, Oliva D, Cousins L, Tohen M, Taylor C, Wang J, Tran P. Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: Results of a multicenter, collaborative trial in Latin America. J Clin Psychopharm 2001 Aug;21(4):375-381.
97. Lim PZ, Tunis SL, Edell WS, Jensik SE, Tohen M. Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. Bipolar Disord 2001:3(4):165-173.
98. Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs T, Toma V, Rater M, Tarazi R, Kim G, Garfield SB, Sohma M, Gonzalez-Heydrich J, Risser R, Nowlin Z. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adol Psychopharm 2001 Fall;11(3):239-250.
99. Tohen M, Zhang F, Keck PE, Feldman PD, Risser RC, Tran PV, Breier A. Olanzapine vs. Haloperidol in schizoaffective disorder, bipolar type. J Affec Disord 2001 Dec;67(1-3):133-140.
100. Tohen M, Chengappa R, Suppes T, Zarate C, Calabrese J, Bowden C, Sachs G, Kupfer D, Baker R, Risser R, Keeter E, Feldman P, Tollefson G, Breier A. Efficacy of Olanzapine in Combination With Valproate or Lithium in the Treatment of Mania in Patients Partially Nonresponsive to Valproate or Lithium Monotherapy. Arch Gen Psych, Vol. 59, Jan. 2002, 62-69.
101. Baker RW, Goldberg JF, Tohen M, Milton D, Stauffer V, Schuh L. The impact of response to previous mood stabilizer therapy on response to olanzapine vs. Placebo for acute mania. Bipolar Disord 2002 Feb;4(1):43-49.
102. Tohen M: Baker RW: Altshuler LA: Zarate CA: Suppes T: Ketter TA: Milton DR: Risser R: Gilmore JA: Breier A: Tollefson GA: Olanzapine versus divalproex for the treatment of acute mania. Am J Psych 2002 Jun;159(6):1011-1017.
103. Keck PE, McElroy SL, Richtand N, Tohen M. What makes a drug a primary mood stabilizer? Molecular Psych 2002;7 Suppl 1:S8-14.
104. McCarley RW, Salisbury DF, Hirayasu Y, Yurgelun-odd DA, Tohen M, Zarate C, Kikinis R, Jolesz FA, Shenton ME. Association between smaller left posterior superior temporal gyurs volume on magnetic resonance imaging and smaller left temporal p300 amplitude in first-episode schizophrenia. Arch Gen Psych 2002 Apr;59(4):321-331.
105. Gonzalez-Pinto A, Tohen M, Lalaguna B, Perez-Heredia JL, Fernandez-Corres B, Gutierrez M, Mico JA. Treatment of bipolar I rapid cycling patients during dysphoric mania with olanzapine. J Clin Psychopharm 2002 Oct;22(5):450-454.
106. Namjoshi MA, Rajamannar G, Jacobs T, Sanger TM, Risser R, Tohen MF, Breier A, Keck PE. Economic, clinical, and quality-of-life outcomes associated with Olanzapine treatment in mania: Results from a randomized controlled trial. J Affec Disord 2002 May;69(1-3):109-118.
107. Russo P, Smith MW, Dirani R, Namjoshi M, Tohen M. Pharmacotherapy patterns in the treatment of bipolar disorder. Bipolar Disord 2002 Dec;4(6):366-377.
108. Goldstein JM, Cohen LS, Horton NJ, Lee H, Andersen S, Tohen M, Crawford AMK, Tollefson G. Sex differences in clinical response to olanzapine compared with haloperidol. Psych Res. 2002 May 15;110(1):27-37.
109. Shi L, Namjoshi MA, Zhang F, Gandhi G, Edgell ET, Tohen M, Breier A, Haro JM. Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. Intl Clin Psychopharm 2002 Sep;17(5):227-237.
110. Sanger TS, Tohen M, Eduard Vieta E, Dunner DL, Bowden C, Calabrese J, Feldman PD, Jacobs TG and Breier A: Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. J Affec Disord 2003 Jan;73(1-2):155-161.
111. Baker RW, Milton DR, Stauffer VL, Gelenberg A, Tohen M. Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania. J Affec Disord 2003 Jan;73(1-2):147-153.
112. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E, Baker RW. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psych July 2003:160(7):1263-1271.
113. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Harkins KA, Hoffman R, Lindborg S, Tohen M, Breier A. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis: I. Study rationale and design, Schiz Res, 2003 May 1;61(1):7-18.
114. Chengappa KNR, Baker RW, Shao L, Yatham LN, Tohen M, Gershon S, Kupfer DJ. Rates of response, euthymia and remission in two placebo-controlled Olanzapine trials for bipolar mania. Bipolar Disord 2003 Feb;5(1):1-5.
115. DelBello MP, Carlson GA, Tohen M, Bromet EJ, Schwiers M, Strakowski SM. Rates and predictors of developing a manic or hypomanic episode 1 to 2 years following a first hospitalization for major depression with psychotic features. J Child Adol Psychopharm 2003 Summer;13:173-185.
116. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM, HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J of Psych 2003 Aug;160(8):1396-1404.
117. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psych 2003 Nov;60(11):1079-1088.
118. Baker RW, Tohen M, Fawcett J, Risser RC, Schuh LM, Brown E, Stauffer VL, Shao L, Tollefson GD. Acute dysphoric mania: treatment response to olanzapine compared to placebo. J Clin Psychopharm 2003 Apr;23(2):132-137.
119. Tohen M, Zarate CA, Hennen J, Khalsa HMK, Strakowski SM, Gebre-Medhin P, Salvatore P, Baldessarini RJ. The McLean-Harvard first-episode mania study: Prediction of recovery and first recurrence. Am J Psych 2003 Dec;160(12):2099-2107.
120. Baldessarini RJ, Hennen J, Wilson M, Calabrese J, Chengappa R, Keck PE, McElroy SL, Sachs G, Vieta E, Welge J, Yatham L, Zarate CA, Baker RW, Tohen M. Olanzapine versus placebo in acute mania - treatment responses in subgroups. J Clin Psychopharm 2003 Aug;23(4): 370-376.
121. Tohen M, Zhang F, Gonzalez-Pinto AM, Azorin JM, Vieta E, Hardy-Bayle MC, Goldberg JF, Lawson WP, Emsley RA, Baker RW, Risser RC, Namjoshi MA, Evans AR, Breier A. A 12-week double-blind comparison of olanzapine versus haloperidol in the treatment of acute mania. Arch Gen Psych 2003:60:1218-1226.
122. Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psych. 2003 Aug 15; 54(4), 453-464.
123. Zarate CA Jr, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psych 2004; 161 Jan;26(1):169-171.
124. Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS, and the HGDH Research Group. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 2004 Feb 1;66(2-3):125-135.
125. Shi L, Namjoshi M, Swindle R, Yu X, Risser R, Baker RW, Tohen M. Effects of olanzapine alone and olanzapine/fluoxetine combination (OFC) on health-related quality of life in patients with bipolar depression: Secondary analysis of a double blind, placebo-controlled trial. Clin Thera 2004 Jan;26(1): 125-134.
126. Tohen M, Chengappa KNR, Suppes T, Baker RW, Zarate CA Jr, Bowden CL, Sachs GS, Kupfer DJ, Feldman PD, Risser RC, Evans AR, Calabrese JR. Prevention of relapse in bipolar disorder with olanzapine in combination with lithium or valproate compared to lithium or valproate monotherapy: an 18-month study. Br J Psych 2004 Apr;184:337-345
127. Lindenmayer JP, Brown E, Baker RW, Schuh LM, Shao L, Tohen M, Ahmed A, Stauffer V. A mania-like symptom subscale from the positive and negative syndrome scale. Schiz Res. 2004 Jun 1;68(2-3):331-337.
128. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of Olanzapine and Olanzapine/fluoxetine in combination in the treatment of bipolar I depression. Arch Gen Psych., 2003;60(11):1079-1088. Erratum in 2004; 61(2): 176.
129. Keefe RSE, Seidman LJ, Christensen BK, Hammer RM, Sharma T, Sitskoorn MM, Lewine RRJ, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA and the HGDH Research Group. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized double-blind trial of olanzapine versus haloperidol. Am J Psych. 2004 Jun;161(6):985-995.
130. Namjoshi MA, Risser R, Shi L, Tohen M. Breier A. Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. J Affect Disord. 81 (2004) 223-229.
131. Vieta E, Calabrese JR, Hennen J, Colom F, Martinez-Aran A, Sanchez-Moreno J, Yatham LN, Tohen M, Baldessarini RJ. Comparison of Rapid-Cycling and Non-Rapid-Cycling Bipolar I Manic Patients During Treatment With Olanzapine: Analysis of Pooled Data. J Clin Psych, 2004 Oct;65(10): 1420-1428.
132. Baker RW, Brown E, Akiskal HS, Calabrese JR, Ketter TA, Schuh LM, Trzepacz PT, Watkin JG, Tohen M. Efficacy of Olanzapine Combined with Valproate or Lithium in the Treatment of Acute Dysphoric Mania. Br J Psychiatry. Br J
Psych 2004 Dec;185:472-478.
133. Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Rock SL, Woolson S, Tohen M, Tollefson GD, Sanger TM, Lieberman JA. For the HGDH Research Group. Two-year Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis. Biol Psych. 2005 Sep1.
134. Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, Sanger TM, Tollefson GD. A double-blind randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharm 2004 Aug;24(4):365-373.
135. Perkins DO, Lieberman JA, Gu H, Tohen M, McEvoy J, Green AI, Zipursky RB, Strakowski SM, Sharma T, Kahn RS, Gur R, Tollefson G, and the HGDH Research Group. Predictors of antipsychotic treatment response in patients with first episode schizophrenia, schizoaffective, and schizophreniform disorders. Br J Psych, 2004 Jul; 185:18-24.
136. Namjoshi MA, Risser R, Shi L, Tohen M, Breier A. Quality of life assessment in patients with bipolar disorder treated with Olanzapine added to lithium or valproaic acid. J Affect Disord, 2004 Sep;81(3):223-229.
137. Baldessarini R, Perlis R, Sachs GS, Tohen M. Weight gain during treatment of Bipolar I patients with olanzapine. J Clin Psych. 2004; 65:1679-1687.
138. Baker RW, Brown E, Akiskal HS, Calabrese JR, Ketter TA, Schuh LM, Trzepacz PT, Watkin JG, Tohen M. Efficacy of Olanzapine Combined with Valproate or Lithium in the Treatment of Acute Dysphoric Mania. Br J Psychiatry 2004; 185:472-478.
139. Shi Lizheng, Tohen Mauricio. Quality of Life and Economics of Bipolar Disorder. Trends in Bipolar Disorder Research, 2004; 161-193.
140. Hennen John, Perlis, Tohen M, Sachs, Baldessarini. Weight Gain During Treatment of Bipolar I Patients with Olanzapine. J Clin Psychiatry 2004 Dec;65(12):1679-1687.
141. Chengappa KNR, Hennen J, Baldessarini RJ, Kupfer DJ, Yatham LN, Gershon S, Baker RW, Tohen M. Recovery and functional outcomes following olanzapine treatment for bipolar I mania. Bipolar Disord 2005 Feb;7(1):68-76.
142. Zhu B, Tunis SL, Zhao Z, Baker RW, Lage MJ, Shi L, Tohen M. Service utilization and costs of Olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial. Curr Med Res Opin. 2005 Apr; 21(4):555-564.
143. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn R, Keefe RSE, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Hkongbin G, Tohen M. Antipsychotic Drug Effects on Brain Morphology in First-Episode Psychosis, Arch Gen Psych 2005 Apr;62(4):361-370.
144. Baethge C, Baldessarini RJ, Khalso H-M K, Hennen J, Salvatore P, Tohen M. Substance Abuse in First-Episode Bipolar I Disorder: Indications for Early Intervention. Am J Psych 2005 May;162(5):1008-1010.
145. Keck P, Corya SA, Altshuler LL, Ketter TA, McElroy SL, Case M, Briggs SD, Tohen M. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination for bipolar depression. J Clin Psych 2005 May;66(5):611-616.
146. Tohen M, Greil W, Calabrese J, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL. Olanzapine Versus Lithium in the Maintenance Treatment of Bipolar Disorder: A 12-Month, Randomized, Double-Blind, Controlled Clinical Trial. Am J Psych 2005 Jul;162(7):1281-1290.
147. Suppes T, Brown E, Schuh LM, Baker RW, Tohen M. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: Post hoc analyses of 47-week data. J Affect Disord 2005 Dec;89 (1-3):69-77.
148. Baker RW, Schuh LM, Tohen M. The use of atypical antipsychotic agents in the treatment of diagnostic subgroups of bipolar disorder: mixed and pure states, psychotic and non-psychotic. Bipolar Disord, 353-368. 2005.
149. Cavazzoni PA, Berg PH, Kryzhanovskaya LA, Briggs SD, Roddy TE, Tohen M, Kane JM. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psych 2006 67(1):107-113.
150. Brown E, McElroy SL, Keck PE, Deldar A, Adams DH, Tohen M, Williamson DJ. A seven-week randomized double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I Depression. J Clin Psych 2006;67: 1025-1033.
151. Williamson D, Brown E, Perlis R, Ahl J, Baker R, Tohen M. Clinical relevance of depressive symptom improvement in bipolar I depressed patients. J Affect Disord 92 (2006) 261-266.
152. Ketter TA, Houston JP, Adams DH, Risser RC, Meyers A, Williamson DJ, Tohen M. Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. J Clin Psych January 2006; 67:95-101.
153. Tohen M, Calabrese JR, Sachs GS, Banov M, Detke H, Risser R, Baker RW, Chou James C.-Y., Bowden C. Randomized, Placebo-Controlled Trial of Olanzapine as Maintenance Therapy in Patients With Bipolar I Disorder Responding to Acute Treatment With Olanzapine. Am J Psych163:2, 247-256, February 2006.
154. McGlashan T, Zipursky R, Perkins D, Addington J, Miller T, Woods S, Hawkins K, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. Am J Psych 163 (5), May 2006.
155. Shi L, Juarez R, Hackworth J, Edgell ET, Haro JM, Vieta E, Tohen M. Open-label olanzapine treatment in bipolar I disorder: clinical and work functional outcomes. Curr Med Res Opin, 22(5):961-966, May 2006.
156. Corya S, Perlis R, Keck P, Lin D, Case M, Williamson D, Tohen M. A 24-Week Open-Label Extension Study of Olanzapine-Fluoxetine Combination and Olanzapine Monotherapy in the Treatment of Bipolar Depression. J Clin Psych May 2006, 5: 798-806.
157. Houston J, Ahl J, Meyers AL, Kaiser CJ, Tohen M, Baldessarini RJ. Reduced Suicidal Ideation in Bipolar I Disorder Mixed-Episode Patients in a Placebo-Controlled Trial of Olanzapine Combined With Lithium or Divalproex. J Clin Psychiatry 67:8, 1246-1252, August 2006.
158. Green A, Lieberman J, Hamer R, Glick I, Gur R, Kahn R, McEvoy J, Perkins D, Rothschild A, Sharma T, Tohen M, Woolson S, Zipursky R, The HGDH Study Group. Olanzapine and Haloperidol in First Episode Psychosis: Two-Year Data. Schizophr Res, 86(1-3):234.43, September 2006.
159. McEvoy J, Johnson J, Perkins D, Lieberman J, Hamer R, Keefe R, Tohen M, Glick I, Sharma T. Insight in First Episode Psychosis. Psychol Med, 36(10): 1385-1393, October 2006.
160. Perlis R, Baker R, Zarate C, Brown E, Schuh L, Jamal H, Tohen M. Olanzapine Vs. Risperidone in the Treatment of Manic or Mixed States in Bipolar I Disorder: a Randomized, Double-Blind Trial. J Clin Psych;67(11):1747-1753, Nov. 2006
161. Tohen M, Bowden C, Calabrese J L, Lin D, Forrester T, Sachs G S, Koukopoulos A, Yatham L, Grunze H. Influence of Subsyndromal Symptoms After Remission From Manic or Mixed Episodes. Br J Psych, 189:515-519, December 2006.
162. Paul S, Tohen M. Conflicts of interest and the credibility of psychiatric research. World Psychiatry, Vol. 6, #1, 33-34, Feb. 2007.
163. Goetz I, Tohen M, Reed C, Lorenzo M, Vieta E. Functional impairment in patients with mania: baseline results of the EMBLEM study. Bipolar Disord, 45-52, February and March, 2007.
164. Rosso IM, Killgore DS, Clintron CM, Gruber SA, Tohen M, Yurgulen-Todd DA. Reduced Amygdala Volumes in First Episode Bipolar Disorder and Correlation with Cerebral White Matter. Biol Psych; 15;61(6): 743-749, March 2007
165. Tamayo JM, Mazzotti G, Tohen M, Zapata R, Castillo JJ, Fahrer RD, Gonzalez-Pinto AM, Vieta E, Azorin JM, Brown E, Brunner E, Rovner J, Baker RW. Treatment of Latino Patients with Acute Mania: Outcomes for Latinos Compared to Caucasians in a Randomized, Double-Blind Trial of Olanzapine versus Haloperidol. J Clin Psychopharmacol, Vol. 27, #2, 126-134, April 2007.
166. Salvatore P, Khalsa HMK, Hennen J, Tohen M, Yurgelun-Todd D, Casolari F, DePanfilis C, Maggini C, Baldessarini RJ. Psychopathology factors in first-episode affective and non-affective psychotic disorders. J Psych Res;41(9):724-736, November 2007; Epub 2006 June 9.
167. Salvatore P, Tohen M, Kaur Khalsa HM, Baethge C, Tondo L, Baldessarini R. Longitudinal research on bipolar disorders. Epidemiologia e Psichiatria Sociale, 16, 2, 2007.
168. Tohen M. Collaborations between academic psychiatry and the pharmaceutical industry: A perspective from industry. Epidemiologia e Psichiatria Sociale, 16,3,197-198, 2007.
169. Dube S, GD, Thase ME, Briggs SD, Van Campen LE, Case M, Tohen M. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord, 2007, 9:618-627.
170. Baldessarini R, Tondo L, Tohen M, Strombom I, Dominguez S, Fawcett J, Licinio J, Oquendo M, Tollefson G, Valuck R. Ecological Studies of Antidepressants and Suicidal Risks", Harvard Review of Psychiatry 2007; 15:133-145.
171. Montoya A, Perez J, Gilaberte I, Gonzalez-Pinto A, Haro J, Vieta E, Tohen M. Patterns of drug treatment for manic episode in the clin. practice. Outcomes of the Spanish sample in the EMBLEM study. Actas Esp Psiquiatr. 2007 June 27.
172. Tohen M, Kryzhanovskaya L, Carlson G, DelBello M, Wozniak J, Kowatch R, Wagner K, Findling R, Lin D, Robertson-Plouch C, Xu W, Dittmann R.W., Biederman J. Olanzapine vs. Placebo in the Treatment of Adolescents with Bipolar Mania. Am J Psych, 164:10, October 2007.
173. Hoffman RE, Woods SW, Hawkins K, Pittman B, Tohen M, Preda A, Breier A, Glist J, Addington J, Perkins DO, McGlashan TH. Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population. Br J Psych, 191, 355-356, 10-1192, bjp.bp.106.031195.
174. Niufan G, Tohen M, Quiqing A, Fude Y, Pope E, McElroy H, Ming L, Gaohua W, Xinbao Z, Huichun L, Liang S. Olanzapine versus Lithium in the Acute Treatment of Bipolar Mania: A double-blind, randomized, controlled trial. J Affect Disord, Vol. 105, 1-3, 2007, 101-108.
175. Tohen M, Calabrese J, Vieta E, Bowden C, Gonzaliz-Pinto A, Lin D, Xu W, Corya S. Effect of Comorbid Anxiety on Treatment Response in Bipolar Depression. J Affect Disord., 104 (2007) 137-146.
176. Berk M, Malhi GS, Cahill C, Carman AC, Hadzi-Pavolvic D, Hawkins MT, Tohen M, Mitchell PB. The Bipolar Depression Rating Scale (BDRS): its development, validation and utility. Bipolar Disord 2007:
177. Khalsa HM, Salvatore P, Baethge C, Hennen J, Tohen M, Baldessarini R. Suicidal Events and Accidents in 216 First-Episode Bipolar I Disorder Patients: Predictive Factors. J Affect Disord, 106 (2008), 179-184.
178. Berk M, Ng F, Wang W, Tohen M, Lubman DI, Vieta E, Dodd S. Going up in smoke: Tobacco smoking is associated with worse treatment outcomes in mania. J Affect Disord, July 2008, pp. 126-134.
179. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive Dyskinesia and the 3-Year course of Schizophrenia: Results From a Large, Prospective, Naturalistic Study. J Clin Psych, 2008, e1-e9.
180. Tohen M. Need for Better Understanding of and Approach to Bipolar Disorder. The Mainichi Medical Journal, July 2008, Vol. 4, No. 7, pp. 541-628.
181. Vieta E, Panicali F, Goetz I, Reed C, Comes M, Tohen M for the EMBLEM Advisory Board. Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study. J Affect Disord 106 (2008) 63-72.
182. Tohen M, Bowden CL, Smulevich AB, Bergstrom R, Quinlan T, Osuntokun O, Wang WV, Oliff HS, Martenyi F, Kryzhanovskaya LA, Greil W Combination of olanzapine and carbamazepine compared with carbamazepine alone in treating manic episodes. B. J. Psychiatry, 2008 Feb;192(2):135-43.
183. Tohen M. Clinical Trials in Bipolar Mania: Implications in Study Design and Drug Development. Arch Gen Psych., Mar 2008; 65: 252 - 253.
184. Berk M, Ng F, Wang W, Calabrese J, Mitchel PS, Malhi GS, Tohen M. The empirical redefinition of the psychometric criteria for remission in bipolar disorder. J Affect Disord, In Press.
185. Karagianis J, Ascher-Svanum H, Citrome L, Silva De Lima M, Rosenbluth M, Tohen M, Treuer T, Heimberger S, Yepez E, Pennachio D. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Current Medical Research and Opinion. In Press.
186. Tohen M, Vieta E, Goodwin G, Sun B, Amsterdam J, Banov M, Shekhar A, Aaronson S, Bardenstein L, Grecu I, Tochilov V, Prelipceanu D, Oliff H, Kryzhanovskaya L, Bowden C. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: A randomized, 12-week, double-blind study. J Clin Psych, In Press.
187. P Salvatore, R J Baldessarini, Tohen M, H-M K Khalsa, J Perez Sanchez-Toledo, C A Zarate Jr, E Vieta, C Maggini. Two-year Stability of DSM-IV Diagnoses in 500 First-Episode Psychotic Disorder Patients. Journal of Clinical Psychiatry 2008, In Press.
188. Thompson PM, Bartzokis G, Hayashi KM, Klunder AD, Lu PH, Edwards N, Hong MS, Yu M, Geaga JA, Toga AW, Charles C, Perkins DO, McEvoy J, Hamer RM, Tohen M, Tollefson GD, Lieberman JA, for the HGDH Study Group (2008). Time-Lapse Mapping Reveals Different Disease Trajectories in Schizophrenia depending on Antipsychotic Treatment, Cerebral Cortex, in press, July 31 2008.
REVIEWS & BOOK CHAPTERS
1. Jonas JM, Pope HG, Hudson JI, Cohen BM, Tohen M. Psychosis in borderline personality disorders. In: Shagass C, Josiassen RC, Bridger WH, eds. Biol Psych Development in Psychiatry, Vole 7. New York: Elsevier, 1985:571 573.
2. Vuckovic A, Tohen M. Schizophrenia. A brief overview of current research and future directions. In: Mirin SM, ed. Current research in private psychiatric hospitals. Washington DC: The Education and Research Foundation of the National Association of Private Psychiatric Hospitals, 1987:13 23.
3. Tsuang MT, Tohen M, Murphy JM. Psychiatric Epidemiology. In: Nicholi A, ed. The New Harvard Guide to Modern Psychiatry. Cambridge: Harvard University Press 1988:761 779.
4. Baldessarini RJ, Tohen M. Is there a long-term protective effect of mood altering agents in unipolar depressive disorder? In: Casey DE, Christensen AV, eds. Current Trends in Psychopharmacology. Heidelberg: Springer Verlag 1988:131 139.
5. Tohen M. Course and treatment outcome in patients with mania. In Mirin SM, Gossett JT, Grob MC, eds. Psychiatric Treatment. Advances in Outcome Research, Washington, D.C. American Psychiatric Association Press 1991:127 142.
6. Tohen M. Arguments made for chronic mania as nosological entity. The Psychiatric Times 1991:7:15 18.
7. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania, digest of neurology and psychiatry, (Webb WZ, editor). Series 59:82, March April, 1991. The Institute of Living, Hartford, CT.
8. 188. Shulman K, Tohen M, Satlin A. The significance of mania in old age. Reviews in Clin Gerontology 1992:2:39 43.
9. Tohen M. Bias and other methodological issues in follow up (cohort) studies. Fava M, Rosenbaum G. eds. Research designs and methods in psychiatry, Amsterdam. Elsevier: 1992:119 125.
10. Shulman KI, Tohen M, Satlin A. Mania revisited. In: Arie T, ed. Recent Advances in Psychogeriatrics (II) London: Churchill Livingstone 1992:71 79.
11. Tohen M. The prognosis of bipolar disorder: Recent findings and informed speculation. Currents in Affective Disorders 1993:12:5-13.
12. Zarate CA and Tohen M. Diagnosis and management of bipolar depression. Clinical Advances in the Treatment of Psychotic Disorders 1994:8:4-7.
13. Tohen M, Goodwin FK. Epidemiology of bipolar disorder in textbook in psychiatric epidemiology. Tsuang, Tohen, Zahner (eds), John Wiley & Sons, NY, NY 1995.
14. Greenfield SF, Weiss RD, Tohen M. Substance abuse and the chronically mentally ill: A description of dual diagnosis treatment services in a psychiatric hospital. Comm Mental Health J 1995Jun;31(3):265-77.
15. Tohen M. Bipolar disorder is a life long condition. Paradigm Mag.: Winter 1996.
16. Tohen M, Bromet E. Epidemiology (Chapter 12). In Psychiatry (Tasman, Kay, Lieberman, Eds). Saunders, New York, NY. 1996.
17. Bowden CL, Brady KT, Foster PL, Goodwin FK, Tohen M. Current concepts in treating bipolar disorder. J Clin Psych 1996:54(4):(suppl 1):12.
18. Tohen M. Mania in acute psychiatric treatments. Sederer L and Rothchild AJ (eds). Williams and Wilkins, Chicago, IL. 1997.
19. Herz MI, Liberman RP, McGlashan TH, Lieberman JA, Wyatt RJ, Marder SR, Wang P, Allgulander C, Baldessarini RJ, Balon R, Bellack AS, Berlin CM Jr., Blackington CH, Buckley P, Carlson DG, Cott J, Cournos F, Desai P, Dickstein L, Fenton WS, Fisher WA, Flaherty LT, Freedman R, Galanter M, Galton E, Ganguli R, Garrettson LK, Goldfinger S, Goldman LS, Goldstein MZ, Gordy TR, Gray SH, Green MR, Greenberg WM, Gunderson JG, Hall LL, Haller E, Hanin E, Hawkins L, Hester TW, Horn T, Hsiao JK, Juthani NV, Kane JM, Kayser A, Kibel HD, Kimmich RA, Koegler RR, Krajeski J, Kuehnel T, Lamberti JS, Lehman A, Leunello J, Martin RL, McCarley R, McGee M, Meltzer HY, Mesulam M, Metzner JL, Mosher LR, Motto JA, Mueser KT, Munoz RA, Nasrallah HA, Newcomer JW, Opler LA, Peterson GN, Rapaport M, Riba M, Rickert VI, Rifkin A, Riverbark JS, Robertson S, Ruiz P, Ryan WG, Sanderson MO, Schiffer RB, Schyve PM, Sebring RH, Shen WW, Shore D, Simpson GM, Soufi HE, Stein LI, Stotland N, Strauss J, Sundberg D, Svendsen D, Tohen M, Tsuang M, Wagnitz JG, Weiner R, Weitzer WD, Wilkerson LJ, Wingerson D, Zarate CA Jr., Zito J, Zonana HV. Practice guidelines for the treatment of patients with schizophrenia. Am J Psych 1997.
20. Tohen M, Grundy S. Polydipsia, water intoxication and hyponatremia. Psychline 1998:2:32-34.
21. Tohen M, Zarate CA Jr. Bipolar disorders and comorbid substance use disorder. In: Joseph Goldberg, ed. APPI, American Psychiatric Press 1998:187-201.
22. Zarate CA Jr., Tohen M. Carbamazepine. Comprehensive Textbook of Psychiatry/VII. Kaplan HI, Sadock BJ, eds. 7th ed. Williams & Wilkins 1998.
23. Murphy J, Tohen M, Tsuang M. Psychiatric Epidemiology In Harvard Review of Psychiatry, (A Nicolai ed) Harvard University, Cambridge, MA. 1999.
24. Zarate C, Tohen M. Antimanic Drugs: Lithium, Valproate, Carbamazepine and other antiepileptic drugs. Psychopharmacology Treatment of Psychiatric Disorders 1999:164-184.
25. Tohen M, Brunner E, Grundy S. Olanzapina - Un Nuevo Antipsicotico. Acta psicquiatrica y psicologica de America Latina: 1999:45:(4):325-337.
26. Tohen M. Antipsychotics in Acute Mania in Bipolar Affective Disorders. Bipolar disorders: 100 years after manic-depressive insanity. Marneros A, Angst J (editors), Kluwer Academic Publishers, Dordecht, The Netherlands. 2000.
27. Tohen M, Tollefson GD. Use of Antipsychotics in Mania. In Bipolar Medications. Mechanism of Action (Manji, Bellmaker, Bowden, eds.), American Psychiatric Press, Washington, DC. 2000.
28. Zarate CA, Tohen MF. Bipolar disorder and comorbid substance use disorders. Substance abuse in the mentally and physically disabled. Marcel Dekker, Inc. 2001:59-75.
29. Tohen M, Angst J. Epidemiology of Bipolar Disorder, Textbook in Psychiatric Epidemiology, Tohen and Tsuang (eds) Second Edition, 427-444 John Wiley & Sons, NY 2002.
30. Lacerda ALT, Soares JC, Tohen M. O Papel Dos Antipsicoticos Atipicos No Tratamento Do transtorno Bipolar: Revisao De Literatura. Revista Brasileira de Psiquiatria". Rev Bras Psiquiatr 2002:24(1):34-43.
31. Wang PS, Tohen M, Bromet E, Angst J. Psychiatric Epidemiology, Psychiatry, Second Edition, John Wiley & Sons, NY 2003.
32. Tohen M. Antipsychotic-induced EPS in bipolar disorder and schizophrenia. Psych Times 2003:20:54. [Review]
33. Tamayo J, Tohen M. Diferencias Terapeuticas de los Antipsicoticos de Segunda Generacion en el Tratamiento de los Trastornos Bipolares. Actualizaciones en Psiquiatria, Vo. 1, 2003.
34. Tamayo J, Tohen M. Diferencias terapeuticas de los antipsicoticos en el tratamiento de los trastornos bipolares [Therapeutic differences of antipsychotics in the treatment of bipolar disorders]. Revista Argentina de Actualizacion en Psiquiatria (Universidad Nacional de la Plata) 2003; 1:9-15.
35. Tamayo JM, Tohen MF, Zarate C, Vieta E. Medicamentos para los trastornos bipolares: revision de sus diferencias therapeuticas y farmacologicas. Parte I: De los antimaniacos a los eutimizantes [Medications for bipolar disorders: a review of their therapeutic and pharmacologic differences. Part I: From antimaniacs to euthymiants]. Actas Esp Psiquiatr. 2004 Jan;32 Suppl 1:3-17.
36. Tohen M, Marneros A, Bowden C, Baker RW, Williamson D, Evans AR, Cassano G. Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. Acta Psychiat Scand 110:39, Suppl. 423, 2004.
37. Tohen M, Marneros A, Bowden C. Olanzapine for bipolar maintenance treatment using syndromic criteria. Acta Psychiat Scand 110:39, Suppl. 423, 2004.
38. Deldar A, Tohen M, Marneros A. Olanzapine vs. lithium in relapse prevention in bipolar disorder. J Affect Disorders 78:S108-S109 (Suppl 1), 2004.
39. Shi Lizheng, Tohen Mauricio. Quality of Life and Economics of Bipolar Disorder. In Trends in Bipolar Disorder Research, Nova Biomedical Books, N.Y. 2004.
40. Tohen M. Classical Neuroleptics Are Still Relevant for Mania, Con. J Bip Disorders: Reviews/Commentaries 2005; IV, 2.
41. Baker RW, Schuh LM, Tohen M. The use of atypical antipsychotic agents in the treatment of diagnostic subgroups of bipolar disorder: mixed and pure states, psychotic and non-psychotic. Cambridge University Press, N.Y. 2005.
42. Perez Sanchez-Toledo J, Tohen M. Estudio McLean-Harvard de primeros episodios. Prediccion de la recaida y factores asociados a la recuperacion de pacientes con primer episodio maniaco o mixto. In Trastornos Bipolares Vazquez-Barquero JL (editor). Elsvier Masson, Barcelona (Spain). 2005.
43. Dando S, Tohen M. Olanzapine - relapse prevention following mania. J Psychopharmacology March 2006; 20:2, 31-38.
44. Tohen M, Lin D. Commentary on N. Ghaemi's "Hippocratic Psychopharmacology of Bipolar Disorder". Maintenance Treatment in Bipolar Disorder. Psychiatry 2006, Vol. 3, No. 6.
45. Tohen M. Nomenclature in Bipolar Disorder. Clin Approaches in Bipolar Disorders 2006; 5: 35.
46. Tohen M, Campbell G, Lin D. Akiskal H, Tohen M. Editors. Olanzapine in treatment for bipolar disorder. Bipolar Psychopharmacology. John Wiley and Sons, West Sussex, 2006.
47. Tohen M, Lin D. Comment on N. Ghaemi's Hippocratic Psychopharmacology of Bipolar Disorder. Psychiatry 2006, Vol. 3, No. 6.
48. Tohen M, Lin D. Olanzapine as Maintenance Therapy in Patients with Bipolar I Disorder. Neurotherapeutics, Progress in Neurotherapeutics and Neuropsychopharmacology, Cambridge University Press, 2007, Vol. 2, 225-237.
49. Wang PS, Tohen M, Bromet E, Angst J, Kessler RC. In Psychiatric Epidemiology, Psychiatry Tasman A, Kay J, Lieberman J, (eds), In Press.
50. Tohen M. Olanzapine use in bipolar disorder. Actas Esp Psiquiatr 2008: 36 (Suppl. 1): 61-63.
LETTERS AND OTHER PUBLICATIONS
1. Tohen M. Reply to Gordon MA: Carbamazepine associated thrombocytopenia. (letter) J Clin Psych 1992:53:378 379.
2. Stoll AL, Tohen M, Baldessarini RJ. Increasing frequency of obsessive compulsive disorder (reply to letter to editor). Am J Psych 1993:150:682 683.
3. Tohen M. Racial-Differences In Leukocyte Counts - Reply. Am J Psych 1996:153(4):587 ISSN: 0002-953X.
4. Gardner DM, Baldessarini RJ, Benzo J, Zarate CA, Tohen M. Switching between clozapine and risperidone treatment. The Canadian J Psych 1997 May;42(4):430-431.
5. Tohen M. Manic illness drugs: patient responses. The Wall Street Journal, Wednesday, December 20, 2000.
6. Tohen , Risser R, Grundy SL. Reply to "Jagadheesan K. Olanzapine in acute bipolar mania". Arch Gen Psych 2002:59(2):188.
7. Tohen M. Book Review: Understanding Depression: what we know and what you can do about it, by J. Raymond DePaulo, Jr., M.D., and Leslie Alan Horvitz, John Wiley & Sons, 2002:304.
8. Tohen M., Risser R. Reply to "Williams AB and Adetunji BA. Olanzapine and Olanzapine-Fluoxetine Combination Treatment and Bipolar I Depression." Arch Gen Psych 2005:62(9): 1052.
9. Tohen M, Lin D. Reply to: Drs. Alexander Moreira-Almeida and Ricardo Pietrobon. Does Olanzapine Have Any Antidepressant Effect? Amer J of Psychiatry, 2006: Vol. 163 (10).
PROCEEDINGS OF PEER-REVIEWED MEETINGS
1. Schak MR, Lira MA, Cuevas ML, Ruiz JA, Tohen M, Fernandez Cerdeno A. Endocrine and physiologic circadian rhythms in patients with depression. Proceedings of the XVIII Annual Meeting of the Mexican Society of Endocrinology, Acapulco, Gro. MX. December 6 10, 1978.
2. Tohen M, Stancer HC, Persad E, Smith I. Cerebral dominance and affective disorders. Research Day, University of Toronto Department of Psychiatry, Toronto, Ontario, Canada. (Abstract 22) September 11, 1981.
3. Kennedy SM, Persad E, Tohen M, Stancer H. Therapy resistant depression. Proceedings of the 31st Annual Meeting Canadian Psychiatric Association, Winnipeg, Manitoba, Canada. (Abstract 69) September 23 25, 1981.
4. Tohen M, Kennedy SM, Persad E, Stancer HC. Therapy resistant depression. Research Day, University of Toronto Department of Psychiatry, Toronto, Ontario, Canada. (Abstract 2) September 10, 1982.
5. Lipinski JF, Cohen BM, Frankenburg F, Tohen M. An open trial of S Adenosylmethionine for treatment of depression. Clin Neuropharm (7):(Suppl 1). NY: Raven Press 1984:100 101.
6. Lipinski JF, Cohen BM, Tohen M, Frankenburg FR. An open trial of s adenosylmethionine for treatment of depression. Proceedings of the 14 Collegium International Neuro Pharmacologicum Congress, Florence, Italy. (Abstract 53) June 19 23, 1984.
7. Dion GL, Tohen M. Medication, medication management and side effects. National Alliance for the Mentally Ill 1986 Annual convention. Boston, MA. (Abstract 8) July 3 6, 1986.
8. Tohen M. Predictors of Relapse in Bipolar Disorder: A four year follow up. Joint Meeting of NIMH Epidemiology and Statistics Training Programs. Columbia Presbyterian Medical Center, New York, NY. March 2, 1988.
9. Dion GL, Tohen M, Anthony W. Symptom and functional outcome in bipolar disorder. 141st Annual Meeting, American Psychiatric Association. Montreal, Quebec, Canada (Abstract 97) May 7 12, 1988.
10. Tohen M. Outcome in bipolar disorder. Proceedings of the Regional Symposium, World Psychiatric Association, Mexico City, MX. October 17, 1988.
11. Tohen M. Alcoholism and substance abuse as predictors of relapse in bipolar disorder. 116th Annual Meeting, American Public Health Association, Boston, MA. (Abstract 3091) November 13 17, 1988.
12. Tohen M, Waternaux CM, Tsuang MT, Dion GL. Four year follow up of seventy five bipolar disorder patients. 142nd Annual Meeting American Psychiatric Association, San Francisco, CA. (Abstract 141) May 6 11, 1989.
13. Tohen M. Outcome in Mania. Proceedings of the McLean Hospital Research Centennial Celebration, Belmont, MA. November 8, 1989.
14. Tohen M, Waternaux CM, Tsuang MT, Hunt AT. A four year follow up of first episode manic patients. 143rd Annual Meeting, American Psychiatric Association, New York, NY. (Abstract 106) May 12 17, 1990.
15. Tohen M, Waternaux CM, Tsuang MT. Predictors of relapse in mania utilizing survival analysis. 5th Congress of the International Federation of Psychiatric Epidemiology, Montreal, Quebec, Canada. (Abstract 156) June 6 8, 1990:156.
16. Tohen M, Tsuang MT. Psychotic features as predictor of outcome in mania. 40th Annual Meeting Canadian Psychiatric Association, Toronto, Ontario, (Abstract 28) Canada. September 12 15, 1990.
17. Tohen M, Strakowski SM, Stoll AL, Faedda GL, Goodwin DC, Baldessarini RJ. Predictors of Recovery and one year outcome after a first episode of psychosis. Proceedings of the 3rd International Congress on Schiz Res. Tucson, AZ. (Abstract 38) April 21 25, 1991.
18. Shulman K, Tohen M, Satlin A, Mallya G, Kalunian D. Significance of mania in old age: An outcome study. 144th Annual Meeting, American Psychiatric Association, New Orleans, LA. (Abstract 97) May 11 16, 1991.
19. Suppes P, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. 39th Meeting of Boston Society of Neurology and Psychiatry. Boston, MA. May, 1991.
20. Tohen M, Tsuang MT, Goodwin DC. Type of psychotic features and outcome in mania. 144th meeting American Psychiatric Association, New Orleans, LA. (Abstract NR46) May 11 16, 1991.
21. Suppes P, Tohen M, Faedda GL, Baldessarini RJ. Risk of discontinuation of lithium in bipolar disorder. 144th meeting American Psychiatric Association, New Orleans, LA. (Abstract NR 52) May 11 16, 1991.
22. Strakowski SM, Tohen M, Greenfield SM, Faedda GL. Comorbidity in bipolar disorder at first episode. 144th meeting American Psychiatric Association, New Orleans, LA. (Abstract NR 53) May 11 16, 1991.
23. Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM, Waternaux CM. Sequence of episodes predicts response to lithium in bipolar disorders. 144th Mtg., American Psychiatric Association, New Orleans, LA. (Abstract NR 55) May 11-16, 1991.
24. Faedda GL, Tondo L, Tohen M, Flores GF, Baldessarini RJ. Outcome after lithium discontinuation in mood disorders: A Prospective Study. 144th meeting American Psychiatric Association, New Orleans, LA. (Abstract NR 56) May 11 16, 1991.
25. Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM. Sequence of episodes predicts response to lithium in bipolar disorders. Proc. Fifth International Congress of Biol Psych, Florence, Italy, June 1991. (Abstract P 05 28) Biol Psych 1991:29:284(SM).
26. Faedda GL, Tondo L, Tohen M, Floris GF, Baldessarini RJ. Outcome after lithium discontinuation in mood disorders. A prospective study. Proc. Fifth International Congress of Biol Psych, Florence, Italy, June 1991. (Abstract 0 11 04 04) Biol Psych 1991:29:236 237SM.
27. Tohen M, Castillo J, Baldessarini RJ, Kando J. Cost effectiveness in close monitoring of clozapine: a pharmaco epidemiologic study. Biennial Congress of the World Federation for Mental Health, Mexico City, MX. August 18 23, 1991.
28. Shulman KI, Tohen M, Satlin A, Mallya G, Kalunian D. The characteristics and outcome of mania compared to depression in old age. 41st Annual Meeting Canadian Psychiatric Association, Saskatoon, Saskatchewan. (Abstract 70) October 1 4, 1991.
29. Strakowski SM, Tohen M, Stoll AL, Faedda GL, Goodwin DC. First episode mania and comorbidity. 41st Annual Meeting, Canadian Psychiatric Association, Saskatoon, Saskatchewan. (Abstract 69) October 1 4, 1991.
30. Tohen M, Castillo J, Baldessarini RJ, Kando J. Pharmacoepidemiologic study of blood dyscrasias with valproic acid and carbamazepine. 41st Annual Meeting, Canadian Psychiatric Association, Saskatoon, Saskatchewan. (Abstract 70) October 1 4, 1991.
31. Tohen M, Strakowski SM, Stoll AL, Goodwin DC, Faedda GL, Baldessarini RJ. The McLean First Episode Psychosis/Mania Project Scientific Advisory Committee (SAC) Research Symposium/Poster Presentations. McLean Hospital. November 18 19, 1991.
32. Tohen M, Strakowski SM, Stoll AL, Goodwin DC, Faedda GL, Baldessarini RJ. Recovery in first episode affective and non affective psychosis. Reg. Symposium World Psychiatric Association, Acapulco, MX. November 19 24, 1991.
33. Stoll AL, Mayer PV, Hanin I, Tohen M, Strakowski SM, Faedda GL, Goodwin DC, Cohen BM. Erythrocyte choline concentration in first-episode psychotic disorders: A predictor of prolonged neuroleptic treatment. American College of Neuropsychopharmacology, San Juan, PR. December 1991.
34. Suppes P, Baldessarini RJ, Faedda GL, Tohen M, Tondo L. Risk of recurrence following discontinuation of long term lithium maintenance treatment in bipolar disorder. American College of Neuropsychopharmacology, San Juan, PR. December, 1991.
35. Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM. Sequence of episodes predicts response to lithium in bipolar disorders. Biol Psych 1991:29:384A.
36. Tohen M, Strakowski SM, Stoll AL, Goodwin DC, Faedda GL, Baldessarini RJ. The McLean First-Episode Psychosis/Mania Project. Harvard School of Public Health's 6th Annual Poster Day, Boston, MA. February 20, 1992.
37. Strakowski SM, Wilson DR, Tohen M, Woods BT, Douglas AW, Stoll AL. Neuroanatomic abnormalities in first episode mania. Stanley Cobb Assembly of the Boston Society for Neurology and Psychiatry, Boston, MA. April 16, 1992.
38. Tohen M, Castillo J, Baldessarini RJ, Kando J. The Course of Leukopenia Caused by Anticonvulsants. 145th Annual Meeting American Psychiatric Association, Washington, DC. May 2 7, 1992.
39. Tohen M, Strakowski SM, Stoll AL, Goodwin DC, Faedda GL, Baldessarini RJ. The McLean First-Episode Psychosis/Mania Project. 145th Annual Meeting American Psychiatric Association, Washington, DC. May 2-7, 1992.
40. Hegarty JD, Tohen M, Baldessarini RJ. One hundred years of schizophrenia. (Abstract NR99) 145th Annual Meeting American Psychiatric Association, Washington, DC. May 2 7, 1992.
41. Faedda GL, Strakowski SM, Tohen M, Suppes T, Stoll AL, Mayer PV, Goodwin DC, Kolbrener ML, Baldessarini RJ. Mixed and dysphoric states in bipolar Patients. (Abstract NR114) 145th Annual Meeting American Psychiatric Association, Washington, DC. May 2 7, 1992.
42. Strakowski SM, Batson SC, Tohen M, Greenfield SF, Kolbrener ML. Dissociation and abuse in first episode psychosis. (Abstract NR207) 145th Annual Meeting, American Psychiatric Association, Washington DC. May 2 7, 1992.
43. Strakowski SM, Tohen M, Stoll AL, Faedda GL, Mayer PV, Kolbrener ML, Goodwin DC. Comorbidity in first episode psychosis. (Abstract NR8) 145th Annual Meeting American Psychiatric Association, Washington DC. May 2 7, 1992.
44. Stormberg D, Ronningstam E, Tohen M, Gunderson J. Pathological narcissism in bipolar and narcissistics. 145th Annual Meeting American Psychiatric Association, Washington DC. May 2 7, 1992.
45. Faedda GL, Strakowski SM, Tohen M, Suppes T, Stoll AL, Mayer PV, Goodwin DC, Kolbrener ML, Baldessarini RJ. Mixed and dysphoric states in bipolar patients. APA Annual Meeting, Washington, D.C. May 2-7, 1992.
46. Sachs GS, Stoll AL, Lafer B, Tohen M, Cohen BM, Rosenbaum J. Buproprion versus desipramine in bipolar depression. Proceedings of the 2nd International Conference on Refractory Depression. Amsterdam. June 13, 1992.
47. Henry A, Tohen M, Clemson C. Functional and symptomatic recovery in first episode psychotic patients. 44th Institute on Hospital & Community Psychiatry, Toronto, Ontario. October 23 27, 1992.
48. Suppes T, Baldessarini RJ, Faedda GL, Tohen M, Tondo L. Lithium discontinuation in bipolar manic depressive disorders (p.38). 31st Annual Meeting American College of Neuropsychopharmacology, San Juan, PR. December 14 18, 1992.
49. Strakowski SM, Wilson DR, Tohen M, Woods BT, Douglas AW, Stoll AL. Neuroanatomic abnormalities in first episode mania. Biol Psych 1992:31:203A.
50. Banov M, Zarate CA Jr., Scialabba D, Tohen M, Wines J, Kim JW. Clozapine therapy in refractory affective disorders: polarity predicts response in long- term follow-up. First Annual Harvard Research Day. April 28, 1993.
51. Zarate CA Jr., Banov M, Tohen M, Cohen BM. Successful long-term treatment of refractory psychotic disorders and comorbid substance abuse with clozapine. First Annual Harvard Research Day. April 28, 1993.
52. Tohen M, Castillo J, Pope H. Concurrent use of valproate & carbamazepine. 146th Annual Mtg. Amer. Psych. Assn., San Francisco, CA, May 22 27, 1993.
53. Banov M, Zarate C, Scialabba D, Tohen M., Wines J, Kim JW. Clozapine therapy in refractory affective disorders: polarity predicts response in long- term follow-up. (NR 163) 146th Annual Meeting American Psychiatric Association, San Francisco, CA, May 22 27, 1993.
54. Stoll A, Mayer PV, Tohen M, Goldstein E, Kolbrener M, Cohen BM. Antidepressant-associated mania. (NR 127) 146th Annual Meeting American Psychiatric Association, San Francisco, CA, May 22 27, 1993.
55. Cole J, Banov M, Green A, Tohen M, Patel J. Clozapine in the treatment of refractory acute bipolar mania. (NR 455) 146th Annual Meeting American Psychiatric Association, San Francisco, CA, May 22-27, 1993.
56. Banov M, Zarate CA Jr., Tohen M. Clozapine therapy in refractory affective disorders: Polarity predicts response in long-term follow-up. 41st Boston Society of Neurology and Psychiatry, Boston, MA, May 1993.
57. Yurgelun-Todd D, Renshaw PF, Gruber SA, Tohen M, Cohen BM. H-MRS of N- acetyl aspartate (naa) in the temporal lobes of first-episode patients. 32nd Annual Meeting American College of Neuropsychopharmacology, Maui, HI, December 13-17, 1993.
58. Zarate CA Jr, Cohen BM, Tohen M, Hegarty J, Centorrino F. The McLean first- episode family study. Second Annual Harvard Research Day. March 10, 1994.
59. Pillay SS, Stoll AL, Cole JO, Weiss M, Tohen M, Zarate CA Jr. The EEG as a predictor of response in patients on clozapine. Second Annual Harvard Research Day. March 10, 1994.
60. Tohen M, Zarate CA Jr., Hegarty J, Turvey C, Weiss M. The McLean first-episode study. Second Annual Harvard Research Day. March 10, 1994.
61. Tohen M. Outcome of mania in adults. 147th Annual Meeting American Psychiatric Association, Philadelphia, PA. May 21-26, 1994.
62. Zarate CA, Cohen BM, Tohen M. The McLean Hospital first-episode psychosis family study. 147th Annual Meeting, American Psychiatric Association, Philadelphia, PA. May 21-26, 1994.
63. Zarate CA, Tohen M, Baraibar G, Kim JW, Castillo J, Kando JC. Liver function tests and anticonvulsants. 147th Annual Meeting, American Psychiatric Association, Philadelphia, PA. May 21-26, 1994.
64. Popli AP, Kando JC, Pillay SS, Tohen M, Cole JO. Seizures during an inpatient psychiatric hospitalization. 147th Annual Meeting, American Psychiatric Association, Philadelphia, PA. May 21-26, 1994.
65. Zarate CA, Tohen M, Baraibar G, Kando JC, Mirin S. Prescribing trends of mood stabilizers in bipolar disorders. 34th Annual Meeting, New Clinical Drug Evaluation Unit Program (NCDEU), Marco Island, FL. May 31-June 3, 1994.
66. Pillay S, Stoll AL, Cole JO, Weiss M, Tohen M. The EEG as a predictor of clinical response in patients on Clozapine. 34th Annual Meeting, New Clinical Drug Evaluation Unit Program (NCDEU), Marco Island, FL. May 31-June 3, 1994.
67. Tohen M, Castillo J, Baldessarini RJ, Kando J. Blood dyscrasias with carbamazepine and valproate: A pharmacoepidemiological study of 2,228 cases at risk. Neuropsychopharmacology, 1994:10:395. XIX Collegium Internationale Neuropsychopharmacologicum, Washington, DC. June 27 - July 5, 1994.
68. Tohen M. The McLean first-episode mania project. XVIII Latin American Congress of Psychiatry, Mexico City, MX. October 27-31, 1994.
69. Tohen M. Epidemiology of bipolar disorders. XVIII Latin American Congress of Psychiatry, Mexico City, MX. October 27-31, 1994.
70. Tohen M. Genetic epidemiology in psychiatry. XVIII Latin American Congress of Psychiatry, Mexico City, MX. October 27-31, 1994.
71. Tohen M. Antidepressants. XVIII Latin American Congress of Psychiatry, Mexico City, MX. October 27-31, 1994.
72. Salisbury DF, Shenton ME, McCarley RW, Tohen M, Matthysse SM, Yurgelun- Todd D, Chang W. Does P3 topography discriminate schizophrenic psychosis from affective psychosis. Society for Neuroscience 1994 Annual Meeting, Miami Beach, FL. November 13-18, 1994.
73. Tohen M, Zarate C, Centorrino F, Hegarty J. Risperidone in the treatment of mania. 33rd Annual Meeting American College of Neuropsychopharmacology, San Juan, PR. December 12-16, 1994.
74. Suppes T, Yurgelun-Todd DA, Tohen M, Faedda GL, Kolbrener, M, Weiss M, Strakowski SM, Mayer PV, Stoll AL. Mixed bipolar states at first hospitalization. Society of Biol Psych Annual Meeting. 1994.
75. Tohen M. The McLean first-episode mania project. 148th Annual Meeting, American Psychiatric Association, Miami, FL. May 22-25, 1995.
76. Tohen M. Outcome in first-episode psychosis (symposium supported by Zeneca Laboratories). 148th Annual Meeting American Psychiatric Association, Miami, FL. May 22-25, 1995.
77. Zarate CA, Tohen M. Algorithm for treatment of first-onset psychosis. 148th Annual Meeting, American Psychiatric Association, Miami, FL. May 22-25, 1995.
78. Nakamura A, Benzo J, Zarate C, Tohen M. Switching from carbamazepine to clozapine. 148th Annual Meeting American Psychiatric Association, Miami, FL. May 22-25, 1995.
79. Zarate CA, Baldessarini RJ, Tohen M, Baraibar G, Zarate S. Shifts in diagnostic frequencies of bipolar disorder subtypes at McLean Hospital: 1981-1993. 148th Annual Meeting American Psychiatric Assn., Miami, FL. May 22-25, 1995.
80. Benzo J, Baraibar G, Castillo J, Gardner D, Zarate CA, Tohen M. Organic mood disorders: clinical characteristics. 148th Annual Meeting American Psychiatric Association, Miami, FL. May 22-25, 1995.
81. Hegarty J, Centorrino F, Baldessarini RJ, Tohen M, Friedberg JW, Weiss M. Duration of hospitalization versus improvement in first psychosis. 148th Annual Meeting American Psychiatric Assn., Miami, FL. May 22-25, 1995.
82. Patel SP, Zarate CA, Tohen M. Trends in quality-of-life assessments in psychiatry. 148th Annual Meeting American Psychiatric Association, Miami, FL. May 22-25, 1995.
83. Tohen M, Zarate CA, Centorrino F, Hegarty JD, Froeschl M, Zarate S. Risperidone in the treatment of mania. 148th Annual Meeting American Psychiatric Association, Miami, FL. May 22-25, 1995.
84. Morabito C, Collins M, Weinstock L, Levin A, Tohen M. Survey of gynecologic and endocrine abnormalities among women with psychosis. 148th Annual Meeting American Psychiatric Association, Miami, FL. May 22-25, 1995.
85. Patel J, Green AI, Banov MD, Tohen M, Schatzberg A, Cole JO. Clozapine use in treatment refractory mania and psychosis.148th Annual Meeting American Psychiatric Association, Miami, FL. May 22-25, 1995.
86. Baldessarini RJ, Tondo L, Suppes T, Faedda GL, Tohen M, Viguera AC. Risks of discontinuing maintenance treatments. 149th Annual Meeting, American Psychiatric Association, New York, NY. May 4-9, 1996.
87. Tohen M. Strategies for management of comorbidity. 149th Annual Meeting, American Psychiatric Association, New York, NY. May 4-9, 1996.
88. Tohen M. Innovative approaches - Difficult Clinical Problems. Symposium Chairman (supported by Janssen Laboratories). 149th Annual Meeting, American Psychiatric Association, New York, NY. May 4-9, 1996.
89. Tohen M. Bipolar disorder (symposium supported by Janssen Laboratories). 149th Annual Meeting, American Psychiatric Association, New York, NY. May 4-9, 1996.
90. Tohen M. Comorbidity of bipolar disorder (symposium supported by Abbott Laboratories). 149th Annual Meeting, American Psychiatric Association, New York, NY. May 4-9, 1996.
91. Weiss R, Greenfield S, Hufford C, Najavits L, Tohen M, Martinez-Raga J. Medication adherence in bipolar substance abusers.149th Annual Meeting, American Psychiatric Association, New York, NY. May 4-9, 1996.
92. Zarate CA Jr, Siegel A, Nakamura A, Tohen M, Cherkerzian T, Baldessarini RJ. Risperidone in the elderly. 149th Annual Meeting, American Psychiatric Association, New York, NY. May 4-9, 1996.
93. Zarate CA Jr, Zarate SB. Thyroid function tests in first-episode mania. 149th Annual Meeting, American Psychiatric Assn., New York, NY. May 4- 9, 1996.
94. Zarate CA Jr, Cohen BM, Tohen M, Sahatjian J, Zarate SB. A family study of first-episode psychoses/mania. 149th Annual Meeting, American Psychiatric Association, New York, NY. May 4-9, 1996.
95. Tohen M. A placebo-controlled trial of olanzapine in psychotic acute mania. Grand National, 9th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland. February 7-13, 1997.
96. Pandit S, Zarate C, Tohen M, Narendran R, Madrid A, Tomasini E. Prescribing trends of antidepressants in bipolar depression: phase II. American Psychiatric Association Annual Meeting, San Diego, CA. May 17-22, 1997.
97. Tohen M, Sanger T, Tollefson G. Gender differences in the response of olanzapine versus haloperidol in the treatment of first-episode psychosis. American Psychiatric Association Annual Meeting, San Diego, CA. May 17-22, 1997.
98. Tohen M, Sanger T, Tollefson G, McElroy SL. Olanzapine versus haloperidol in the treatment of schizoaffective bipolar patients. American Psychiatric Association Annual Meeting, San Diego, CA. May 17-22, 1997.
99. Sanger TM, Lieberman JA, Tohen M, Tollefson GD. Olanzapine versus haloperidol in the treatment of first episode psychosis. American College of Neuropsycho- pharmacology, 36th Annual Meeting, Waikoloa, HI. December 8-12, 1997.
100. Yurgelun-Todd DA, Gruber SA, Tohen M, Baird AA, Lange NS, Renshaw PF, Cohen BM. Antipsychotic drug effects on cortical activation, as measured by fmri in schizophrenia. American College of Neuropsychopharmacology, 36th Annual Meeting, Waikoloa, HI. December 8-12, 1997.
101. Tohen M, Sanger TM, Tollefson GD, McElroy SL, Greaney MG, Toma V. Olanzapine versus placebo in the treatment of acute mania. American College of Neuropsychopharmacology, 36th Annual Mtg., Waikoloa, HI. December 8-12, 1997.
102. Sanger T, Tohen M, Tollefson GD, McElroy S, Greaney M, Toma V. Olanzapine versus placebo in the treatment of acute mania. Schizophrenia GMC and 9th Biennial Winter Workshop On Schizophrenia: Zurich, Switzerland, February 5-7, 1998 and Davos, Switzerland. February 7-13, 1998.
103. Sanger T, Tohen M, Tollefson G, David S, Greaney M. Olanzapine vs. Placebo in rapid-cycling bipolar disorder. European Neuropsychopharmacology 1998:8(Suppl 2):S227.
104. Sanger T, Tohen M, Tollefson G, David S, Greaney M. Olanzapine vs. Placebo in rapid-cycling bipolar disorder. Schiz Res 1998:29:(1-2):152.
105. Sanger T, Lieberman J, Tohen M, Tollefson GD. Olanzapine versus haloperidol in the treatment of first episode psychosis. Schizophrenia GMC and 9th Biennial Winter Workshop On Schizophrenia: Zurich, Switzerland February 5-7, 1998, and Davos, Switzerland February 7-13, 1998.
106. Sanger T, Tohen M, Tollefson GD, Jacobs T, David S. Olanzapine versus placebo in rapid-cycling bipolar disorder. Schizophrenia GMC and 9th Biennial Winter Workshop On Schizophrenia: Zurich, Switzerland: February 5-7, 1998, and Davos, Switzerland, February 7-13, 1998.
107. Sanger T, Lieberman J, Tohen M, Tollefson GD. Olanzapine versus haloperidol in the treatment of first episode psychosis. American Psychiatric Association Annual Meeting, Toronto, Canada. May 30-June 4, 1998.
108. Tohen M, Zarate C, Strakowski S, Stoll A, Hennen J, Gaedda G, Suppes T, Gebre-Medhin P, Gannon K, Baldessarini R. Symptomatic and functional outcome in first-episode psychosis: prospective, six-month study of 257 patients. American Psychiatric Association Annual Meeting, Toronto, Canada. May 30-June 4, 1998.
109. Tohen M, Zhang F, Taylor C, Burns P, Zarate C, Sanger T, Tollefson GD. Neuroleptic use in bipolar disorder: a pharmacoepidemiologic review. American Psychiatric Association Annual Meeting, Toronto, Canada. May 30-June 4, 1998.
110. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Greaney M, Toma V. Olanzapine versus placebo in the treatment of acute mania. American Psychiatric Association Annual Meeting, Toronto, Canada. May 30-June 4, 1998.
111. Tohen M. Experience using olanzapine in the treatment of acute bipolar mania. American Psychiatric Association Annual Meeting, Toronto, Canada. May 30-June 4, 1998.
112. Tohen M, Zarate C, Hennen J, Gebre-Medhin P, Baldessarini, RJ. Symptomatic and functional outcome first-episode psychosis: prospective, six-month study of 257 patients. American Psychiatric Association Annual Meeting, Toronto, Canada. May 30-June 4, 1998.
113. Tohen M, Zhang F, Taylor C, Burns P, Zarate C, Sanger T, Tollefson G. Neuroleptic use in bipolar disorder: a pharmacoepidemiologic review. Amer. Psychiatric Assn. Annual Meeting, Toronto, Canada. May 30-June 4, 1998.
114. Cohen LS, Goldstein JM, Lee H, Tohen M, Andersen S, Tollefson GD. Sex and neuroendocrine differences following treatment with typical and atypical antipsychotics. American Psychiatric Association Annual Meeting, Toronto, Canada. May 30-June 4, 1998.
115. Tohen M, Sanger T, Tollefson GD, McElroy SL, Greaney MG, Toma V. Olanzapine versus placebo in the treatment of acute mania. New Clinical Drug Evaluation Unit Program (NCDEU) 38th Annual Meeting, Boca Raton, FL. June 10-13, 1998.
116. Tohen M, Sanger T, Tollefson GD, McElroy SL, Grundy SL, Greaney MG, Jacobs T, David S, Andersen S, Toma V. Olanzapine versus placebo in the treatment of acute mania. Deutsche Gesellschaft fur Psychiatrie, Psychotherapie und Nervenheilkunde, Kongress 1998, Essen. June 17-20, 1998.
117. Sanger T, Lieberman J, Tohen M, Tollefson GD. Olanzapine vs. Haloperidol in the treatment of first episode psychosis. XXIst Congress Of The Collegium Internationale Neuro-Psychopharmacologicum (CINP), Glasgow, Scotland. July 12-16, 1998.
118. Sanger T, Tohen M, Tollefson GD, Jacobs T, Davis S. Olanzapine vs. Placebo in rapid-cycling bipolar disorder. XXIst Congress Of The Collegium Internationale Neuro-Psychopharmacologicum (CINP), Glasgow, Scotland. July 12-16, 1998.
119. Tohen M, Sanger T, Tollefson GD, McElroy S, Greaney M, Toma V. Olanzapine versus placebo in the treatment of acute mania. XXIst Congress Of The Collegium Internationale Neuro-Psychopharmacologicum (CINP), Glasgow, Scotland. July 12-16, 1998.
120. Tohen M, Zarate CA Jr. A placebo-controlled trial of olanzapine in psychotic acute mania. Schiz Res 1998:29(1-2):204.
121. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KNR, David GD, Petty F, Centorrino F, Wang R, Grundy S, Greaney M, Jacobs T, David S, Toma V. Olanzapine versus placebo in the treatment of acute mania. Schiz Res 1998:29 (1-2):152.
122. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KNR, David GD, Petty F, Centorrino F, Wang R, Grundy S, Greaney M, Jacobs T, David S, Toma V. Olanzapine versus placebo in the treatment of acute mania. European Neuropsychopharm 1998:8(Suppl 2):S178.
123. Tohen M. Evaluating the efficacy and safety of antipsychotics in co-morbid and psychotic disorders, the role of antipsychotics in managing co-morbid mood and psychotic disorders. Halifax, Nova Scotia, September 18, 1998.
124. Sanger T, Tohen M, Tollefson GD, David S, Greaney MG. Olanzapine versus placebo in rapid-cycling bipolar disorder. XIth Congress of the European College of Neuropsychopharmacology, Paris, France. October 31-November 4, 1998.
125. Sanger T, Lieberman J, Tohen M, Grundy S, Beasley C, Tollefson G. Olanzapine vs. haloperidol treatment in first-episode psychosis. XIth Congress of the European College of Neuropsychopharmacology, Paris, France. October 31-November 4, 1998.
126. Tohen M, Sanger T, McElroy S, Tollefson GD, Grundy S, Greaney M, Jacobs T, Davis S, Toma V, and the Olanzapine HGEH Study Group. Olanzapine versus placebo in the treatment of acute mania. XIth Congress of the European College of Neuropsychopharmacology, Paris, France. October 31-November 4, 1998.
127. Tollefson GD, Shelton R, Tohen M, Stahl S, Jacobs T, Buras W, Gannon K. Efficacy of olanzapine, fluoxetine and combination therapy in treatment-resistant major depressive disorder without psychotic features. XIth Cong. of the Euro. College of Neuropsychopharmacology, Paris, France. Oct. 31-Nov. 4, 1998.
128. Tran P, Costa e Silva J, Gattaz W, Mazzoti G, Ospina J, Larach V, Alvarez N. Starkstein S, Oliva D, Tohen M, Cousins L, Tollefson GD. Olanzapine as alternative therapy for patients intolerant to haloperidol-induced extrapyramidal symptoms. XIth Congress of the European College of Neuropsychopharmacology, Paris, France. October 31-November 4, 1998
129. Tohen M, Jacobs T, Gannon K, Sanger T, Greaney M, Toma V, Tollefson G: Antimanic effect and cognitive improvement in bipolar I patients treated with olanzapine. 1998 Annual Meeting of the American College of Neuropsycho- pharmacology (ACNP), Las Croabas, PR. December 14-18, 1998.
130. Sanger T, Tohen M, Jacobs T, Greaney M, Gannon K, Tollefson GD. Long-term safety of olanzapine in the treatment of Bipolar I disorder. 1998 Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Las Croabas, PR. December 14-18, 1998.
131. Sanger T, Tohen M, Jacobs T, Grundy S, Greaney M, Toma V, Gannon K, Tollefson GD. Safety of the novel antipsychotic olanzapine in the acute treatment of Bipolar I disorder. 1998 Annual Meeting of the American College of Neuropsycho- pharmacology (ACNP), Las Croabas, PR. December 14-18, 1998.
132. Tollefson GD, Shelton R, Tohen M, Stahl S, Jacobs T, Buras W, Spencer K, Gannon K. The study of olanzapine combined with fluoxetine in patients with treatment-resistant major depressive disorder without psychotic features. 1998 Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Las Croabas, PR. December 14-18, 1998.
133. Tohen M, Jacobs T, Gannon K, Sanger T, Greaney M, Toma V, Tollefson GD. Antimanic effect and cognitive improvement in psychotic and nonpsychotic Bipolar I patients treated with olanzapine. Mt. Sinai Conference on Cognition in Schizophrenia, Sante Fe, NM. April 16-17, 1999.
134. Zhang F, Tohen M, Sanger T, Gannon K, Tollefson GD. Olanzapine versus haloperidol: assessment of cognitive function in patients with schizoaffective disorder, bipolar type. Mt. Sinai Conference on Cognition in Schizophrenia, Sante Fe, NM. April 16-17, 1999.
135. Sanger T, Tohen M, Jacobs T, Greaney, Gannon K, Tollefson GD. Long-term safety of olanzapine in the treatment of Bipolar I disorder. International Congress on Schizophrenia Research (ICSR), Sante Fe, NM. April 17-21, 1999.
136. Tohen M, Jacobs T, Gannon K, Sanger T, Greaney M, Toma V, Tollefson GD. Long-term olanzapine treatment: cognitive and symptom improvement in psychotic and nonpsychotic manic patients. International Congress on Schizophrenia Research (ICSR), Sante Fe, NM. April 17-21, 1999.
137. Tohen M, Jacobs T, Gannon K, Sanger T, Greaney M, Toma V, Tollefson GD. Olanzapine versus placebo: antimanic effect and cognitive function in psychotic and nonpsychotic Bipolar I patients, International Congress on Schizophrenia Research (ICSR), Sante Fe, NM. April 17-21, 1999.
138. Shelton R, Tollefson GD, Tohen M, Jacobs T, Buras W, Spencer K, Gannon K, Stahl S. Safety and efficacy of olanzapine plus fluoxetine in treatment-resistant manor depressive disorder. International Congress on Schizophrenia Research (ICSR), Sante Fe, NM. April 17-21, 1999.
139. Tohen M, Jacobs T, Sanger T, Grundy S, Greaney M, Toma V, Gannon K, Tollefson GD. Safety of the novel antipsychotic olanzapine in the acute treatment of Bipolar I disorder, International Congress on Schizophrenia Research (ICSR), Sante Fe, NM. April 17-21, 1999.
140. Zhang F, Tohen M, Sanger, Gannon K, Tollefson GD. Olanzapine versus haloperidol in schizoaffective disorder, bipolar type: a repeated measures analysis. International Congress on Schizophrenia Research (ICSR), Sante Fe, NM. April 17-21, 1999.
141. Tohen M, Jacobs T, Gannon K, Sanger T, Toma V. Olanzapine versus placebo: antimanic effect and cognitive function in psychotic and nonpsychotic bipolar I patients. American Psychiatric Association Meeting, Washington, DC. May 15-20, 1999.
142. Tohen M, Zhang F, Sanger T, Gannon K, Tollefson GD. Olanzapine versus haloperidol in schizoaffective bipolar disorder: a repeated measures analysis. American Psychiatric Association Meeting, Washington, DC. May 15-20, 1999.
143. Sanger T, Tohen M, Jacobs T, Gannon K, Greaney M, Tollefson GD. Long-term olanzapine treatment of mania: improvement in symptoms and cognitive function. American Psychiatric Association Meeting, Washington, DC. May 15-20, 1999.
144. Tollefson GD, Shelton RC, Tohen M, Stahl S, Jacobs T, Gannon K. The study of olanzapine plus fluoxetine in treatment-resistant mdd without psychotic features. American Psychiatric Association Meeting, Washington, DC. May 15-20, 1999.
145. Tohen M, Baldessarini R, Hennen J, Strakowski SM, Zarate C, Stoll A. First-episode affective disorders with psychotic features: outcome. American Psychiatric Association Meeting, Washington, DC. May 15-20, 1999.
146. Tohen M, Jacobs T, Gannon K, Sanger T, Greaney M, Toma V, Tollefson G. Long-term olanzapine treatment: efficacy and safety in manic patients with and without psychotic features. The New Clinical Drug Evaluation Unit 39th Annual Meeting, Boca Raton, FL. June 1-4, 1999.
147. Namjoshi M, Jacobs T, Sanger T, Gannon K, Tohen M, Breier A. Changes in health-related quality of life of patients with bipolar disorder treated with olanzapine. The New Clinical Drug Evaluation Unit 39th Annual Meeting, Boca Raton, FL. June 1-4, 1999.
148. Zhang F, Tohen M, Sanger T, Gannon K, Tollefson GD. Olanzapine versus haloperidol in schizoaffective disorder, bipolar type: repeated measures analysis of efficacy and cognitive function. The New Clinical Drug Evaluation Unit 39th Annual Meeting, Boca Raton, FL. June 1-4, 1999.
149. Sanger T, Tohen M, Jacobs T, Gannon K, Greaney M, Toma V, Tollefson GD. Olanzapine in the treatment of rapid cycling Bipolar I patients. Third International Conference on Bipolar Disorder, Pittsburgh, PA. June 17-19, 1999.
150. Tohen M, Hennen J, Zarate C, Baldessarini R, Strakowski, Stoll S. The McLean First-Episode Project: Two-year syndromal and functional recovery in 219 cases of major affective disorders with psychotic features. Third International Conference on Bipolar Disorder, Pittsburgh, PA. June 17-19, 1999.
151. Tohen M, Jacobs T, Gannon K, Sanger M, Toma V, Tollefson GD. Efficacy of olanzapine in the acute treatment of bipolar disorder, with and without psychotic features. Third International Conference on Bipolar Disorder, Pittsburgh, PA. June 17-19, 1999.
152. Namjoshi M, Jacobs T, Sanger T, Gannon K, Tohen M, Tollefson GD. Changes in health-related quality of life of patients with bipolar disorder treated with Olanzapine. Third International Conference on Bipolar Disorder, Pittsburgh, PA. June 17-19, 1999.
153. Tohen M, Jacobs T, Sanger T, Gannon K, Greaney M, Tollefson GD. Long-term efficacy of olanzapine in the treatment of bipolar disorder. Third International Conference on Bipolar Disorder, Pittsburgh, PA. June 17-19, 1999.
154. Tohen M. Use of antipsychotics in bipolar disorder. Third International Conference on Bipolar Disorder, Pittsburgh, PA. June 17-19, 1999.
155. Sanger T, Tohen M, Jacobs T, Greaney M, Gannon K, Tollefson GD. Long-term safety of olanzapine in the treatment of bipolar I disorder. XI World Congress of Psychiatry (WPA): Hamburg, Germany. August 6-11, 1999.
156. Tollefson GD, Shelton R, Tohen M, Stahl S, Jacobs T, Buras W, Spencer K, Gannon K. The study of olanzapine combined with fluoxetine in patients with treatment-resistant major depressive disorder without psychotic features. XI World Congress of Psychiatry (WPA): Hamburg, Germany. August 6-11, 1999.
157. Tohen M, Jacobs T, Gannon K, Spencer K, Meyers T, Dugan L, Gates S, Sanger T, Tollefson GD. Olanzapine combined with mood stabilizers in the treatment of bipolar disorder. XI World Congress of Psychiatry (WPA), Hamburg, Germany. August 6-11, 1999.
158. Tohen M, Zhang F, Sanger T, Gannon K, Tollefson GD. Olanzapine vs. Haloperidol in schizoaffective disorder, bipolar type: a repeated measures analysis. XI World Congress of Psychiatry (WPA), Hamburg, Germany. August 6-11, 1999.
159. Tohen M. Safety of the novel antipsychotic olanzapine in the treatment of bipolar I disorder. WPA, Hamburg, Germany. August 6-11, 1999.
160. Tohen M. Olanzapine plus fluoxetine: double-blind and open-label results in treatment-resistant major depressive disorder. WPA, Hamburg, Germany. August 6-11, 1999.
161. Tohen M. Olanzapine: acute and long-term efficacy in bipolar I patients. WPA, Hamburg, Germany. August 6-11, 1999.
162. Tohen M. Olanzapine in the treatment of rapid cycling bipolar I patients. WPA, Hamburg, Germany. August 6-11, 1999.
163. Tohen M. Olanzapine in the treatment of mania: a placebo-controlled four-week study. WPA, Hamburg, Germany. August 6-11, 1999.
164. Tohen M. Olanzapine versus haloperidol in schizoaffective bipolar disorder: a repeated measures analysis. WPA, Hamburg, Germany. August 6-11, 1999.
165. Tohen M. New pharmacological interventions in the treatment of schizophrenia and bipolar disorders. 49th Annual Meeting of the Canadian Psychiatric Association, Westin Harbour Castle, Toronto, Canada. September 15, 1999.
166. Tohen M. Current and emerging clinical data with atypical antipsychotics in the treatment of bipolar disorder. 49th Annual Meeting of the Canadian Psychiatric Association, Westin Harbour Castle, Toronto, Canada. September 15, 1999.
167. Tohen M. Long-term olanzapine treatment: efficacy and safety in manic patients with and without psychotic features. 12th Congress of the European College of Neuropsychopharmacology, London, UK. September 21-25, 1999.
168. Tohen M. Olanzapine plus fluoxetine: double-blind open-label results in treatment-resistant major depressive disorder. 12th Congress of the European College of Neuropsychopharmacology, London, UK. September 21-25, 1999.
169. Tohen M. Olanzapine in the treatment of mania: a placebo-controlled four-week study. 12th Congress of the European College of Neuropsychopharmacology, London, UK. September 21-25, 1999.
170. Tohen M. Olanzapine vs. Haloperidol in schizoaffective bipolar disorder: a repeated measures analysis. 12th Congress of the European College of Neuropsychopharmacology, London, UK. September 21-25, 1999.
171. Tohen M. New advancements in the management of bipolar disorder. 12th Congress of the European College of Neuropsychopharmacology, London, UK. September 21-25, 1999.
172. Tohen M. Changes in health-related quality of life of patients with bipolar disorder treated with olanzapine. 12th Congress of the European College of Neuropsychopharmacology, London, UK. September 21-25, 1999.
173. Tohen M. "Switch strategy from traditional antipsychotics to the last generation antipsychotics". XVII Psychiatric Brazilian Congress, Sao Paulo, Brazil. October 14-17, 1999.
174. Tohen M, Jacobs T, Sanger T. Is olanzapine a mood stabilizer? 1999 Annual Mtg: American College of Neuropsychopharmacology, Acapulco, MX. December 1999.
175. Frazier JA, Biederman J, Jacobs TG, Tohen M, Toma V, Feldman PD, Rater MA, Tarazi RA, Kim GA, Garfield SB, Golzalez-Heydrich J, Nowlin ZM. "Olanzapine in the treatment of bipolar disorder in juveniles". Schiz Res, 2000:41(1):194. 10th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland. Feb. 5-11, 2000.
176. Shelton RC, Tohen M, Stahl S, Jacobs T, Gannon KS, Tollefson GD. "The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features". Schiz Res, 2000:41(1):192-193. 10th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland. February 5-11, 2000.
177. Tohen M, Jacobs T, Toma V, Francis J, Zhang F, Gannon KS, Sanger TM, Breier A. "Is olanzapine a mood stabilizer?" Schiz Res, 2000:41(1):193-194. 10th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland. Feb. 5-11, 2000.
178. Tohen M, Jacobs T, Gannon KS, Sanger TM, Greaney M, Toma V, Tollefson GD. Olanzapine: acute and long-term efficacy in bipolar I patients. Schiz Res. 2000:41(1):192.
179. Tohen M, Jacobs T, Gannon KS, Sanger T, Greaney M, Breier A. Safety of the novel antipsychotic olanzapine in the treatment of bipolar disorder. Schiz Res. 2000:41(1):19
180. Tohen M, Baker R, Breier A, Feldman P, Jacobs T, Keeter E, Risser R, Timpe T, Tollefson G. Efficacy of olanzapine added to valproate or lithium in the acute treatment of Bipolar I Disorder. ECNP 2000.
181. Tohen M, Baker R, Davis A, Gilmore J, Milton D, Risser R, Richey A. Olanzapine versus divalproex for the treatment of acute mania. ECNP 2000.
182. Tohen M, Baker R, Davis A, Gilmore J, Milton D, Risser R, Richey A. Olanzapine vs. Divalproex sodium in the treatment of acute mania. Stanley Foundation 2000.
183. Tohen M, Jacobs T, Feldman P, Toma V, Francis J, Zhang F, Sanger T, Breier A. Is olanzapine a mood-stabilizer? Society of Biol Psych. May 11-13, 2000.
184. Tohen M, Jacobs T, Feldman P, Toma V, Francis J, Zhang F, Sanger T, Breier A. Is olanzapine a mood-stabilizer? American Psychiatric Assn. May 13-18, 2000.
185. Frazier J, Biederman J, Jacobs T, Tohen M, Toma V, Feldman P, Rater, Tarazi, Kim, Garfield, Gonzalex-Heydrich, Nowlin Z. Olanzapine in the treatment of juvenile bipolar disorder. American Psychiatric Association. May 13-18, 2000.
186. Tohen M, Jacobs T, Meyers T, Risser R, Keeter E, Feldman P, Breier A. Efficacy of olanzapine combined with mood stabilizers in the treatment of bipolar disorder. American Psychiatric Association. May 13-18, 2000.
187. Baker R, Tohen M, Milton D, Stauffer G. Mania improvement during olanzapine treatment is unaffected by outcome of previous mood stabilizer therapy. American Psychiatric Association. May 13-18, 2000.
188. Namjoshi M, Gopalan R, Jacobs T, Feldman P, Sanger TM, Tohen M, Breier AF. Clinical, humanistic and economic outcomes associated with long-term olanzapine treatment of mania. American Psychiatric Assn. May 13-18, 2000.
189. Tohen M, Baker RW, Gilmore J, Milton D, Risser R. Olanzapine versus divalproex for the treatment of acute mania. Institute on Psychiatric Services, Philadelphia, PA. October 2000.
190. Yurgelun-Todd DA, Gruber SA, Kilgore WDS, Tohen M. Neuropsychological performance in first episode bipolar disorder. CINP, Collegium Internationale Neuropsychopharmacologicum, Brussels, Belgium. July 9-13, 2000.
191. Tohen M, Jacobs TG, Meyers TM, Risser RC, Keeter EL, Feldman PD, Breier A. Efficacy of olanzapine combined with mood stabilizers in the treatment of bipolar disorder. CINP, Collegium Internationale Neuropsychopharmacologicum, Brussels, Belgium. July 9-13, 2000.
192. Namjoshi M, Rajamannar G, Risser R, Tohen M, Breier A. Impact of olanzapine added to lithium or valproate on the quality of life of patients with bipolar disorder. CINP, Collegium Internationale Neuropsychopharmacologicum, Brussels, Belgium. July 9-13, 2000.
193. Frazier JA, Biederman J, Jacobs TG, Tohen MF, Toma V, Feldman PD, Rater MA, Tarazi RA, Kim GA, Garfield SB, Golzalez-Heydrich J, Nowlin AM. Olanzapine in the treatment of bipolar disorder in juveniles. CINP, Collegium Internationale Neuropsychopharmacologicum, Brussels, Belgium. July 9-13, 2000.
194. Tohen MF, Jacobs TG, Feldman PD, Toma V, Francis BJ, Zhang F, Sanger TM, Breier A. Is olanzapine a mood-stabilizer? CINP, Collegium Internationale Neuropsychopharmacologicum, Brussels, Belgium. July 9-13, 2000.
195. Frazier JA, Biederman J, Jacobs TG, Tohen MF, Toma V, Feldman PD, Rater MA, Tarazi RA, Kim GA, Garfield SB, Golzalez-Heydrich J, Nowlin AM. Olanzapine in the treatment of bipolar disorder in juveniles. CINP, Collegium Internationale Neuropsychopharmacologicum, Brussels, Belgium. July 9-13, 2000.
196. Tohen MF, Jacobs TG, Feldman PD, Toma V, Francis BJ, Zhang F, Sanger TM, Breier A. Is olanzapine a mood-stabilizer? CINP, Collegium Internationale Neuropsychopharmacologicum, Brussels, Belgium. July 9-13, 2000.
197. Tohen M, Baker R, Breier A, Feldman P, Jacobs T, Keeter E, Risser R, Timpe T, Tollefson G. Efficacy of olanzapine added to valproate or lithium in the acute treatment of Bipolar I disorder. 13th ECNP, Munich, Germany. Sept. 9-13, 2000.
198. Tohen M, Baker R, Davis A, Gilmore J, Milton D, Risser R, Richey A. Olanzapine versus divalproex for the treatment of acute mania. 13th ECNP, Munich, Germany. September 9-13, 2000.
199. Frazier JA, Biederman J, Jacobs TG, Tohen M, Toma V, Feldman PD, Rater MA, Tarazi RA, Kim GA, Garfield SB, Gonzalez-Heydrich J, Nowlin ZM. Olanzapine in the treatment of bipolar disorder in juveniles. 13th ECNP, Munich, Germany. September 9-13, 2000.
200. Frazier JA, Tohen M, Biederman J, Jacobs T, Toma V, Feldman P. Olanzapine in the treatment of juvenile bipolar disorder. 13th ECNP, Munich, Germany. September 9-12, 2000.
201. Namjoshi MA, Rajamannar G, Risser RC, Tohen M, Breier A. Impact of olanzapine added to lithium or valproate on the quality of life of patients with bipolar disorder. 13th ECNP, Munich, Germany. September 9-13, 2000.
202. Namjoshi MA, Rajamannar G, Jacobs TG, Feldman PD, Sanger TM, Tohen M, Breier A. Clinical humanistic, and economic outcomes associated with long-term treatment of mania with olanzapine. 13th ECNP, Munich, Germany. September 9-13, 2000.
203. Baker R, Tohen M, Milton D, Risser R, Gilmore J. Olanzapine versus divalproex in the treatment of acute mania. 13th ECNP, Munich, Germany. Sept. 9-13, 2000.
204. Baker R, Tohen M, Risser R, Stauffer VL. Depression during mania: treatment response to olanzapine or placebo. 13th ECNP, Munich, Germany. September 9-13, 2000.
205. Namjoshi MA, Rajamannar G, Jacobs TG, Feldman PD, Sanger TM, Tohen M, Breier A. Clinical humanistic, and economic outcomes associated with long-term treatment of mania with olanzapine. 2nd Annual Stanley Foundation Conference on Bipolar Disorder, Amsterdam. September 21-22, 2000.
206. Baker RW, Risser RC, Stauffer VL, Tohen M. Depression during mania: treatment response to olanzapine or placebo? 2nd Annual Stanley Foundation Conference on Bipolar Disorder, Amsterdam. September 21-22, 2000.
207. Tohen M, Jacobs TG, Meyers TM, Risser RC, Keeter EL, Feldman PD, Breier A. Efficacy of olanzapine combined with mood stabilizers in the treatment of bipolar disorder. 2nd Annual Stanley Foundation Conference on Bipolar Disorder, Amsterdam. September 21-22, 2000.
208. Namjoshi MA, Rajamannar G, Risser RC, Tohen M, Breier A. Impact of olanzapine added to lithium or valproate on the quality of life of patients with bipolar disorder. 2nd Annual Stanley Foundation Conference on Bipolar Disorder, Amsterdam. September 21-22, 2000.
209. Feldman PD, Tohen MF, Jacobs TG, Toma V, Francis BJ, Zhang F, Sanger TM, Breier A. Is olanzapine a mood stabilizer? 2nd Annual Stanley Foundation Conference on Bipolar Disorder, Amsterdam. September 21-22, 2000.
210. Frazier JA, Biederman J, Jacobs TG, Tohen M, Toma V, Feldman PD, Rater MA, Tarazi RA, Kim GA, Garfield SB, Gonzalez-Heydrich J, Nowlin ZM. Olanzapine in the treatment of bipolar disorder in juveniles. 2nd Annual Stanley Foundation Conference on Bipolar Disorder, Amsterdam. September 21-22, 2000.
211. Baker RW, Milton DR, Tohen MF, Stauffer VL, Breier A. Olanzapine is not associated with exacerbation of bipolar mania. 2nd Annual Stanley Foundation Conference on Bipolar Disorder, Amsterdam. September 21-22, 2000.
212. Tohen MF, Baker RW, Milton DR, Risser RC, Gilmore JA, Davis AR, Richey AL. Olanzapine versus divalproex sodium in the treatment of acute mania. 2nd Annual Stanley Foundation Conference on Bipolar Disorder: Amsterdam. September 21-22, 2000.
213. Tohen M, Hennen J, Zarate C Jr, Baldessarini RJ, Strakowski SM, Stoll AL. The McLean First-Episode Project: two-year syndromal and functional recovery in 219 cases of major affective disorders with psychotic features. 2nd Annual Stanley Foundation Conference on Bipolar Disorder, Amsterdam. Sept. 21-22, 2000.
214. Tohen M. Use of antipsychotics in bipolar disorder. Bipolar disorder: from biological mechanisms to treatment. Canadian Psychiatric Association 50th Annual Meeting, Victoria, BC. October 5, 2000.
215. Tohen M, Baker RW, Gilmore J, Milton D, Risser R. Olanzapine versus divalproex for the treatment of acute mania. Institute on Psychiatric Services, Philadelphia, PA. October 2000.
216. Tohen M. The course of mania and schizobipolar variants. The coming of age of the bipolar spectrum. San Diego, CA. November 18-19, 2000.
217. Green AI, Tohen MF, Strakowski SM, Lieberman JA, Glick ID, Clarke SW, HGDH Study Group. Comorbid substance use disorder and first episode schizophrenia: acute effects of olanzapine vs. haloperidol. ACNP (American College of Neuropsychopharmacology), 39th Annual Meeting, San Juan, PR. December 10-14, 2000.
218. Meehan K, Zhang F, David SR, Tohen M, Koch KE, Rizk RT, Baris M, Walker D, Tran PV. Efficacy and safety of intramuscular (im) olanzapine vs. im lorazepam and im placebo in acutely agitated patients diagnosed with mania associated with bipolar disorder. ACNP (American College of Neuropsychopharmacology), 39th Annual Meeting, San Juan, PR. December 10-14, 2000.
219. Williamson DJ, Andersen SW, Ven Campen LE, Sam LM, Sanger TM, Tohen M, Tollefson G. A double-blind study of olanzapine-fluoxetine combination for treatment of psychotic major depression. Biol Psych 2001:49 (suppl) (8S):104S.
220. Baker RW, Milton Dr, Tohen M, Stauffer VL, Breier A. Olanzapine is not associated with exacerbation of bipolar mania. Biol Psych, 2001:49:1S-176S, APA, New Orleans. May 5-10, 2001.
221. Williamson DJ, Andersen SW, Van Campen LE, Sam LM, Sanger TM, Tohen M, Tollefson GD. A double blind study of olanzapine-fluoxetine combination for treatment of psychotic major depression. Biol Psych, 2001:49:1S-176S, APA 2001, New Orleans. May 5-10, 2001.
222. Williamson DJ, Andersen SW, Van Campen LE, Sam LM, Sanger TM, Tohen M, Tollefson GD. A double blind study of olanzapine-fluoxetine combination for treatment of psychotic major depression. European J Neuropsychopharm 2001:11(Suppl 3):S203.
223. Tohen M, Baker RW, Milton DR, Risser RC, Gilmore JA, Altshuler L, Zarate CA, Ketter TA. Olanzapine vs. Divalproex sodium for the treatment of acute mania. Biol Psych, 2001:49:1S-176S, APA 2001, New Orleans. May 5-10, 2001.
224. Meehan K, Zhang F, David S, Tohen M, Koch K, Rizk RT, Bari M, Breier A. Efficacy and safety of intramuscular (im) olanzapine vs. Im lorazepam and Im placebo in acutely agitated patients diagnosed with mania associated with bipolar disorder. Biol Psych, 2001:49:1S-176S; APA New Orleans. May 5-10, 2001.
225. Tohen M, Jacobs TG, Timpe TM, Risser RC, Keeter EL, Chengappa KNR, Suppes TR, Feldman PD, Breier A. Efficacy of olanzapine combined with valproate or lithium in the treatment of bipolar disorder. Biol Psych, 2001:49:1S-176S, APA, New Orleans. May 5-10, 2001.
226. Tohen M, Zarate CA Jr., Hennen J, Baldessarini RJ. The McLean-Harvard First Episode Mania Study. Biol Psych, 2001:49:1S-176S, APA, New Orleans. May 5-10, 2001.
227. Namjoshi M, Lizheng S, Zhang F, Edgell E, Tohen M, Breier A. Olanzapine vs. Haloperidol: improvements in quality of life and compliance with treatment in patients with bipolar disorder. APA, New Orleans. May 5-10, 2001.
228. Namjoshi M, Risser R, Lizheng S, Edgell E, Tohen M, Breier A. Impact of olanzapine added to lithium or valproate on the quality of life of patients with bipolar disorder. APA, New Orleans. May 5-10, 2001.
229. Lizheng S, Namjoshi M, Tohen M, Zhang F, Breier A, Edgell E. Olanzapine vs. Haloperidol: a prospective comparison of clinical and humanistic outcomes in bipolar disorder. APA, New Orleans. May 5-10, 2001.
230. Tohen M, Zhang F, Feldman P, Evans A, Breier A. Olanzapine vs. Haloperidol treatment of acute mania. APA, ` New Orleans. May 5-10, 2001.
231. Lim P, Tunis S, Edell W, Jensik S, Tohen M. Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines. Bipolar Disorders 2001:3.
232. Tohen M, Baker RW, Milton D, Risser R, Gilmore J, Davis A, Richey A. Olanzapine vs. Divalproex sodium for the treatment of acute mania. APA New Orleans. May 5-10, 2001.
233. Tohen M, Baker RW, Milton D, Risser R, Gilmore J, Davis A, Richey A. Olanzapine vs. Divalproex sodium for the treatment of acute mania. 7th World Congress of Biol Psych, Berlin, Germany. July 1-6, 2001.
234. Tohen M, Zhang F, Feldman P, Evans A, Breier A. Olanzapine vs. Haloperidol in the treatment of acute mania. 7th World Congress of Biol Psych, Berlin, Germany. July 1-6, 2001.
235. Tohen M, Risser R, Chengappa K, Suppes T, Breier A. Efficacy of olanzapine combined with valproate or lithium in the treatment of bipolar disorder. 7th World Congress of Biol Psych, Berlin, Germany. July 1-6, 2001.
236. Baker RW, Milton D, Tohen M, Stauffer V, Breier A. Olanzapine is not associated with exacerbation of bipolar mania. 7th World Congress of Biol Psych, Berlin, Germany. July 1-6, 2001.
237. Tohen M, Zhang F, Feldman P, Evans A, Breier A. Olanzapine vs. Haloperidol treatment of acute mania. WPA Madrid, Spain. September 30-October 4, 2001.
238. Tohen M, Baker RW, Milton D, Risser R, Gilmore J, Davis A, Richey A. Olanzapine vs. Divalproex sodium for the treatment of acute mania. WPA Madrid, Spain. September 30-October 4, 2001.
239. Baker RW, Tohen M, Altshuler L, Zarate CA, Suppes T, Ketter T, Risser RC, Schuh L. Olanzapine versus divalproex sodium for treatment of acute mania and maintenance of remission: a 47-week study. American College of Neuro-psychopharmacology 40th Annual Meeting, Waikoloa, HI. December 9-13, 2001.
240. Tohen M, Chengappa RKN, Suppes T, Baker RW, Risser RC, Evans AR, Calabrese JR. Olanzapine combined with mood stabilizers in prevention of recurrence in bipolar disorder: an 18-month study. American College of Neuropsycho-pharmacology 40th Annual Meeting, Waikoloa, HI. December 9-13, 2001.
241. Young RC, Kennedy JS, Kaiser C, Ahl JS, Tohen M. Olanzapine, divalproex and placebo treatment comparisons in older adult acute mania. American College of Neuropsychopharmacology 40th Annual Mtg., Waikoloa, HI. December 9-13, 2001.
242. Tohen M, Baker R, Altshuler L, Zarate CA, Suppes T, Ketter TA, Risser R, Brown EB, Luther MF, Gilmore JA, Schuh LM. Olanzapine vs. divalproex sodium for bipolar mania: a 47-week study. XITH Biennial Winter Workshop on Schizophrenia, Davos, Switzerland. February 24-March 1, 2002.
243. Tohen M, Chengappa RKN, Suppes T, Baker RW, Risser RC, Evans AR, Calabrese JR. Olanzapine combined with mild stabilizers in prevention of recurrence in bipolar disorder: an 18-month study. XITH Biennial Winter Workshop on Schizophrenia, Davos, Switzerland. February 24-March 1, 2002.
244. Cavazzoni P, Berg PH, Baker RW, Evans AR, Tohen M. Extrapyramidal symptoms of olanzapine vs. Placebo or haloperidol in the treatment of acute mania and contrasts to schizophrenia. XITH Biennial Winter Workshop on Schizophrenia, Davos, Switzerland. February 24-March 1, 2002.
245. Tohen MF, Chengappa KNR, Suppes P, Baker RW, Risser R, Evans AR, Calabrese JR. Olanzapine combined with lithium or valproate for relapse prevention of bipolar disorder: an 18-month study. APA Philadelphia, PA. May 18-23, 2002.
246. Baker RW, Tohen MF, Altshuler LL, Zarate CM, Suppes P, Ketter TA, Riccer RC. Olanzapine vs. divalproex sodium for mania: a 47-week study. APA Philadelphia, PA. May 18-23, 2002.
247. Cavazzoni PA, Berg PH, Baker RW, Evans AR, Tohen MF. Increased rates of antipsychotic-induced eps in mood disorders: myth or reality? APA Philadelphia, PA. May 18-23, 2002.
248. Tohen MF, Hennen J, Zarate CM, Strakowski SM, Baldessarini RJ. Predictors of syndromal and functional recovery in patients with first-episode mania. APA Philadelphia, PA. May 18-23, 2002.
249. McGlashan TH, Zipursky RB, Perkins DO, Addington JM, Tohen MF, Breier A, Woods SW. Intervention in the schizophrenic prodrome: rationale, studies and ethics. APA Philadelphia, PA. May 18-23, 2002.
250. Breier A, Zipursky RB, Perkins DO, Addington JM, Tohen MF, David SR, McGlashan TH. A trial of olanzapine vs. Pbo in the prodrome: protocol and baseline sample. APA Philadelphia, PA. May 18-23, 2002.
251. Tohen MF, Risser RC, Baker RW, Evans AR, Tollefson GD, Breier AF. Olanzapine in the treatment of bipolar depression. APA Philadelphia, PA. May 18-23, 2002.
252. Tohen M, Vieta E, Ketter T, Centorino F, Calabrese J, Sachs G, Bowden C, Risser R, Baker R, Evans A, Dube S, Tollefson G, Breier A. Olanzapine in the treatment of bipolar depression. NCDEU, 42nd Annual Meeting, Boca Raton, FL. June 10-13, 2002. [abstract] European Neuropsychopharm 202:12(Suppl 3):S238.
253. Baker R, Tohen M, Brown E, Schuh L, Zarate C, Suppes T. Olanzapine versus divalproex sodium for bipolar mania in rapid cyclers. NCDEU, 42nd Annual Meeting, Boca Raton, FL. June 10-13, 2002.
254. Cavazzoni P, Berg PH, Baker RW, Millikan MD, Evans AR, Tohen M. Increased rates of eps in mood disorders: myth or reality? XXIII CINP Congress, Montreal. June 23-27, 2002.
255. Shi L, Juarez R, Namjoshi M, Edgell ET, Tohen M. Breier A, Haro J. Olanzapine versus haloperidol as initial treatment in acute mania: prospective comparison of work functional outcomes. XXIII CINP Congress, Montreal. June 23-27, 2002.
256. Shi L, Wilson MG, Namjoshi M, Baker RW, Tohen M. Cognitive function associated with olanzapine in the treatment of acute mania: is cognitive improvement a marker of clinical improvement in manic symptoms? XXIII CINP Congress, Montreal. June 23-27, 2002.
257. Shi L, Namjoshi M, Yu X, Baker RW, Tohen M, Breier A. Olanzapine improves health-related quality of life in patients with bipolar depression. XXIII CINP Congress, Montreal. June 23-27, 2002.
258. Tohen M, Vieta E, Ketter T, Centorino F, Calabrese J, Sachs G, Bowden C, Mitchel P, Risser R, Baker RW, Evans AR, Dube S, Tollefson G, Breier A. Olanzapine in the treatment of bipolar depression. XXIII CINP Congress, Montreal. June 23-27, 2002.
259. Tohen M, Chengappa KNR, Suppes T, Baker RW, Risser RC, Evans AR, Calabrese JR. Olanzapine combined with mood stabilizers in prevention of recurrence in bipolar disorder: an 18-month study. XXIII CINP Congress, Montreal. June 23-27, 2002.
260. Baker R, Tohen M, Risser R, Brown E, Luther M, Gilmore J, Schuh L, Altshuler L, Zarate C Jr, Suppes T, Ketter T. Olanzapine versus divalproex sodium for bipolar mania: a 47-week study. XXIII CINP Congress, Montreal. June 23-27, 2002.
261. Corya S, Dube S, Anderson SW, Sanger TM, Clemos D, Tohen M, Tollefson G. Olanzapine-fluoxetine combination for psychotic major depression. XXIII CINP Congress, Montreal. June 23-27, 2002.
262. Baker R, Lindenmayer JP, Gelenberg A, Mcelroy SL, Brown E, Shao L, Schuh L, Stauffer V, Tohen M. Indication of manic-like symptoms in patients with schizophrenia treated with olanzapine, haloperidol, or placebo. XXIII CINP Congress, Montreal. June 23-27, 2002.
263. Baker R, Lindenmayer P, Brown E, Shao L, Schuh L, Tohen M, Stauffer V. Validation of a manic-like symptom scale from the positive and negative syndrome scale. XXIII CINP Congress, Montreal. June 23-27, 2002.
264. Tohen M. Olanzapine and olanzapine+fluoxetine in the treatment of bipolar depression. XII World Congress of Psychiatry, Yokohama, Japan. August 24-29, 2002.
265. Tohen M, Baker RW, Altshuler L, Zarate C, Ketter TA, Risser R. Olanzapine versus divalproex sodium for bipolar mania: a 47-week study. XII World Congress of Psychiatry, Yokohama, Japan. August 24-29, 2002.
266. Tohen M, Vieta E, Ketter T, Centorrino F, Calabrese J. Olanzapine improves outcome in bipolar depression. XII World Congress of Psychiatry, Yokohama, Japan. August 24-29, 2002.
267. Cavazzoni P, Berg PH, Baker RW, Millikan MD, Evans AR, Tohen M. Increased rates of eps in mood disorders: myth or reality? XII World Congress of Psychiatry, Yokohama, Japan. August 24-29, 2002.
268. Dube S, Andersen SW, Sanger TM, Tohen M, Tollefson GD. Olanzapine-fluoxetine for psychotic depression. XII World Congress of Psychiatry, Yokohama, Japan. August 24-29, 2002.
269. Tohen M, Chengappa KNR, Suppes T, Baker RW, Risser RC. Olanzapine cotherapy for bipolar relapse prevention. XII World Congress of Psychiatry, Yokohama, Japan. August 24-29, 2002.
270. King KG, Tohen M, Vieta E, Ketter TA, Centorrino F, Calabrese JR. Olanzapine in the treatment of bipolar depression. XII World Congress of Psychiatry, Yokohama, Japan. August 24-29, 2002.
271. Dube S, Andersen SW, Sanger TM, Clemow D, Tohen M, Tollefson GD. Olanzapine-fluoxetine combination for psychotic major depression. The Int'l J Neuropsychopharm 2002:5 (Suppl 1):S144.
272. Dube S, Andersen SW, Sanger TM, Clemow D, Tohen M, Tollefson GD. Olanzapine-fluoxetine combination for psychotic major depression. [abstract] European Neuropsychopharm 2002:12(Suppl 3):S180.
273. Shi L, Namjoshi M, Yu X, Baker R, Tohen M, Breier A. Olanzapine improves health-related quality of life in patients with bipolar depression. The Int'l J Neuropsychopharm 2002:5 (Suppl 1):S109.
274. Tohen M, Vieta E, Ketter E, Centorino F, Calabrese J, Sachs G, Bowden C, Mitchel P, Risser R, Baker RW, Evans AR, Dube S, Tollefson G, Breier A. Olanzapine in the treatment of bipolar depression. The Int'l J Neuropsychopharm 2002:5 (Suppl 1): S109.
275. Dube S, Anderson SW, Tohen M, Vieta E, Briggs SD, Van Campen LE, Sanger TM, Thase ME. Onset of action of olanzapine-fluoxetine combination for bipolar depression. [abstract] European Neuropsychopharm 2002:12(Suppl 3):S202.
276. Tohen M, Vieta E, Ketter T, Centorino F, Calabrese J, Sachs G, Bowden C, Risser R, Baker R, Evans A, Dube S, Tollefson G, Breier A. Olanzapine and olanzapine-fluoxetine combination (ofc) in the treatment of bipolar depression. J Psychopharm Suppl to V16(3). September 2002.
277. Tohen M, Marneros A, Bowden C, Calabrese J, Greil W, Koukopoulis A, Belmaker H, Jacobs T, Baker RW, Williamson D, Evans AR, Cassano G. Olanzapine vs. Lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. Third European Stanley Foundation Conference on Bipolar Disorder, Freiburg, Germany. September 12-14, 2002. Bipolar Disorders 135.
278. Dube S, Anderson SW, Clemow DB, Sanger TM, Tohen M, Tollefson GD. Olanzapine-fluoxetine combination for treatment of psychotic depression. [abstract] European Psychiatry 2002:17(Suppl 1):130.
279. Dube S, Anderson SW, Clemow DB, Sanger TM, Tohen M, Tollefson GD. Olanzapine-fluoxetine combination for treatment of psychotic depression. [abstract] Biol Psych 2002:51(Suppl 2)(8S):66S.
280. Tohen M. Bipolar depression: novel treatment solutions. IFMAD, International J Psych in Clin Practice 2002:6(4).
281. Baker RW, Vieta E, Ketter TA, Centorrino F, Calabrese J, Sachs G, Bowden C, Risser R, Evans AR, Dube S, Tollefson GD, Tohen M. Olanzapine and olanzapine-fluoxetine combination (ofc) in the treatment of bipolar depression. ACNP 41st Annual Meeting, San Juan, PR. December 8-12, 2002.
282. Tohen M, Marneros A, Bowden C, Greil W, Koukopoulis A, Belmaker H, Calabrese JR, Yatham LN, Jacobs T, Baker RW, Williamson D, Evans AR, Dossenbach M, Cassano G. Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. ACNP 41st Annual Meeting, San Juan, PR. December 8-12, 2002.
283. Tollefson G, Thase M, Case M, Briggs S, Van Campen L, Vallarino C, Tohen M, Dube S. Onset of action of olanzapine/fluoxetine combination in bipolar depression. ACNP 41st Annual Meeting, San Juan, PR. December 8-12, 2002.
284. Dube S, Keck P, Andersen S, Iyengar S, Tohen M. Treatment of rapid-cycling bipolar depression with olanzapine/fluoxetine. ACNP 41st Annual Meeting, San Juan, PR. December 8-12, 2002.
285. Keefe R, Seidman LJ, Christensen BK, Hamer RM, Yurgelun-Todd D, Lewine R, Sitskoorn M, Sharma T, Tohen M, Lieberman JA. Effects of olanzapine and low-dose haloperidol on neurocognition: a two-year treatment study in first episode psychosis. ACNP 41st Annual Meeting, San Juan, PR. December 8-12, 2002.
286. Lieberman J, Charles C, Sharma T, Zipursky R, Kahn R, Gur R, Tohen M, Green AI, McEvoy J, Perkins D, Hamer RM, Nemeroff C, Rothchild A, Kuldau J, Strakowski S, Tollefson G, HGDH R. Group. Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia. ACNP 41st Annual Meeting, San Juan, PR. December 8-12, 2002.
287. Baldessarini RJ, Salvatore P, Kaurkhalsa HM, Imez-Exteberria H, Gonzalez-Pinto A, Tohen M. Course of manic depressive illness: is there progressive cycle-shortening? ACNP 41st Annual Meeting, San Juan, PR. December 8-12, 2002.
288. Tohen M, Bowden C, Greil W, Jacobs T, Baker RW, Evans AR, Cassano G. Olanzapine in relapse prevention of bipolar disorder. ACNP 41st Annual Meeting, San Juan, PR. December 8-12, 2002.
289. Cavazzoni P, Tohen M, Baker RW, Brown EB, Schuh LM. Patters of weight gain in bipolar patients treated with olanzapine or divalproex. ACNP 41st Annual Meeting, San Juan, PR. December 8-12, 2002.
290. Renshaw PF, Yurgulen-Todd DA, Wei H, Charles C, Cohen BM, Tohen M, Sharma T, Zipursky R, Kahn R, Gur R, Green AI, McEvoy J, Perkins D, Hamer RM, Nemeroff C, Rothchild A, Kuldau J, Strakowski S, Tollefson G, Lieberman J, The HGDH Research Group. Olanzapine induced reductions in frontal lobe lactate levels correlate with treatment response in first episode psychosis. ACNP 41st Annual Meeting, San Juan, PR. December 8-12, 2002.
291. Tohen M, Marneros A, Bowden C, Greil W, Koukopoulis A, Belmaker H, Jacobs T, Baker RW, Evans AR, Dossenbach M, Cassano G. Olanzapine in the relapse prevention of bipolar disorder based on DSM-IV syndromic criteria. Third Int'l. Expert Review of Bipolar Disorders, Munich, Germany. April 6-8, 2003.
292. Shi L, Namjoshi M, Yu X, Baker R, Dube S, Tohen M, Breier A. Olanzapine alone and olanzapine in combination with fluoxetine improve health-related quality of life in patients with bipolar depression. The Third International Expert Review of Bipolar Disorders, Munich, Germany. April 6-8, 2003.
293. Tohen M, Vieta E, Ketter T, Centorrino F, Calabrese J, Sachs G, Bowden C, Risser R, Baker RW, Evans AR, Dube S, Tollefson G, Breier A. Olanzapine and olanzapine/fluoxetine combination (ofc) in the treatment of bipolar depression. The Third International Expert Review of Bipolar Disorders, Munich, Germany. April 6-8, 2003.
294. Tollefson GD, Thase ME, Case M, Briggs SD, Van Campen LE, Vallarino CR, Tohen M, Dube S. Onset of action of olanzapine fluoxetine combination in bipolar depression. The Third International Expert Review of Bipolar Disorders, Munich, Germany. April 6-8, 2003.
295. Tohen M, Chengappa KNR, Suppes T, Baker RW, Risser RC, Evans AR, Calabrese JR. Olanzapine combined with mood stabilizers in prevention of recurrence in bipolar disorder: an 18-month study. 58th Annual SOBP (Society of Biol Psych) Annual Convention, San Francisco, CA. May 15-17, 2003.
296. Dube S, Keck P, Andersen S, Tohen M. Olanzapine/fluoxetine combination in rapid cycling bipolar disorder. 58th Annual SOBP (Society of Biol Psych) Annual Convention, San Francisco, CA. May 15-17, 2003.
297. Dube S, Keck P, Andersen S, Tohen M. Olanzapine/fluoxetine combination in rapid cycling bipolar disorder. [abstract] Bipolar Disorders 2003:5(Suppl 1):43.
298. Dube S, Keck P, Andersen S, Tohen M. Olanzapine/fluoxetine combination in rapid cycling bipolar disorder. [abstract] Biol Psych 2003:53 (Suppl):196S.
299. Tohen M, Marneros A, Bowden C, Jacobs T, Baker RW, Evans AR, Cassano G. Olanzapine versus lithium in relapse prevention in bipolar disorder. APA (American Psychiatric Association) Annual Meeting, San Francisco, CA. May 17-22, 2003.
300. Tohen M, Ketter TA, Calabrese J, Andersen S, Detke HC, Risser R, Corya S. Long-term use of olanzapine or olanzapine/fluoxetine for bipolar depression. APA (American Psychiatric Association) Annual Meeting, San Francisco, CA. May 17-22, 2003.
301. Dube S, Tollefson GD, Thase ME, Briggs SD, Van Campen LE, Case M, Tohen M. Onset of action of olanzapine/fluoxetine combination in bipolar depression. APA (American Psychiatric Association) Annual Meeting, San Francisco, CA. May 17-22, 2003.
302. Dube S, Andersen S, Briggs SD, Van Campen LE, Tollefson GD, Tohen M. Sustained effect of olanzapine/fluoxetine combination and olanzapine in bipolar depression. APA (American Psychiatric Association) Annual Meeting, San Francisco, CA. May 17-22, 2003.
303. Keck P, Corya S, Andersen SW, Plewes J, Tohen M. Olanzapine/fluoxetine combination use in rapid-cycling bipolar depression. APA (American Psychiatric Association) Annual Meeting, San Francisco, CA. May 17-22, 2003.
304. Keck P, Corya S, Case M, Tohen M. Analysis of treatment-emergent mania with olanzapine/fluoxetine combination. APA (American Psychiatric Association) Annual Meeting, San Francisco, CA. May 17-22, 2003.
305. Shi L, Vallarino C, Prabhakar V, Juarez R, Namjoshi M, Tohen M. Olanzapine/fluoxetine combination improves long-term quality of life in bipolar depression. APA (American Psychiatric Association) Annual Meeting, San Francisco, CA. May 17-22, 2003.
306. Shi L, Vallarino C, Namjoshi M, Tohen M. Olanzapine/fluoxetine combination and QOL in rapid-cycling bipolar depression. APA (American Psychiatric Association) Annual Meeting, San Francisco, CA. May 17-22, 2003.
307. Tohen M, Vieta E, Ketter T, Mitchel PB, Centorrino F, Calabrese J, Sachs G, Bowden C, Risser R, Baker RW, Evans AR, Dube S, Tollefson GD, Breier A. Olanzapine and olanzapine/fluoxetine combination in the treatment of bipolar depression. APA (American Psychiatric Association) Annual Meeting, San Francisco, CA. May 17-22, 2003.
308. Tohen M. Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. NCDEU (New Clinical Drug Evaluation Unit), Boca Raton, FL. May 27-30, 2003.
309. Tohen M. Olanzapine's efficacy for relapse prevention in bipolar disorder: a randomized double-blind placebo-controlled 12-month clinical trial. NCDEU (New Clinical Drug Evaluation Unit), Boca Raton, FL. May 27-30, 2003.
310. Tohen M, Vieta E, Ketter TA, Calabrese J, Andersen S, Detke HC, Risser R, Corya S. Open-label maintenance treatment for bipolar depression using olanzapine or olanzapine/fluoxetine combination. ICBD (Stanley Foundation Conference on Bipolar Disorder, 5th International Conference on Bipolar Disorder), Pittsburgh, PA. June 12-14, 2003.
311. Keck P, Corya S, Andersen S, Tohen M. Analysis of olanzapine/fluoxetine combination in the treatment of rapid-cycling bipolar depression. ICBD (Stanley Foundation Conference on Bipolar Disorder, 5th International Conference on Bipolar Disorder), Pittsburgh, PA. June 12-14, 2003.
312. Keck P, Corya S, Case M, Tohen M. Analysis of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. ICBD (Stanley Foundation Conference on Bipolar Disorder, 5th International Conference on Bipolar Disorder), Pittsburgh, PA. June 12-14, 2003.
313. Tohen M, Vieta E, Ketter T, Centorrino F, Calabrese J, Sachs G, Bowden C, Risser R, Baker RW, Evans AR, Dube S, Tollefson GD, Breier A. Olanzapine and olanzapine/fluoxetine combination (ofc) in the treatment of bipolar depression. ICBD (Stanley Foundation Conference on Bipolar Disorder, 5th International Conference on Bipolar Disorder), Pittsburgh, PA. June 12-14, 2003.
314. Dube S, Tollefson GD, Thase ME, Briggs SD, Van Campen LE, Case M, Tohen M. Onset of action of olanzapine/fluoxetine combination in bipolar depression. ICBD (Stanley Foundation Conference on Bipolar Disorder, 5th International Conference on Bipolar Disorder), Pittsburgh, PA. June 12-14, 2003.
315. Baker RW, Brown E, Tohen M, Schuh LM, Trzepacz P. Dysphoric mania: a controlled study of the benefits of olanzapine combined with valproate or lithium. Bipolar Disorder, 5th International Conference on Bipolar Disorder, Pittsburgh, PA. June 12-14, 2003. Bipolar Disorders 2003:5:(Suppl 1).
316. Baker RW, Brown E, Schuh L, Pinaire J, Tohen M. Patterns of weight gain in bipolar patients treated with olanzapine or divalproex. Bipolar Disorder, 5th International Conference on Bipolar Disorder, Pittsburgh, PA. June 12-14, 2003. Bipolar Disorders 2003:(5):(Suppl 1).
317. Dube S, Tollefson GD, Thase ME, Briggs SD, Van Campen LE, Case M, Tohen M. Onset of action of olanzapine/fluoxetine combination in bipolar depression. Bipolar Disorder, 5th International Conference on Bipolar Disorder, Pittsburgh, PA. June 12-14, 2003. Bipolar Disorders 2003:(5):(Suppl 1).
318. Tohen M, Bowden C, Calabrese J, Chou J C-Y, Jacobs T, Baker RW, Williamson D, Evans AR. Olanzapine's efficacy for relapse prevention in bipolar disorder: a randomized double-blind placebo-controlled 12-month clinical trial. Bipolar Disorder, 5th International Conference on Bipolar Disorder, Pittsburgh, PA. June 12-14, 2003. Bipolar Disorders 2003:(5):(Suppl 1).
319. Tohen M, Marneros A, Bowden C, Greil W, Koukopoulos A, Belmaker H, Jacobs T, Baker RW, Williamson D, Evans AR, Dossenbach M, Gassano G. Olanzapine vs. lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. Bipolar Disorders, 5th International Conference on Bipolar Disorder, Pittsburgh, PA. June 12-14, 2003. Bipolar Disorders 2003:(5):(Suppl 1).
320. Tohen M, Bowden C, Calabrese J, Chou J, Jacobs T, Baker RW, Williamson D, Evans AR. Olanzapine's efficacy for relapse prevention in bipolar disorder: A randomized double-blind placebo-controlled 12-month clinical trial. Bipolar Disorders, 5th International Conference on Bipolar Disorders, Pittsburgh, PA. June 12-14, 2003. Bipolar Disorders 2003:(5):(Suppl 1).
321. Dube S, Tollefson GD, Thase ME, Briggs SD, Van Campen LE, Case M, Tohen M. Onset of action of olanzapine/fluoxetine combination in bipolar disorder. Bipolar Disorders, 5th International Conference on Bipolar Disorders, Pittsburgh, PA. June 12-14, 2003. Bipolar Disorders 2003:(5):(Suppl 1).
322. Corya S, Keck P, Calabrese J, Andersen S, Gillig M, Baker R, Tohen M. Analysis of olanzapine/fluoxetine combination in the treatment of rapid-cycling bipolar depression. European Neuropsychopharm 2003:13(Suppl 4):S250.
323. Keck P, Corya S, Case M, Tohen M. Analysis of treatment-emergent mania with olanzapine/fluoxetine combination. European Neuropsychopharm 2003:13 (Suppl 4):S212.
324. Tohen M, Shi L, Vallarino C, Prabhakar V, Juarez R, Namjoshi M. Olanzapine/ fluoxetine combination improves long-term quality of life in bipolar depression. European Neuropsychopharm 2003:13(Suppl 4):S212.
325. Vieta E, Tohen M, Ketter TA, Calabrese J, Andersen S, Detke HC, Risser R, Corya S. Long-term use of olanzapine or olanzapine/fluoxetine for bipolar depression. European Neuropsychopharm 2003:13(Suppl 4):S207.
326. Evans AR, Tohen M, Marneros A, Bowden C, Greil W, Koukopoulis A, Belmaker H, Jacobs T, Baker RW, Williamson D, Dossenbach M, Cassano G. Olanzapine versus lithium in relapse prevention in bipolar disorder: A randomized double-blind controlled 12-month clinical trial. European Neuropsychopharm 2003:13(Suppl 4):S213.
327. Tohen M, Baker RW, Brown E, Schuh L, Trzepacz PT, Dando S. Dysphoric mania: A controlled study of the benefits of olanzapine combined with valproate or lithium. European Neuropsychopharm 2003:13(Suppl 4):S228.
328. Tohen M, Bowden C, Calabrese J, Chou J, Jacobs T, Baker RW, Williamson D, Evans AR. Olanzapine's efficacy for relapse prevention in bipolar disorder: A randomized double-blind placebo-controlled 12-month clinical trial. European Neuropsychopharm 2003:13(Suppl 4):S212.
329. Tohen M, Chengappa KNR, Suppes T, Baker RW, Risser RC, Evans AR, Calabrese JR. Olanzapine combined with mood stabilizers in prevention of recurrence in bipolar disorder: An 18-month study. Biol Psych 2003:53(Suppl):134S.
330. Tohen M, Marneros A, Bowden C, Greil W, Koukopoulis A, Belmaker H, Jacobs T, Baker RW, Williamson D, Evans AR, Dossenbach M, Cassano G. Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. Bipolar Disord 2003:5(Suppl 1).
331. Tohen M, Bowden C, Calabrese J, Chou JC, Jacobs T, Baker RW, Williamson D, Evans AR. Olanzapine's efficacy for relapse prevention in bipolar disorder: A randomized double-blind placebo-controlled 12-month clinical trial. Int'l Society for Bipolar Disorders 1st Regional Group Conference (poster), Sydney, Australia, February 5-7, 2004.
332. Tohen M, Mameros A, Bowden C, Baker RW, Evans AR, Cassano G. Olanzapine in the relapse prevention of bipolar disorder based on DSM-IV syndromic criteria. Int'l Society for Bipolar Disorders 1st Regional Group Conference (poster), Sydney, Australia, February 5-7, 2004.
333. Keck PE, Corya SA, Briggs SD, Case M, Tohen M. Analysis of treatment-emergent mania with olanzapine/fluoxetine combination. Int'l Society for Bipolar Disorders 1st Regional Group Conference (poster), Sydney, Australia, February 5-7, 2004.
334. Keck PE, Calabrese JR, Corya SA, Andersen SW, Gillig M, Baker RW, Tohen M. Olanzapine/fluoxetine combination in the treatment of rapid-cycling bipolar depression. Int'l Society for Bipolar Disorders 1st Regional Group Conference (poster), Sydney, Australia, February 5-7, 2004.
335. Ketter TA, Tohen M, Vieta E, Calabrese J, Andersen S, Detke HC, Risser R, Corya S. Open-label maintenance treatment for bipolar depression using olanzapine or olanzapine/fluoxetine combination. Int'l Society for Bipolar Disorders 1st Regional Group Conference (poster), Sydney, Australia, February 5-7, 2004.
336. Tohen M, Bowden C, Calabrese J, Chou JC, Baker RW, Williamson D, Evans AR. Olanzapine's efficacy for relapse prevention in bipolar disorder: A randomized double-blind placebo-controlled 12-month clinical trial. 1st Int'l Congress of Biological Psychiatry (poster) (sponsored by WFSBP), Sydney, Australia, February 9-13, 2004.
337. Tohen M, Marneros A, Bowden C, Baker RW, Williamson D, Evans AR, Cassano G. Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. 1st Int'l Congress of Biological Psychiatry (poster) (sponsored by WFSBP), Sydney, Australia, February 9-13, 2004.
338. Tohen M, Bowden CL, Risser R, Detke HC, Calabrese JR. Olanzapine versus placebo in the prevention of relapse for mixed index versus manic index episode patients. 1st Int'l Congress of Biological Psychiatry (poster) (sponsored by WFSBP), Sydney, Australia, February 9-13, 2004.
339. Keck PE, Corya SA, Briggs SD, Case M, Tohen M. Analysis of treatment- emergent mania with olanzapine/fluoxetine combination. 1st Int'l Congress of Biological Psychiatry (poster) (sponsored by WFSBP), Sydney, Australia, February 9-13, 2004.
340. Corya SA, Briggs SD, Case M, Tohen M. Olanzapine/fluoxetine combination for treatment-resistant depression with current SSRI failure. 1st Int'l Congress of Biological Psychiatry (poster) (sponsored by WFSBP), Sydney, Australia, February 9-13, 2004.
341. Keck PE, Calabrese JR, Corya SA, Andersen SW, Gillig M, Baker RW, Tohen M. Olanzapine/fluoxetine combination in the treatment of rapid-cycling bipolar depression. 1st Int'l Congress of Biological Psychiatry (poster) (sponsored by WFSBP), Sydney, Australia, February 9-13, 2004.
342. Ketter TA, Tohen M, Vieta E, Calabrese JR, Andersen SW, Detke HC, Risser RC, Corya SA. Open-label maintenance treatment for bipolar depression using olanzapine or olanzapine/fluoxetine combination. 1st Int'l Congress of Biological Psychiatry (poster) (sponsored by WFSBP), Sydney, Australia, February 9-13, 2004.
343. Baldessarini RJ, Tondo L, Tohen M, Salvatore P, Gonzalez-Pinto A, Hennen J, Ghaemi SN, Faedda GL: Effects of lithium on bipolar depression and suicidal risk (Abstract S79). Ital J Psychopathology 2004:10(Suppl):168. Italian Society for Psychopathology (SOPSI), Rome, February 2004.
344. Tohen M, Bowden C, Calabrese J, Chou JC, Baker RW, Williamson D, Evans AR. Olanzapine's efficacy for relapse prevention in bipolar disorder: A randomized double-blind placebo-controlled 12-month clinical trial. First Int'l Congress of Biological Psychiatry (WFSBP) (abstract), Sydney, Australia, February 2004.
345. Tohen M, Marneros A, Bowden C, Baker RW, Williamson D, Evans AR, Cassano G. Olanzapine versus lithium in relapse prevention in bipolar disorder: a randomized double-blind controlled 12-month clinical trial. First Int'l Congress of Biological Psychiatry (WFSBP) (poster), Sydney, Australia, February 2004.
346. Tohen M, Bowden CL, Risser R, Detke HC, Calabrese JR. Olanzapine versus placebo in the prevention of relapse for mixed versus manic index episode patients. First Int'l Congress of Biological Psychiatry (WFSBP) (poster), Sydney, Australia, February 2004.
347. Keck PE, Corya SA, Riggs SD, Case M, Tohen M. Analysis of treatment-emergent mania with olanzapine/fluoxetine combination. First Int'l Congress of Biological Psychiatry (WFSBP) (poster), Sydney, Australia, February 2004.
348. Corya SA, Briggs SD, Case M, Tohen M. Olanzapine/fluoxetine combination for treatment-resistant depression with current SSRI failure. First Int'l Congress of Biological Psychiatry (WFSBP) (poster), Sydney, Australia, February 2004.
349. Keck PE, Calabrese JR, Corya SA, Andersen SW, Gillig M, Baker RW, Tohen M. Olanzapine/fluoxetine combination in the treatment of rapid-cycling bipolar depression. First Int'l Congress of Biological Psychiatry (WFSBP) (poster), Sydney, Australia, February 2004.
350. Ketter TA, Tohen M, Vieta E, Calabrese JR, Andersen SW, Detke HC, Risser RC, Corya SA. Open-label maintenance treatment for bipolar depression using olanzapine or olanzapine/fluoxetine combination. First Int'l Congress of Biological Psychiatry (WFSBP) (poster), Sydney, Australia, February 2004.
351. Tohen M, Bowden C, Calabrese J, Chou JC, Jacobs T, Baker RW, Williamson D, Evans AR. Olanzapine's efficacy for relapse prevention in bipolar disorder. A randomized double-blind placebo-controlled 12-month clinical trial. Int'l Society for Bipolar Disorders 1st Regional Group Conference (poster), Sydney, Australia, February 2004.
352. Tohen M, Marneros A, Bowden C, Baker RW, Evans AR, Cassano G. Olanzapine in the relapse prevention of bipolar disorder based on DSM-IV syndromic criteria. Int'l Society for Bipolar Disorders 1st Regional Group Conference (poster), Sydney, Australia, February 2004.
353. Keck PE, Corya SA, Briggs SD, Case M, Tohen M. Analysis of treatment-emergent mania with olanzapine/fluoxetine combination. Int'l Society for Bipolar Disorders 1st Regional Group Conf. (poster), Sydney, Australia, February 2004.
354. Keck PE, Calabrese JR, Corya SA, Andersen SW, Gillig M, Baker RW, Tohen M. Olanzapine/fluoxetine combination in the treatment of rapid-cycling bipolar depression. Int'l Society for Bipolar Disorders 1st Regional Group Conference (poster), Sydney, Australia, February 2004.
355. Ketter TA, Tohen M, Vieta E, Calabrese J, Andersen S, Detke HC, Risser R, Corya S. Open-label maintenance treatment for bipolar depression using olanzapine or olanzapine/fluoxetine combination. Int'l Society for Bipolar Disorders 1st Regional Group Conference (poster), Sydney, Australia, February 2004.
356. Tohen M, Zarate Jr. C, Hennen J, Khalsa H-M K, Strakowski SM, Gebre-Medhin P, Salvatore P, Baldessarini RJ. Prediction of recovery and recurrence in patients with first episode mania. J of Affective Disorders 78 (2004) S1.2 from ISAD 2nd Biennial Conference (Symposium abstract), Cancun, Mexico, March 2004
357. Dube S, Corya S, Tollefson G, Andersen S, Risser R, Case M, Briggs S, Tohen M. Olanzapine and Fluoxetine in difficult-to-treat depressions. J of Affective Disorders 78 (2004) S19.3 from ISAD 2nd Biennial Conference (Symposium abstract), Cancun, Mexico, March 2004
358. Tohen M. Predictors of Outcome in 52 cases of psychotic nonaffective disorders. CME Syllabus & Proceedings Summary. 2004 APA Annual Meeting, New York, NY, May 1-6, 2004.
359. Tohen M, Risser R, Detke H, Forrester T, Corya S. Time in Euthymia for bipolar patients receiving olanzapine or lithium maintenance treatment. Poster No. 67. NCDEU 44th Annual Meeting, Phoenix, AZ, June 1-4, 2004.
360. Lipkovich I, Ahmed S, Ahl J, Hardy T, Haldane D, Baker RW, Tohen M. Early weight gain as a predictor of substantial weight: Results from seven studies of olanzapine for the treatment of bipolar disorder. Poster No. 61. NCDEU 44th Annual Meeting, Phoenix, AZ, June 1-4, 2004.
361. Corya S, Briggs S, Case M, Tohen M. Varying the criteria for response and remission in bipolar depression. Poster No. 62. NCDEU 44th Annual Meeting, Phoenix, AZ, June 1-4, 2004.
362. Tohen M, Vieta E, Ketter T, Bowden C, Mitchel P, Risser R, Baker RW, Evans A. Acute and maintenance treatment of bipolar depression: Focus on rapidly evolving methodology. Panel 1. NCDEU 44th Annual Meeting, Phoenix, AZ, June 1-4, 2004.
363. Ahmed S, Duan Y, Healey K, Lipkovich I, Tohen M. Comparison of olanzapine and lithium treatment groups based on lithium blood levels: A 52-week bipolar relapse prevention study. Poster No. 79. NCDEU 44th Annual Meeting, Phoenix, AZ, June 1-4, 2004.
364. Tohen M. Redefining issues in patient care: Exploring early options to impact treatment during the maintenance phase. Int'l J of Neuropsychopharmacology, XXIV CINP Congress, Paris, June 20-24, 2004.
365. Tohen M, Bowden C, Calabrese J, Sachs G, Risser R, Detke H, Shen H. Predictors of time to relapse in bipolar I disorder. Int'l J of Neuropsychopharmacology, XXIV CINP Congress, Paris, June 20-24, 2004.
366. Corya S, Briggs S, Case M, Tohen M. Effect of Olanzapine/Fluoxetine on core mood symptoms in bipolar depression. Int'l J of Neuropsychopharmacology, XXIV CINP Congress, Paris, June 20-24, 2004.
367. Corya S, Vieta E, Briggs S, Case M, Tohen M. Olanzapine/Fluoxetine combination for bipolar depression with comorbid anxiety symptoms. Int'l J of Neuropsychopharmacology, XXIV CINP Congress, Paris, June 20-24, 2004.
368. Yurgelun-Todd D, Gruber S, Wei H, Risser R, Tohen M. Improved cognitive outcome associated with olanzapine treatment in bipolar patients. Int'l J of Neuropsychopharmacology, XXIV CINP Congress, Paris, June 20-24, 2004.
369. Tohen M, Bowden C, Risser R, Detke H, Calabrese J. Olanzapine vs. placebo in the prevention of relapse for mixed index vs. manic index episode patients. Int'l J of Neuropsychopharmacology, XXIV CINP Congress, Paris, June 20-24, 2004.
370. Corya S, Case M, Briggs S, Tohen M. Olanzapine/fluoxetine combination for treatment-resistant depression with current SSRI failure. Int'l J of Neuropsychopharmacology, XXIV CINP Congress, Paris, June 20-24, 2004.
371. Tohen M, Vieta E, Calabrese J, Ketter T, Mitchell P, Briggs S, Case M. Clinical predictors of response to olanzapine or olanzapine/fluoxetine combination for bipolar depression. Int'l J of Neuropsychopharmacology, XXIV CINP Congress, Paris, June 20-24, 2004.
372. Tohen M, Risser R, Detke H, Forrester T, Corya S. Time in euthymia for bipolar patients receiving olanzapine or lithium maintenance treatment. Int'l J of Neuropsychopharmacology, XXIV CINP Congress, Paris, June 20-24, 2004.
373. Tohen M. El Proyecto McLean-Harvard de primeros episodios psicoticos. VII Congreso Nacional De Psiquiatria. Bilboa, Spain. October 26-30, 2004.
374. Tohen M, Bowden C, Calabrese J, Sachs G, Risser R, Detke H, Shen H, Predictors of time to relapse in Bipolar I Disorder. World Psychiatric Association International Congress, Florence, Italy. November 10-13, 2004.
375. Tohen M, Risser R, Detke H, Forrester T, Corya S. Time in euthymia for bipolar Patients receiving olanzapine or lithium maintenance treatment. World Psychiatric Association International Congress, Florence, Italy. Nov. 10-13, 2004.
376. Corya S, Case M, Briggs S, Tohen M. Olanzapine/Fluoxetine combination for Treatment-Resistant Depression. World Psychiatric Association International Congress, Florence, Italy. November 10-13, 2004.
377. Tohen M. New advances in treatment options during the maintenance phase: Two pivotal maintenance studies. World Psychiatric Association International Congress, Florence, Italy. November 10-13, 2004.
378. Corya S, Briggs S, Case M, Tohen M. Effect of Olanzapine/Fluoxetine combination on core mood symptoms in bipolar depression. World Psychiatric Association International Congress, Florence, Italy. November 10-13, 2004.
379. Baldessarini R J., Salvatore P, Tohen M, Khalsa H K, Hennen J, Gonzalez-Pinto A, Baethge C. Morbidity from Onset in First-episode Bipolar I Disorder Patients: The International 300 Study, Neuropsychopharmacology, Vol 29, Supplement 1, ACNP 43rd Annual Meeting, December 12-16, 2004, San Juan, Puerto Rico.
380. Yurgelun-Todd, D A, Gruber S A, Risser R, Briggs S, Tohen M, Neurocognitive Function after Treatment with Lithium or Olanzapine: A Double Blind Study Neuropsychopharmacology, Vol 29, Supplement 1, ACNP 43rd Annual Meeting, December 12-16, 2004, San Juan, Puerto Rico.
381. Corya SA, Case M, Briggs SD, Tohen M. Olanzapine/fluoxetine combination in treatment-resistant depression with current SSRI failure. Eur Psychiatry. 2004;19 (suppl 1): 216S.
382. Tohen M, Bowden CL, Risser R, Detke HC, Calabrese JR. Olanzapine vs. placebo in the prevention of relapse for mixed index vs. manic index episode patients. Eur Psychiatry. 2004: 19(suppl. 1): 205S.
383. Tohen M, Vieta E, Calabrese J, Ketter TA, Mitchell P, Briggs SD, Case M. Clinical predictors of response to olanzapine or olanzapine/fluoxetine combination for bipolar depression. 12th Congress of the Association of European Psychiatrists, April 14-18, 2004; Geneva, Switzerland.
384. Yurgelun-Todd DA, Gruber SA, Wei H, Risser RC, Tohen M. Improved cognitive outcome is associated with olanzapine treatment in bipolar patients. Eur Psychiatry. 2004:19 (suppl 1): 205S.
385. Corya SA, Briggs SD, Case M, Tohen M. Olanzapine/Fluoxetine Combination for Bipolar Depression with Comorbid Anxiety Symptoms. Biological Psychiatry. Vol 55, Number 85, 59th Annual Convention and Scientific Program, April 29-May 1, 2004, New York, New York.
386. Woods SW, Miller TJ, Zipursky RB, Perkins DO, Addington J, Tohen M, Breier A, McGlashan TH. Olanzapine Treatment of First Episode Pyschosis after Zero DUP. Biological Psychiatry. Vol 55, No 85, 59th Annual Convention and Scientific Program, April 29-May 1, 2004, New York, New York.
387. Houston JP, Degenhardt EL, Kaiser C, Ahl J, Baker RW, Tohen M. Suicidal Ideation Changes in Depressed Bipolar 1 Patients Treated with Olanzapine/Fluoxetine Combination. Biological Psychiatry. Vol 55, No 85, 59th Annual Conv. and Scientific Program, April 29-May 1, 2004, New York, NY.
388. Corya S, Keck P, Vieta E, Niswander J, Xu W, Tohen M, Risser R. Olanzapine/Fluoxetine and Olanzapine Treatment for Bipolar Depression: Open-Label Continuation in Rapid Cycling Patients. 5th International Review of Bipolar Disorders, April 21-23, 2005; Lyon, France.
389. Yurgelun-Todd DA, Gruber SA, Risser R, Briggs SD, Tohen M. Neurocognitive Function after Treatment with Lithium or Olanzapine: A Double-Blind Study. Biological Psychiatry. Vol 57, No 8S, 6th Annual Convention and Scientific Program, May 19-May 21, 2005, Atlanta, Georgia.
390. Ketter T, Houston JP, Risser RC, Adams DH, Meyers A, Williamson D, Tohen M. Olanzapine and Lithium Prophylaxis of Bipolar Disorder and Episode History. Biological Psychiatry. Vol 57, No 8S, 6th Annual Convention and Scientific Program, May 19-May 21, 2005, Atlanta, Georgia.
391. Yurgelun-Todd DA, Gruber SA, Risser RC, Briggs SD, Bauer TA, Tohen M. Neurocognitive Function After Treatment with Lithium or Olanzapine: A Double Blind Study. 45th Annual Meeting NCDEU, National Institute of Mental Health, June 6-9, 2005, Boca Raton, Florida.
392. Houston JP, Ketter TA, Risser RC, Adams DH, Meyers A, Williamson D, Tohen M. Olanzapine and Lithium Prophylaxis of Bipolar Disorder and Episode History. 45th Annual Meeting NCDEU, National Institute of Mental Health, June 6-9, 2005, Boca Raton, Florida.
393. Corya S, Keck Jr. PE, Vieta E, Niswander JM, Xu W, Tohen M. Olanzapine/Fluoxetine and Olanzapine Treatment for Bipolar Depression: Open-Label Continuation in Rapid Cycling Patients. 45th Annual Meeting NCDEU, National Institute of Mental Health, June 6-9, 2005, Boca Raton, Florida.
394. Berk M, Malhi GS, Cahill C, Carman AC, Hadzi-Pavlovic D, Hawkins MT, Tohen M, Mitchell PB. The utility development and validation of the Bipolar Depression Rating Scale (BDRS). Vol 7, Sup 2, 6th International Conference of Bipolar Disorder, June 16-18, 2005, Pittsburgh, Pennsylvania.
395. Corya SA, Keck Jr PE, Vieta E, Niswander JM, Xu W, Tohen M. Olanzapine/fluoxetine and olanzapine treatment for bipolar depression: open-label continuation in rapid cycling patients. Vol 7, Sup 2, 6th International Conference of Bipolar Disorder, June 16-18, 2005, Pittsburgh, Pennsylvania.
396. Corya SA, Williamson D, Case M, Lin D, Tohen M. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. Vol 7, Sup 2, 6th International Conference of Bipolar Disorder, June 16-18, 2005, Pittsburgh, Pennsylvania.
397. Houston JP, Ketter TA, Risser RC, Adams DH, Meyers A, Williamson DJ, Tohen M. Olanzapine and lithium prophylaxis of bipolar disorder and episode history. Vol 7, Supp 2, 6th International Conference of Bipolar Disorder, June 16-18, 2005, Pittsburgh, Pennsylvania.
398. Salvatore P, Baldessarini RJ, Tohen M, Khalsa H-MK, Hennen J, Gonzalez-Pinto A, Baethge C. Morbidity from onset in first-episode bipolar-I-disorder patients: The Bipolar International-300 Study. Vol 7, Sup 2, 6th International Conference of Bipolar Disorder, June 16-18, 2005, Pittsburgh, Pennsylvania.
399. Berk M, Vieta E, Yatham L, Tohen M. Moving the field forward: The impact of research driven educational initiatives on bipolar patients and providers. Symposium 12, International Society for Bipolar Disorders. June 16 - 18, 2005, Pittsburgh, Pennsylvania.
400. Brown E, Dunner D, Adams D, Degenhardt E, Tohen, M, Williamson D, Houston J. Olanzapine/Fluoxetine Combination Versus Lamotrigine in the Long-Term Treatment of Bipolar I Depression. 44th ACNP Annual Meeting, December 11-15, 2005, Waikoloa, Hawaii.
401. Tohen M., Kryzhanovskaya L, Carlson G, DelBello M, Wozniak J, Kowatch R, Wagner K, Findling R, Lin D, Robertson-Plouch C, Xu W, Huang X, Dittman R, Biederman J. Olanzapine in the Treatment of Acute Mania in Adolescents with Bipolar I Disorder: A 3-Week Randomized Double-Blind Placebo-Controlled Study. 44th ACNP Annual Meeting, December 11-15, 2005, Waikoloa, Hawaii.
402. Kryzhanovskaya L, Schulz C, McDougle C, Frazier J, Shen J, Dittman R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Corya S, Tohen M. A Double-Blind, Placebo-Controlled Study of Olanzapine in Adolescents with Schizophrenia. 44th ACNP Annual Meeting, December 11-15, 2005, Waikoloa, Hawaii.
403. Kryzhanovskaya L, Schulz C, McDougle C, Frazier J, Shen J, Dittman R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Corya S, Tohen M. A Double-Blind, Placebo-Controlled Study of Olanzapine in Adolescents with Schizophrenia. 44th ACNP Annual Meeting, December 11-15, 2005, Waikoloa, Hawaii.
404. Brown E, Dunner D, Adams DH, Degenhardt E, Tohen M, Williamson D, Houston JP. Olanzapine/Fluoxetine Combination versus Lamotrigine in the Long-Term Treatment of Bipolar I Depression. Biol Psychiatry 2006;59(81), Toronto, Ontario, May 2006.
405. Tohen M, Kryzhanovskaya L, Carlson G, DelBello M, Wozniak J, Kowatch R, Wagner K, Findling R, Lin D, Robertson-Plouch C, Xu W, Huang Xiaohong, Dittmann R, Biederman J. Olanzapine in the Treatment of Acute Mania in Adolescents with Bipolar I Disorder; A 3-Week Randomized Double-Blind Placebo-Controlled Study. Biol Psychiatry 2006;59(387), Toronto, Ontario, May 2006.
406. Ascher-Svanum H, Zhu B, Fairies D, Kinon B, Tohen M. The 3-Year Course of Schizophrenia Among Persons with Tardive Dyskinesia and Persons Without. Biol Psychiatry 2006;59(672), Toronto, Ontario, May 2006.
407. Kryzhanovskaya L, Schulz C, McDougle CJ, Frazier JA, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang WV, Carlson J, Tohen M. A Double-Blind, Placebo-Controlled Study of Olanzapine in Adolescents with Schizophrenia. Biol Psychiatry 2006;59(733), Toronto, Ontario, May 2006.
408. Kryzhanovskaya L, Schulz C, McDougle CJ, Frazier JA, Dittmann RW, Robertson-Plouch C, Bauer T, Xu W, Wang WV, Carlson J, Tohen M. A Double-Blind, Placebo-Controlled Study of Olanzapine in Adolescents with Schizophrenia. Schizophrenia Research 81 (Supplement 1), S44-45, Toronto, Ontario, May 2006.
409. Kryzhanovskaya L, Schulz C, McDougle CJ, Frazier JA, Dittmann RW, Robertson-Plouch C, Bauer T, Xu W, Wang WV, Carlson J, Tohen M. A Double-Blind, Placebo-Controlled Study of Olanzapine in Adolescents with Schizophrenia. European Psychiatry, 21 (Supplement 1), S104-105, Toronto, Ontario, May 2006.
410. Baethge C, Gonzalez-Pinto A, Khalsa HMK, Salvatore P, Tohen M, Tondo L. Lecture: Overview of recent research on the course and morbidity in bipolar I disorder. Sixth International Bakirkoy Days, May 8-10, 2006, Istanbul, Turkey.
411. Tohen M., Kryzhanovskaya L, Carlson G, DelBello M, Wozniak J, Kowatch R, Wagner K, Findling R, Lin D, Robertson-Plouch C, Xu W, Huang X, Dittman R, Biederman J. Olanzapine in the Treatment of Acute Mania in Adolescents with Bipolar I Disorder: A 3-Week Randomized Double-Blind Placebo-Controlled Study. SOBP, May 18-20, 2006, Toronto, Canada.
412. Ascher-Svanum H, Zhu B, Faries D, Kinon B, Tohen M. The 3-Year Course of Schizophrenia Among Persons With Tardive Dyskinesia and Persons Without. SOBP, May 18-20, 2006, Toronto, Canada
413. Kryzhanovskaya L, Schulz C, McDougle C, Frazier J, Shen J, Dittman R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Corya S, Tohen M. A Double-Blind, Placebo-Controlled Study of Olanzapine in Adolescents with Schizophrenia. SOBP, May 18-20, 2006, Toronto, Canada.
414. Dunner D, Degenhardt E, Tohen M, Williamson D. Symbyax vs. Lamotrigine for the Treatment of Bipolar Depression-Time to Relapse. SOBP, May 18-20, 2006, Toronto, Canada.
415. Kryzhanovskaya L, Schulz C, McDougle CJ, Frazier JA, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang WV, Carlson J, Tohen M. A Double-Blind, Placebo-Controlled Study of Olanzapine in Adolescents with Schizophrenia. APA, Toronto, Canada, May 20-26, 2006.
416. Ascher-Svanum H, Zhu B, Faries D, Kinon B, Tohen M. The 3-Year Course of Schizophrenia Among Persons With Tardive Dyskinesia and Persons Without (SCAP). APA, Toronto, Canada, May 20-26, 2006.
417. Tohen M. Baseline Characteristics And Outcomes in First And Multiple Episode Patients with Acute Mania. APA, Toronto, Canada, May 20-26, 2006.
418. Tohen M. Olanzapine vs. Placebo in the Treatment of Mania in Adolescents with Bipolar I Disorder. APA, Toronto, Canada, May 20-26, 2006.
419. Tohen M. Olanzapine vs. Placebo in the Treatment of Mania in Adolescents with Bipolar I Disorder. APA, Toronto, Canada, May 20-26, 2006.
420. Ascher-Svanum H, Zhu B, Faries D, Kinon B, Tohen M. The 3-Year Course of Schizophrenia Among Persons With Tardive Dyskinesia and Persons Without. NCDEU, Boca Raton, Florida, June 12-15, 2006.
421. Tohen M. Analyses of Treatment Efficacy in Subtypes of Adolescent Patients with Bipolar Disorder Treated with Olanzapine for Acute Mania: A 3-Week Randomized Double-Blind Placebo-Controlled Study. NCDEU, 46th Annual Meeting, Boca Raton, Florida, June 12-15, 2006.
422. Vieta E, Panicali F, Goetz I, Reed C, Comes M, Tohen M. Emblem Advisory Board. Outcome of Mania with Olanzapine in a Large Multicentre, Observational Study Across Europe: The Emblem. CINP, Chicago, IL. July 9-13, 2006.
423. Tohen M, Kryzhanovskaya L, Carlson G, DelBello M, Wozniak J, Kowatch R, Wagner K. Findling R, Lin D. Robertson-Plouch C, Xu W, Huang X, Dittmann R, Biederman J. Analyses of Treatment Efficacy in Subtypes of Adolescent Patients w. Bipolar Disorder Treated with Olanzapine for Acute Mania: A 3-Week Randomized Randomized Double-Blind Placebo-Controlled Study. CINP, Chicago, IL. July 9-13, 2006.
424. Kryzhanovskaya L, Dittmann RW, Robertson-Plouch C, Bauer T, Xu W, Wang WV, Carlson J, Tohen M. Efficacy of Olanzapine in Adolescents with Schizophrenia: Results from a Double-Blind, Placebo-Controlled Study. CINP, Chicago, IL. July 9-13, 2006.
425. Tohen M, Kryzhanovskaya L, Carlson G, DelBello M, Wozniak J, Kowatch R, Wagner K, Rindling R, Lin D, Robertson-Plouch C, Xu W, Dittmann R, Biederman J. Efficacy of Olanzapine for the Treatment of Acute Mania in Subtypes of Adolescent Patients: A 3-Week Randomized Double-Blind Placebo-Controlled Study. 2nd Biennial Conference of the International Society for Bipolar Disorders. Edinburgh, Scotland, August 2-4, 2006.
426. Brown E, Dunner D, Adams D, Degenhardt E, Tohen M, Williamson D, Houston J. Olanzapine/Fluoxetine Combination vs. Lamotrigine in the Long-Term Treatment of Bipolar I Depression. 2nd Biennial Conference of the International Society for Bipolar Disorders. Edinburgh, Scotland, August 2-4, 2006.
427. Vieta E, Panicali F, Goetz I, Reed C, Comes M, Tohen M. Olanzapine in the Treatment of Mania: 12-Week Results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Observational Study. 2nd Biennial Conference of the International Society for Bipolar Disorders. Edinburgh, Scotland, August 2-4, 2006.
428. Tohen M. Update on the treatment of Bipolar Disorders, Lilly Neuroscience Symposium. 2006 Taiwan Soc. of Psych. Ann. Mtg., Taipei, Taiwan, Nov 5, 2006.
429. Tohen M, Bowden C, Smulevich A, Kryzhanovskaya L, Bergstrom R, Quinlan T,Osuntokun O, Wang WV, Martenyi F. Olanzapine Plus Carbamazepine Vs. Carbamazepine in the Treatment of Mania: A 6-week, Double-blind, Randomized Trial. Neuropsychopharmacology 2006; 31(S1); S221 (abstract #59).
430. Tohen M, Lin D. Olanzapine in the treatment of bipolar disorder. International Congress on Bipolar Disorders. Rome May 3, 2007 Emerging Evidence and Hot Issues.
431. Tohen M. 86. Nomenclature in Course and Outcome in Bipolar Disorders. 7th International Conference on Bipolar Disorder, Pittsburgh, PA. June 2007.
432. Montoya A, Gilaberte I, Polavieja P, Vazquez I, Vieta E, Tohen M. Functional remission in bipolar patients in syndromic remission: REMFYS baseline findings. 7th International Conference on Bipolar Disorder, Pittsburgh, PA. June 2007.
433. Severus E, Lipkovich I, Young AH, Tohen M. Do lithium levels to prevent depressive episodes differ from those to prevent manic/mixed episodes in bipolar disorder? A post-hoc analysis. 7th International Conference on Bipolar Disorder, Pittsburgh, PA. June 2007.
434. Tohen M, Sutton V. Maintenance treatment of mixed mania in patients who remitted after acute treatment with olanzapine: a double-blind, placebo-controlled study. 7th International Conference on Bipolar Disorder, Pittsburgh, PA. June 2007.
435. Tohen M, Bowden CL, Smulevich AB, Kryzhanovskaya LA, Osuntokun O, Wang WV, Martenyi F. Olanzapine plus carbamazepine versus carbamazepine in the treatment of mania: a 6-week, double-blind, randomized trial. 7th International Conference on Bipolar Disorder, Pittsburgh, PA. June 2007.
436. Tohen M. Defining Mood Stabilizers. 2nd International symposium on Bipolar Disorders, Budapest, Hungary, September 23-24, 2007.
437. Tohen M. Outcome and maintenance treatment in bipolar disorder. Australasian Society for Bipolar Disorders Conference 2007, Sydney, Australia, September 20 - September 22, 2007.
438. Tohen M. Predictors of syndromal and functional recovery in patients with a first-episode of mania. Australasian Society for Bipolar Disorders Conference 2007, Sydney, Australia, September 20 - September 22, 2007.
439. Calabrese JR, Ganocy S, Brecher M, Carlson B, Edwards S, Eudicone J, Evoniuk, Jansen W, emp DE, McQuade R, Millen B, Minkwitz M, Owen R, Pikalov A, Szegedi A, Tohen M, Vester-Biokland EV, van Willigenburg, A. Early Improvement as a Predictor of Later Response and Remission in 3,369 Patients from 10 Placebo-Controlled Acute Bipolar I or II Depression Trials. ACNP, Boca Raton, Florida, December 9 - 13, 2007.
440. Calabrese JR, Ganocy S, Brecher M, Carlson BX, Edwards S, Eudicone J, Evoniuk G, Jansen WT, Kemp D, McQuade R, Millen B, Minkwitz M, Owen R, Pikalov A, Szegedi A, Tohen M, Vester-Blokland E, van Willigenburg APP. Early Improvement as a Predictor of Response and Remission from 10 Placebo-Controlled Acute Bipolar I or II Depression Trials. 3rd Biennial Conference of the International Society for Bipolar Disorders. Delhi, India January 27-28, 2008, Agra, India January 30, 2008.
441. Cruz N, Goikolea JM, Tohen M, Baldessarini RJ, Vieta E. Placebo Response in Placebo-Controlled Trials. 3rd Biennial Conference of the International Society for Bipolar Disorders. Delhi, India January 27-28, 2008, Agra, India January 30, 2008.
442. Yatham LN, Tohen M, Wang W. Developed and Non-Developed Countries: Is There a Difference in Active Treatment and Placebo Response in Patients with Bipolar Depression. 3rd Biennial Conference of the International Society for Bipolar Disorders. Delhi, India January 27-28, 2008, Agra, India January 30, 2008.
443. Calabrese JR, Ganocy S, Brecher M, Carlson BX, Edwards S, Eudicone J, Evoniuk G, Jansen W.T., Kemp D, McQuade R, Millen B, Minkwitz M, Owen R, Pikalov A, Szegedi A, Tohen M, Vester-Biokland E, van Willigenburg APP. Early Improvement as a Predictor of Response and Remission from 10 Placebo-Controlled Acute Bipolar I or II Depression trials. 3rd Biennial Conference of the International Society for Bipolar Disorders. Delhi, India January 27-28, 2008, Agra, India January 30, 2008.
444. Cruz N, Goikolea JM, Tohen M, Baldessarini RJ, Vieta E. Placebo Response in Placebo-Controlled Trials. 3rd Biennial Conference of the International Society for Bipolar Disorders. Delhi, India January 27-28, 2008, Agra, India January 30, 2008.
445. Yatham L, Tohen M, Wang W. Developed and Non-Developed countries: Is There a Difference in active Treatment and Placebo Response in Patients with Bipolar Depression. 3rd Biennial Conference of the International Society for Bipolar Disorders. Delhi, India January 27-28, 2008, Agra, India January 30, 2008.
EDUCATIONAL MATERIAL
1. Tohen M, Young D. San Fernando Hospital. Pew Curriculum Center for Health Policy and Management, Harvard School of Public Health, Boston, MA. President and Fellows of Harvard College, 1983:3.
2. Tohen M, Grundy S. The use of mood stabilizers for treating psychotic disorders in acute mania. J Clin Psych, Audiograph Series 1998:1(6).
3. Tohen M. Course of mania and schizobipolar variants, audio-digest psychiatry. 2001:30(4).
BOOKS, MONOGRAPHS, AND TEXTBOOKS
1. Tsuang MT, Tohen M, Zahner M. (Eds) Textbook in Psychiatric Epidemiology, (First edition) John Wiley & Sons, New York, New York, 1995:483.
2. Shulman KI, Tohen M, Kutcher S (Eds) Mood Disorders Throughout the Lifespan. John Wiley & Sons, New York, NY. 1996:318.
3. Tohen M.(ed) Comorbidity in Affective Disorders. Marcel Decker, NY, 1999.
4. Tsuang MT, Tohen M (eds). Textbook in Psychiatric Epidemiology (Second edition), John Wiley & Sons, New York, NY 2002:722.
5. McDonald C, Schulze K, Murray RM, Tohen M (eds). Bipolar Disorder: The Upswing In Research and Treatment, Taylor & Francis, London and New York, 2005.
6. Akiskal HS, Tohen M (eds). Bipolar Psychopharmacotherapy: Caring for the Patient. John Wiley and Sons, New York, N Y 2006.
DISSERTATION OR THESIS
1. Tohen M. Depression y Ritmo Circadiano. (Dissertation for specialty in Internal Medicine), Mexico City, Mexico: Universidad Nacional Autonoma De Mexico, 1979. 101 pp.
2. Tohen M. Cerebral Dominance and Affective Disorders. (Dissertation for The Diploma in Psychiatric Research). Toronto, Ontario, Canada: University of Toronto, 1983:20 pp
